<SEC-DOCUMENT>0001213900-17-012064.txt : 20171114
<SEC-HEADER>0001213900-17-012064.hdr.sgml : 20171114
<ACCEPTANCE-DATETIME>20171114155309
ACCESSION NUMBER:		0001213900-17-012064
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171114
DATE AS OF CHANGE:		20171114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54716
		FILM NUMBER:		171201237

	BUSINESS ADDRESS:	
		STREET 1:		10006 LIATRIS LANE
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55347
		BUSINESS PHONE:		(952) 237-7412

	MAIL ADDRESS:	
		STREET 1:		10006 LIATRIS LANE
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55347

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0917_neuroonemedicaltech.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#9746; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quarterly
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">for the Quarterly Period Ended September 30,
2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-OR-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#9744; <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transition Report Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">for the transaction period from _________ to________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number<B>: 000-54716</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>NeuroOne
Medical Technologies Corporation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>27-0863354</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or Other Jurisdiction of</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation or Organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer<BR>
Identification Number)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10006
    Liatris Lane, Eden Prairie, MN </B></FONT></TD>
    <TD STYLE="text-align: center; padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>55347</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
Telephone Number, Including Area Code: <B>952-237-7412</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
Applicable</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former name or former address, if changed since last
report)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes&nbsp;&#9746;&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&nbsp;&#9746;&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer&rdquo;, &ldquo;accelerated filer&rdquo;,
&ldquo;smaller reporting company&rdquo;, and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="width: 35%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</FONT></TD>
    <TD STYLE="width: 13%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">&#9744;</TD>
    <TD NOWRAP STYLE="width: 46%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer</FONT></TD>
    <TD STYLE="width: 6%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">&#9746;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif">&#9744;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&nbsp;&#9744; No&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of outstanding shares of the
registrant&rsquo;s common stock as of November 10, 2017 was 7,864,994.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEUROONE
MEDICAL TECHNOLOGIES CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-align: center; background-color: White"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PART
1 &ndash; FINANCIAL INFORMATION</FONT></TD>
    <TD STYLE="text-align: center; background-color: White">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1. </FONT></TD>
    <TD STYLE="width: 83%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</FONT></TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Balance Sheets as of September 30, 2017 (unaudited) and December 31, 2016</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016 (unaudited)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016 (unaudited)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Condensed Consolidated Financial Statements (unaudited)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-align: center; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II - OTHER INFORMATION</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior Securities</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6. </FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
I &ndash; FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1. Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne
Medical Technologies Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed
Consolidated Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne, Inc.</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December&nbsp;31,</B></P></TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; padding-left: 10pt">Cash</TD><TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">70,029</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">522,217</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,146</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">53,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">576,040</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Intangible assets, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">190,637</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">180,890</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">267,812</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">756,930</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and Stockholders&rsquo; Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">916,734</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">264,343</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Short-term promissory notes and unsecured loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">204,074</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Convertible promissory notes, net and accrued interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,459,841</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,197</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Premium debt conversion derivative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">441,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">137,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,022,472</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">677,190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">774,172</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">345,960</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,796,644</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,023,150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies (Note 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stockholders&rsquo; deficit:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Preferred stock, $0.001 par value; 10,000,000 and 5,000,000 shares authorized as of September 30, 2017 and
December 31, 2016, respectively; no shares issued or outstanding as of September 30, 2017 and December 31, 2016.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Common stock, $0.001 par value ; 100,000,000 and 45,000,000 shares authorized as of September 30, 2017 and
December 31, 2016, respectively; and 7,864,994 and 5,216,565 shares issued and outstanding as of September 30, 2017 and December
31, 2016, respectively.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,865</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid&ndash;in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162,741</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,699,438</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(266,370</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,528,832</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(266,220</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total liabilities and stockholders&rsquo; deficit</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">267,812</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">756,930</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne
Medical Technologies Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed
Consolidated Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">NeuroOne LLC</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">NeuroOne LLC</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nine months ended </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&nbsp;30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">622,141</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">1,941</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">1,798,131</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">6,009</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">271,651</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,408</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">893,792</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,941</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,298,539</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,009</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(893,792</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,941</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,298,539</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,009</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(515,377</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,635</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,134,529</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,698</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,409,169</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,576</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,433,068</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(16,707</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Net loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.19</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.55</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Number of shares used in per share calculations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,540,135</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,217,076</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">See accompanying notes to condensed consolidated
financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne
Medical Technologies Corporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed
Consolidated Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">NeuroOne LLC</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September&nbsp;30, 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended September&nbsp;30, 2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,433,068</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(16,707</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,368</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,823</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Forgiveness of share subscription agreement for founders&rsquo; shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Non-cash interest on convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Non-cash discount amortization on short-term promissory notes and convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">943,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Non-cash note issuance costs attributed to warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,119</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Revaluation of premium debt conversion derivative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Revaluation of warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,707</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 18pt">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,677</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 18pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">642,099</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,884</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,509,669</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of short-term promissory notes and convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">675,705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from issuance of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">502,415</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Repayment of short-term unsecured loan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance costs related to short-term promissory notes and convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(38,719</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Issuance costs related to warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(31,920</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,057,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net decrease in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(452,188</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Cash at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">522,217</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Cash at end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">70,029</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-align: left"><P STYLE="margin: 0pt 0">Supplemental non-cash investing and financing transactions:</P>


</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Bifurcation of premium conversion derivative related to convertible promissory notes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">213,961</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Accrued issuance costs attributed to short term promissory notes and convertible promissory notes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">42,811</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Accrued issuance costs attributed to warrant liability</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">38,119</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Common stock issued in connection with purchase of intangible assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23,115</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to condensed consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Notes to Condensed Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(unaudited)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 &ndash; Organization and Basis of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify">On July 20, 2017, NeuroOne Medical Technologies
Corporation , a Delaware Corporation, (the &ldquo;Company&rdquo;), through a wholly owned acquisition subsidiary, acquired 100%
of the outstanding capital stock of NeuroOne, Inc. (&ldquo;NeuroOne&rdquo;) in a reverse triangular merger and reorganization
pursuant to Section 368(a) of the Internal Revenue Code (the &ldquo;Acquisition&rdquo;). The Acquisition was accounted for as
a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in this transaction. As such, the historical
financial statements of NeuroOne and its predecessor NeuroOne LLC (the &ldquo;LLC&rdquo;) reflect operations of the Company for
all periods presented prior to the date of Acquisition. NeuroOne, Inc. was formed on October 7, 2016 and acquired the LLC on October
27, 2016 (the &ldquo;Merger&rdquo;) as described more fully below. The accompanying condensed consolidated financial statements
subsequent to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to the Acquisition, the Company&rsquo;s operating activities are the same as those of NeuroOne, an early-stage medical technology
company, engaged in the development of comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation
solutions to diagnose and treat patients with epilepsy, Parkinson&rsquo;s disease, dystonia, essential tremors, and other brain
related disorders. The Company is based in Eden Prairie, Minnesota.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquisition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transactions contemplated by the agreement were consummated on July 20, 2017 (the &ldquo;Closing&rdquo;) and, pursuant to the
terms of the agreement, (i) all outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the &ldquo;NeuroOne
Shares&rdquo;) were exchanged for shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Company Shares&rdquo;)
based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the &ldquo;Exchange Ratio&rdquo;), resulting
in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares,
(ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with
corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for
issuance upon the exercise of options, (iii) all warrants of NeuroOne, Inc. were replaced with warrants to purchase Company Shares
and (iv) the Company assumed the outstanding convertible promissory notes of NeuroOne. NeuroOne options had been issued pursuant
to the NeuroOne 2016 Equity Incentive Plan. Pursuant to the agreement, the Company assumed the NeuroOne 2016 Equity Incentive
Plan upon the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Acquisition, the Company acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became
the Company&rsquo;s wholly-owned subsidiary. Also at the Closing, Mr. Samad (the majority owner of the Company prior to the Acquisition)
tendered for cancellation 3,500,000 Company Shares held by him as part of the conditions to Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time of Acquisition, the Company had authorized 100,000,000 shares of common stock with a par value of $0.001 and 10,000,000
shares of preferred stock with a par value of $0.001.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All issued and outstanding common
stock share amounts, options for common stock and per share amounts contained in the condensed consolidated financial statements
were retroactively adjusted to reflect the Exchange Ratio for all periods presented. The number of authorized shares for common
and preferred stock and their respective par values per share as of December 31, 2016 reflect those of the Company prior to the
Acquisition.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Merger</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLC was formed on December 12, 2013 and operated as a limited liability company until it was merged with and into NeuroOne on
October 27, 2016 with NeuroOne as the surviving entity of the &ldquo;Merger&rdquo;. NeuroOne was formed on October 7, 2016 under
different ownership than the LLC. As a result of the Merger, all of the properties, rights, privileges, powers and franchises
of the LLC vested in NeuroOne, and all debts, liabilities and duties of the LLC became the debts, liabilities and duties of NeuroOne
with the exception of the LLC&rsquo;s license agreement with Wisconsin Alumni Research Foundation (&ldquo;WARF&rdquo;) which required
WARF&rsquo;s approval for transfer (See Note 4 &ndash; Commitments and Contingencies). The purpose of the Merger was to change
the jurisdiction of NeuroOne&rsquo;s incorporation from Minnesota to Delaware, change the ownership of the LLC&rsquo;s underlying
assets, and to convert from a limited liability company to a corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
and the LLC were not entities under common control. As the LLC did not have an integrated set of activities that contained the
required complement of inputs, processes and outputs to be considered a business, the Merger was accounted for as an asset acquisition
as prescribed under Accounting Standards Codification (ASC) 805 &ndash; <I>Business Combinations</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of presentation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared by the Company, without audit, pursuant to the rules
and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in
accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and
regulations. The condensed consolidated financial statements may not include all disclosures required by U.S. GAAP; however, the
Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed
consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto for
the fiscal year ended December 31, 2016 included in the NeuroOne Current Report on Form 8-K filed on July 20, 2017. The condensed
balance sheet at December 31, 2016 was derived from the audited financial statements of NeuroOne.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly
the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations
for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 &ndash; Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going
concern. The Company has incurred losses since inception and had an accumulated deficit of $3,699,438 as of September 30, 2017.
Prior to the Merger, the LLC also incurred losses since its inception and had cumulative losses of $49,930 as of the date of the
Merger. The Company does not have adequate liquidity to fund its operations throughout fiscal 2018 without raising additional
funds. These factors raise substantial doubt about its ability to continue as a going concern. The condensed consolidated financial
statements do not include any adjustments that might result from the outcome of this condition. Management intends to seek additional
financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse
effect on the operations of the Company and the development of its technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Through September 30, 2017, the Company
has completed both a $253,000 short-term promissory note financing and a $1,625,120 convertible promissory note financing of a
planned $2.5 million subscription. The Company does not have adequate liquidity to fund its operations throughout fiscal 2017 without
raising additional funds. Management believes that the currently available resources from the short-term promissory note and convertible
promissory note financings combined with funds expected to be raised in the last quarter of fiscal 2017 will be sufficient to enable
the Company to meet its operating plan through at least September 30, 2018. However, if the Company is unable to raise additional
funds, or the Company&rsquo;s anticipated operating results are not achieved, management believes planned expenditures may need
to be reduced in order to extend the time period that existing resources can fund the Company&rsquo;s operations. If management
is unable to obtain the necessary capital, it may have to cease operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 &ndash; Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Management&rsquo;s
Use of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the
United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements
and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentration
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&rsquo;s cash is
held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management
believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the
financial institution. As of September 30, 2017, the Company did not have deposits in excess of federally insured amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to October 27, 2016, the LLC did not maintain a bank account. Any expenses incurred while the LLC was organized as a limited liability
company were paid by the sole member of the LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; text-indent: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value of Financial Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value
in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards
Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements)
and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of
the fair value hierarchy are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the
    measurement date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly
    or indirectly, for substantially the full term of the asset or liability.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are
    not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability
    at measurement date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2017 and December 31, 2016, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated
their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term
promissory notes and the convertible promissory notes of the Company was based on amortized cost which was deemed to approximate
fair value. The fair value of the warrant liability and premium conversion derivative associated with the convertible promissory
notes was based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing
expected returns by market participants for similar instruments which were based on Level&nbsp;3 inputs. There were no transfers
between fair value hierarchy levels during the three and nine month periods ended September 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of financial instruments measured on a recurring basis is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September 30,&nbsp;2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: 0in; padding-left: 0in">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">774,172</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">774,172</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Premium conversion derivative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">441,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">441,823</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Total liabilities at fair value</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,215,995</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,215,995</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December&nbsp;31,&nbsp;2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Description</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;1</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;2</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Level&nbsp;3</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: 0in; padding-left: 0in">Warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">345,960</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">345,960</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Premium conversion derivative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">137,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">137,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Total liabilities at fair value</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">483,610</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">483,610</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a roll-forward of the warrant liability and premium conversion derivative measured at fair value on a
recurring basis using unobservable level&nbsp;3 inputs for the nine months ended September 30, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Warrant liability</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended <BR> September&nbsp;30,<BR>
 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-indent: 0in; padding-left: 0in">Balance as of beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">345,960</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Issuance of warrants in connection with convertible promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">440,919</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Change in fair value of warrant liability</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(12,707</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: 0in; padding-left: 0.125in">Balance as of end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">774,172</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Premium conversion derivative</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine months ended <BR> September&nbsp;30,<BR>
 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-indent: 0in; padding-left: 0in">Balance as of beginning of period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">137,650</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Value assigned to the underlying derivative in connection with convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,961</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Change in fair value of premium conversion derivative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">90,212</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: 0in; padding-left: 0.125in">Balance as of end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">441,823</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no financial instruments measured on a fair value recurring basis during the nine month period ended September 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
and the LLC have entered into two licensing agreements with major research institutions, which allows for access to certain patented
technology and know-how. Milestone payments under those agreements are capitalized and amortized to general and administrative
expense over the expected useful life of the acquired technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of Long-Lived Assets </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates their long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events
or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the
recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through
undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as
the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2017, the Company has
not impaired any long-lived assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Debt
Issuance Costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
issuance costs are recorded as a reduction of the short-term promissory notes and convertible promissory notes. Amortization of
debt issuance costs is calculated using the straight-line method over the term of respective short-term and convertible promissory
notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed consolidated
statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. Research and development expenses may comprise costs incurred in performing
research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials
as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services
that will be used in future research and development activities are expensed when the activity is performed or when the goods
have been received, rather than when payment is made, in accordance with ASC 730, <I>Research and Development</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrant
Liability</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued warrants to purchase equity securities in connection with the issuance of the convertible promissory notes (see
Note 8 &ndash; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at
fair value as the number of shares were not fixed and determinable at the issuance date. Additionally, issuance costs associated
with the warrants are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements
of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or
expiration of the warrant, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the
warrants will be classified in stockholders&rsquo; (deficit) equity provided that there are sufficient authorized and unissued
shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock.
Any future change in fair value of the warrant liability will be recognized as a component of interest expense in the condensed
consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Premium
Debt Conversion Derivative</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded
derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated
from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized
and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the
effective interest method.&nbsp; The separated embedded derivative is accounted for separately on a fair market value basis. The
Company records the fair value changes of a separated embedded derivative to interest expense at each reporting period. The Company
issued convertible promissory notes that contained a 125% conversion premium in the event that a qualified financing occurs at
a price under $2.25 per common share (see Note 8 &ndash; Convertible Promissory Notes and Warrant Agreements). We also issued
2017 Convertible Notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under
$2.8125 per common share (see Note 13 &ndash; Subsequent Events). The Company determined that the redemption feature under the
convertible promissory notes qualified as an embedded derivative and was separated from its debt host.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For NeuroOne, income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base
and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred
tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset
will not be realized.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne on October 27, 2016.
As such, it was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included in
the financial statements for the period from January 1, 2016 through October 26, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Net
Loss Per Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLC was a single-member LLC for which no units were outstanding. Accordingly, earnings per share is not presented for the LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
NeuroOne, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common
stock outstanding during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average
shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive.
The Company&rsquo;s stock options, convertible promissory notes and warrants are considered common stock equivalents for this
purpose. Diluted earnings is computed utilizing the treasury method for the stock options and warrants. Diluted earnings with
respect to the convertible promissory notes utilizing the if-converted method was not applicable during the three and nine months
ended September 30, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock
equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss
reported for the three and nine months ended September 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following potential common shares were not considered in the computation of diluted net loss per share as their effect would have
been anti-dilutive for the three and nine month periods ended September 30, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 89%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,074,181</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">365,716</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Accounting Pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2016, the FASB issued ASU No.&nbsp;2016-01, <I>Financial Instruments&nbsp;&mdash; Overall: Recognition and Measurement
of Financial Assets and Financial Liabilities</I>. The guidance affects the accounting for equity investments, financial liabilities
under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective
in the first quarter of fiscal 2018 for public entities and for all other entities in the first quarter of fiscal 2019. Early
adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently
evaluating the impact of the new guidance on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2017, the FASB issued ASU 2017-09, <I>Compensation - Stock Compensation (Topic 718):&nbsp;Scope of Modification Accounting
(ASU 2016-09)</I>,&nbsp;which provides guidance about which changes to the terms or conditions of a share-based payment award
require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods
beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the requirements of this new
guidance and has not yet determined its impact on the Company&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017, the FASB issued ASU No. 2017-11, <I>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and
Hedging</I>, which changes the accounting and earnings per share for certain instruments with down round features. The amendments
in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment
to each period presented and is effective for annual periods beginning after December&nbsp;15, 2018 for public business entities
and after December 15, 2019 for all other entities, including interim periods within those fiscal years. Early adoption is permitted.
The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&rsquo;s
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &ndash; Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>WARF
License Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2014, the LLC entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation
(&ldquo;WARF&rdquo;) for WARF&rsquo;s neural probe array and thin film electrode technology (the &ldquo;2014 WARF Agreement&rdquo;).
The LLC was to make $110,000 in milestone payments depending on achievement of certain development and approval milestones or
within twelve months of signing the 2014 WARF Agreement. Additionally, if the LLC was successful in obtaining regulatory approval,
the LLC was to pay royalties to WARF on a percentage of net sales of products of the licensed technology. Under the terms of the
2014 WARF Agreement, amounts that remained unpaid more than 30 days after they were due, accrued interest at 1 percent per month.
Milestone payments due in 2015 were not made to WARF. From October 27, 2016 until the 2014 WARF Agreement was amended as described
below, the LLC was in default under the 2014 WARF Agreement. In addition, the LLC was not able to transfer the rights and obligations
under the 2014 WARF Agreement to NeuroOne at the time of the Merger (October 27, 2016) without the consent of WARF, which was
received when the 2014 WARF Agreement was amended in February 2017 as described below. In connection with the Merger and in accordance
with ASC 805-50, NeuroOne estimated the fair value of consideration payable to WARF and recorded an intangible asset of $90,000
with a corresponding accrued expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
agreement was subsequently amended in February 2017 (as so amended, the &ldquo;2017 WARF Agreement&rdquo;) whereby WARF consented
to the transfer of the rights and obligations under the license agreement from the LLC to NeuroOne (which are now the Company&rsquo;s
rights and obligations, following the Acquisition). In the 2017 WARF Agreement, a contingent payment amount of $120,000 is due
in the event that the Company completes a qualified financing. The Company is also obligated to pay royalties to WARF based on
a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for calendar years
2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the 2017 WARF Agreement. Subject
to earlier termination, the WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed
thereunder remain. The Company expects the latest expiration of a licensed patent to occur in 2030. The 2017 WARF Agreement is
also subject to certain cancellation provisions with 90 days&rsquo; notice should the Company elect not to continue to use the
licensed technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to diligently develop, manufacture, market and sell products under the WARF License in the United States during
the term of the agreement and, specifically, that the Company will submit a business plan to WARF by February 1, 2018 and file
an application for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate the 2017 WARF Agreement in
the event that the Company fails to meet these milestones on 30 days&rsquo; written notice, if the Company defaults on the payments
of amounts due to WARF or fails to timely submit development reports, actively pursue the development plan or breaches any other
covenant in the 2017 WARF Agreement and fails to remedy such default in 90 days or in the event of certain bankruptcy events involving
the Company. WARF may also terminate this license (i) on 90 days&rsquo; notice if the Company fails to have commercial sales of
one or more FDA-approved products under the 2017 WARF Agreement by March 31, 2019 or (ii) if, after royalties earned on sales
begin to be paid, such earned royalties cease for more than four calendar quarters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mayo
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify">On October 3, 2014, the LLC entered into
an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&ldquo;Mayo&rdquo;)
related to certain intellectual property and development services for thin film electrode technology (&ldquo;2014 Mayo Agreement&rdquo;).
The LLC was to make milestone payments depending on achievement of certain development and approval milestones and sales targets,
none of which were met as of December 31, 2015. Additionally, if the LLC was successful in obtaining regulatory approval, the
LLC was to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of
the 2014 Mayo Agreement, set to expire May 25, 2037. Also, the LLC was obligated to issue common stock to Mayo if certain events
occurred. Upon the LLC&rsquo;s Merger with NeuroOne on October 27, 2016, the rights under the 2014 Mayo Agreement transferred
to NeuroOne, and certain milestones were attained. Therefore, NeuroOne recorded $300 related to 10,000 shares of common stock
issued to Mayo and $91,709 for the intellectual property. Milestone payments due under the 2014 Mayo Agreement and accrued were
$91,709 as of September 30, 2017 and December 31, 2016. Under the terms of the 2014 Mayo Agreement, amounts that remained unpaid
accrued interest at 2 percent above the prime rate. Milestone payments due in 2016 were not made to Mayo. As such, prior to the
amendment of the 2014 Mayo Agreement in May 2017), NeuroOne was in default under the 2014 Mayo Agreement. Mayo and NeuroOne amended
and restated the 2014 Mayo Agreement in May 2017 (as so amended and restated, the &ldquo;2017 Mayo Agreement&rdquo;). Pursuant
to the 2017 Mayo Agreement, NeuroOne issued 50,556 shares of common stock to Mayo to settle the amount of common stock NeuroOne
was previously obligated to issue under the 2014 Mayo Agreement and to amend the terms of the 2014 Mayo Agreement. NeuroOne recorded
an additional $23,115 to intangible assets related to the fair value of the 2017 stock issuance to Mayo. As a part of the 2017
Mayo Agreement, as amended in November 2017, the $91,709 milestone payment is to be paid upon the earlier of a qualified financing
or December 31, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
received a letter in May 2017 from the former employer of certain employees of NeuroOne, claiming that NeuroOne and those individuals
have wrongfully used or disclosed alleged trade secrets of the former employer and that the individuals breached non-competition
or non-solicitation agreements with such party. The Company and the individuals intend to vigorously defend against these claims,
if litigation results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 &ndash; Intangibles</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consisted of the following at September 30, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Useful
    Life</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    agreement, October 27, 2016</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-13
    years</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">182,159</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: amortization</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,269</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Intangibles,
    December 31, 2016</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">180,890</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License agreement
    amendment</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,115</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: amortization</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,368</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Intangibles,
    September 30, 2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">190,637</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $4,264 and $13,368 for NeuroOne and the Company for the three and nine months ended September 30, 2017, respectively,
and $1,941 and $5,823 for the LLC for the three and nine months ended September 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 &ndash; Accrued Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following at September 30, 2017 and December 31, 2016:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30,<BR>
 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR>
 2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0in; padding-left: 0in">Accrued license fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">182,009</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">182,009</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Accrued services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">531,607</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,186</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Accrued issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,306</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Accrued compensation and payroll related costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">170,812</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,252</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Accrued interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">881</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0.125in">Total accrued expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">916,734</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">264,343</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 &ndash; Short-Term Promissory Notes and Unsecured Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short-Term
Promissory Notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2017, the Company&rsquo;s Board
of Directors authorized and the Company issued short-term unsecured promissory notes (the &ldquo;Short-Term Notes&rdquo;) for aggregate
gross proceeds of $253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and are being amortized
ratably to interest expense over the term of the Short-Term Notes. For the three and nine month period ended September 30, 2017,
discount amortization charged to interest expense related to the issuance costs was $733. The Short-Term Notes do not bear interest
on principal and require the Company to repay the principal upon maturity on February&nbsp;18, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, upon maturity, under the provisions of the Short-Term Notes, the holders will receive 126,500 common stock purchase
warrants upon maturity with a term of 5 years at an exercise price of $1.80 which will be immediately exercisable upon issue.
A portion of the proceeds from the Short-Term Notes was allocated to the warrants based on their relative fair value to the underlying
Short-Term Notes. The proceeds allocated to the warrants were recorded as additional paid in capital in the accompanying condensed
consolidated balance sheets and were discounted from the Short-Term Notes in the amount of $61,496. The relative fair value of
the warrants was based on the Black-Scholes method with the following assumptions: risk-free interest rate 1.77 percent; expected
volatility 48 percent; expected life 5.5 years; and expected dividend yield 0 percent. The underlying stock price used in the
analysis is on a non-marketable basis and is according to a separate 409A valuation analysis. The discount related to the warrants
is being amortized to interest expense ratably over the term of the Short-Term Notes which amounted to $14,868 during the three
and nine month period ended September 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unsecured
Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
received a $50,000 short-term unsecured loan in November 2016 from the placement agent for its convertible promissory note financing
(see Note 8 &ndash; Convertible Promissory Notes and Warrant Agreements). NeuroOne incurred no fees or interest costs for this
temporary loan and it was repaid in full in February 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 &ndash; Convertible Promissory Notes and Warrant Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Promissory Notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2016 and then amended in June 2017, the Company&rsquo;s Board of Directors authorized the Company to issue convertible
promissory notes (the &ldquo;Convertible Notes&rdquo;) and common stock purchase warrants for aggregate gross proceeds of up to
$2.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2017, the Company has issued $1,625,120 of Convertible Notes and common stock purchase warrants to investors.
The Convertible Notes are unsecured. The Convertible Notes bear interest at a fixed rate of 8 percent per annum and require the
Company to repay the principal and accrued and unpaid interest thereon at the earlier of November 21, 2017 or the consummation
of the next equity or equity-linked round of financing resulting in more than $3.0 million in gross proceeds (a &ldquo;Qualified
Financing&rdquo;). If a Qualified Financing occurs before November 21, 2017, the outstanding principal and accrued and unpaid
interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on
the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes
divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the
price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by November 21, 2017,
the Convertible Notes will be immediately due and payable on such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a change of control transaction or initial public offering occurs prior to a Qualified Financing, the Convertible Notes would,
at the election of the holders of a majority of the outstanding principal of the Convertible Notes, either become payable on demand
as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction
at a price per share equal to the lesser of the per share value as determined by the Company&rsquo;s Board of Directors as if
in connection with the granting of stock based compensation, or in a private sale to a third party in an arms&rsquo; length transaction,
or at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another
entity in which the Company&rsquo;s stockholders do not own more than 50 percent of the outstanding voting power of the surviving
entity or the disposition of all or substantially all of the assets of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number
of shares issuable upon the conversion of the Convertible Notes, or (ii) if exercised prior to conversion of the Convertible Notes,
the number of shares of common stock equal to the outstanding principal and accrued interest on the Convertible Note held by such
warrant holder divided by $1.80. The warrants were immediately exercisable on the date of issuance and expire on November 21,
2021. In June 2017, however, the Company amended the terms of the common stock purchase warrants under the Convertible Notes to
be exercisable only in the event of conversion of the outstanding principal and accrued interest on the related Convertible Notes.
The amount of warrant shares to be issued are now fixed to the number of shares of common stock received by the holder of the
Convertible Notes upon conversion of such holder&rsquo;s Convertible Notes, and to an exercise price equal to the price at which
the Convertible Notes convert into common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants were accounted for as a liability because there is no set exercise price. A Monte Carlo simulation model was used to
estimate the aggregate fair value of the warrants as of September 30, 2017. Input assumptions used were as follows: risk-free
interest rate 1.79 percent; expected volatility 50 percent; expected life 4.14 years; and expected dividend yield 0 percent. The
underlying stock price used in the analysis is on a non-marketable basis and is according to a separate 409A valuation analysis.&nbsp;The
convertible promissory note proceeds assigned to the warrants were $440,919 and $345,640 during the nine months ended September
30, 2017 and for the period from October 7, 2016 to December 31, 2016, respectively, which represented their fair value at issuance,
and were discounted from the Convertible Notes and reflected as a warrant liability. The discount is being amortized to interest
expense over the term of the Convertible Notes using the straight-line method which approximates the effective interest method.
The amortization expense was $284,637 and $601,794 for the three and nine months ended September 30, 2017, respectively. The Company
recorded the fair value changes of the warrant liability associated with the Convertible Notes to interest expense which amounted
to $6,546 and $(12,707) for the three and nine months ended September 30, 2017, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time of their issuance, the Convertible Notes contained a 125% conversion premium in the event that a Qualified Financing
occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Convertible Notes
qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its
debt host resulted in a discount to the Convertible Notes in the amount of $213,961 and $137,564 during the nine months ended
September 30, 2017 and during the period from October 7, 2016 to December 31, 2016, respectively. The discount is being amortized
to interest expense over the term of the Convertible Notes using the straight-line method which approximates the effective interest
method. The amortization expense was $133,367 and $266,848 for the three and nine month period ended September 30, 2017, respectively.
The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes
of the premium debt conversion derivative associated with the Convertible Notes to interest expense which amounted to $15,406
and $90,212 for the three and nine months ended September&nbsp;30, 2017, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement
agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant
to the placement agent (the &ldquo;placement agent warrant&rdquo;) which will have an exercise price of $2.00 per share of common
stock and had a total fair value of $4,855 at September 30, 2017 and (iii) legal expenses of $33,450. The placement agent warrant
is issuable at the time the private placement transaction closes. The placement agent warrant will be immediately exercisable
on the date of issuance and will expire five years following the date of issuance. The placement agent is to receive a placement
agent warrant to purchase shares of common stock in an amount equal to 8 percent of the common stock (or common stock equivalents)
purchased by investors in the private placement transaction. As of September 30, 2017 and December 31, 2016, the Company has an
obligation to issue a placement agent warrant for the purchase of approximately 63,000 and 29,000 shares of common stock, respectively.
The Company recorded an issuance cost discount to the Convertible Notes in the amount of $39,781 and $37,469 for the nine months
ended September 30, 2017 and for the period from October 7, 2016 to December 31, 2016, respectively, of which $27,317 and $59,184
was amortized to interest expense during the three and nine months ended September 30, 2017, respectively. The balance of the
issuance costs in the amount of zero and $38,119 was attributed to the common stock purchase warrants and was immediately recorded
as interest expense upon issuance during the three and nine months ended September 30, 2017, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent is also entitled to receive warrants to purchase common stock in an amount equal to 10 percent of the common stock
(common stock equivalents) purchased by certain investors in subsequent equity financing rounds (see Note 13 &ndash; Subsequent
Events). Such warrants if issued will have an exercise price determined in relation to the pricing of the subsequent financing
rounds and will be immediately exercisable once issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 &ndash; Investment Banker Fee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investment
Banker Fee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
paid a $50,000 non-refundable fee to an investment banker in December 2016 to raise equity financing. This fee is reflected in
NeuroOne&rsquo;s December 31, 2016 balance sheet as a prepaid expense. NeuroOne subsequently concluded that the investment banker
was not expected to raise any equity and therefore expensed the fee in March 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
10 &ndash; Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne formally adopted an equity incentive
plan (&ldquo;the 2016 Plan&rdquo;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition.
In addition, the Company adopted a 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;) on April 17, 2017. The 2016 and 2017
Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company.
The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for
issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards
in the second quarter of 2017. During the three and nine-month period ended September 30, 2017, zero and 365,716 stock options
for shares of common stock were granted, respectively, to directors and consultants at a weighted average exercise price of $0.035
per share. The stock options granted during the nine month period ended September 30, 2017 had a weighted average grant date fair
value of $0.014 per share with various vesting periods and expire in ten years. In addition, the Company issued zero and 215,453
shares of restricted common stock with performance vesting conditions from the 2016 Plan during the three and nine month period
ended September 30, 2017, respectively. All performance vesting conditions for the restricted common stock were met as of September
30, 2017. Compensation expense associated with restricted common stock shares was $7,220.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense was included in general and administrative and research and development costs as follows in the accompanying
condensed statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Three Months Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Nine Months Ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">September 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">September&nbsp;30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2017</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: 0in; padding-left: 0in">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,065</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">64,945</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">74,729</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Total stock-based compensation</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">64,945</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">76,794</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during
the three and nine month periods ended September 30, 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Three Months <BR> Ended</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Nine Months <BR> Ended</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0in; padding-left: 0in">Expected stock price volatility</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">47.8</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Expected life of options (years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.9</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended September 30, 2017, 42,525 and 365,716 stock options vested, respectively, and zero and 215,453
restricted stock awards vested, respectively. The weighted average fair value per share of options vesting during the three and
nine months ended September 30, 2017 was $0.014. No stock options were forfeited during the three and nine months ended September
30, 2017. As of September 30, 2017, 1,711,096 shares were available for future issuance on a combined basis under the 2016 and
2017 Plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
was no unrecognized stock-based compensation cost for stock options and restricted common stock as of September 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
11 &ndash; Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
effective tax rate for the three and nine months ended September 30, 2017 was zero percent. As a result of the analysis of all
available evidence as of&nbsp;September 30, 2017&nbsp;and&nbsp;December&nbsp;31, 2016, the Company recorded a full valuation allowance
on its net deferred tax assets. Consequently, the Company reported&nbsp;no&nbsp;income tax benefit during the&nbsp;three and nine
month periods ended&nbsp;September 30, 2017. If the Company&rsquo;s assumptions change and the Company believes that it will be
able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax
assets will be recognized as a reduction of future income tax expense.&nbsp;&nbsp;If the assumptions do not change, each period
the Company could record an additional valuation allowance on any increases in the deferred tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne on October 27, 2016.
As such, the LLC was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included
in the financial statements for the three or nine month periods ended September 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
12 &ndash; Stockholders&rsquo;/Member Deficit</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2017, the purchase price owed by the seven individuals for the founders&rsquo; shares of NeuroOne under their respective
subscription agreements totaling $9,051 was forgiven by NeuroOne prior to the Acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Condensed Consolidated Financial Statements, continued</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify; border-top: black 1pt solid; border-bottom: black 2.25pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
13 &ndash; Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2017, the Company entered into a Subscription Agreement (the &ldquo;Subscription Agreement&rdquo;) with certain accredited
investors (the &ldquo;Subscribers&rdquo;), pursuant to which the Company, in a private placement (the &ldquo;Private Placement&rdquo;),
agreed to issue and sell to the Subscribers 8% convertible promissory notes (each, a &ldquo;Note&rdquo; and collectively, the
&ldquo;2017 Convertible Notes&rdquo;) and warrants (the &ldquo;New Warrants&rdquo;) to purchase shares of the Company&rsquo;s
capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial closing of the Private Placement
was consummated on October 4, 2017, and, on that date, the Company issued Notes in an aggregate principal amount of $150,000 to
the Subscribers. Between November 2, 2017 and November 7, 2017, the Company entered into Subscription Agreements with additional
Subscribers, and issued Notes in a principal amount of $215,000 to those Subscribers. The Company may conduct any number of additional
closings so long as the final closing occurs on or before the five-month anniversary of the initial closing date and the amount
does not exceed $1,000,000 or a higher amount determined by the Board of Directors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2017 Convertible Notes bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued
and unpaid interest thereon on October 4, 2022 (the &ldquo;Maturity Date&rdquo;). If the Company raises more than $3,000,000 in
an equity financing before the Maturity Date (the &ldquo;Qualified Financing&rdquo;), the outstanding principal and accrued and
unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in such financing
based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the
2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the Notes multiplied by 1.25,
divided by the price paid per security in such financing. If a change of control transaction occurs prior to the earlier of a
Qualified Financing or the Maturity Date, the 2017 Convertible Notes would, at the election of the holders of a majority of the
outstanding principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction
or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser
of (i) the per share value of the common stock as determined by our Board of Directors as if in connection with the granting of
stock based compensation or in a private sale to a third party in an arms&rsquo; length transaction or (ii) at the per share consideration
to be paid in such transaction (the date of any such conversion of the 2017 Convertible Notes pursuant to this paragraph, is referred
to herein as the &ldquo;Conversion Date&rdquo;). Change of control means a merger or consolidation with another entity in which
our stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or
substantially all of the Company&rsquo;s assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
New Warrant grants the holder the option to purchase the number of shares of capital stock of the Company issuable upon the conversion
of the 2017 Convertible Notes held by such holder at a per share exercise price equal to the price at which the 2017 Convertible
Notes converted. The New Warrants are exercisable commencing on the Conversion Date and expire on the five year anniversary of
the Conversion Date. The exercise price and number of the shares of our common stock issuable upon exercising the New Warrants
will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization
or similar transaction, as described therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent is also entitled to receive a warrant to purchase common stock in an amount equal to 10 percent of the common
stock (common stock equivalents) purchased by certain investors in subsequent equity financing rounds. Such warrant, if issued
will have an exercise price determined in relation to the pricing of the subsequent financing and will be immediately exercisable
once issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In such subsequent equity financing rounds,
the placement agent is also entitled to receive a cash fee equal to 10 percent of the total amount of capital received by the Company,
as well as a cash amount representing a non-accountable expense allowance equal to 3% of the aggregate gross proceeds raised in
such financing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Subscription Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Subscription Agreements,
the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of
the 2017 Convertible Notes or New Warrants, and the right to purchase the 2017 Convertible Notes or New Warrants on the same terms
as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving
written notice. The Company has granted the Subscribers indemnification rights with respect to its representations, warranties,
covenants and agreements under the Subscription Agreements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
2. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion of our financial condition and results of operations should be read in conjunction with the financial statements
and notes included in Part I &ldquo;Financial Information&rdquo;, Item I &ldquo;Financial Statements&rdquo; of this Quarterly
Report on Form 10-Q and the audited financial statements and related footnotes included in our Current Report on Form 8-K, filed
on July 20, 2017 and our Current Report on Form 8-K/A, filed on August 14, 2017.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Forward-Looking
Statements</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certain
statements contained in this Quarterly Report on Form 10-Q are not statements of historical fact and are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended (the &ldquo;Exchange Act&rdquo;). Forward-looking statements give current expectations or forecasts of future
events or our future financial or operating performance. We may, in some cases, use words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo;
or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these
forward-looking statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>These
forward-looking statements reflect our management&rsquo;s beliefs and views with respect to future events, are based on estimates
and assumptions as of the date of this report and are subject to risks and uncertainties, many of which are beyond our control,
that could cause our actual results to differ materially from those in these forward-looking statements. Moreover, we operate
in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management
to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination
of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.
Given these uncertainties, you should not place undue reliance on these forward-looking statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should read the following discussion and analysis of financial condition and results of operations of NeuroOne Medical Technologies
Corporation together with our financial statements and the related notes included elsewhere in this Report. Some of the information
contained in this discussion and analysis or set forth elsewhere in this Report, including information with respect to our plans
and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the
&ldquo;Risk Factors&rdquo; section of this Report for a discussion of important factors that could cause actual results to differ
materially from the results described in or implied by the forward-looking statements contained in the following discussion and
analysis.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Any
forward-looking statement made by us in this report speaks only as of the date hereof or as of the date specified herein. We undertake
no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or
otherwise, except as may be required by applicable laws or regulations.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in the State of Nevada on August 20, 2009 as Original Source Entertainment, Inc. (&ldquo;OSE&rdquo;).
OSE was originally formed to license songs to the television and movie industry. From our inception and prior to the acquisition
of NeuroOne, Inc. on July 20, 2017 (the &ldquo;Acquisition&rdquo;), as described more fully below, our operations have been primarily
limited to organizational, start-up, and capital formation activities. Upon completion of the Acquisition, more fully described
below, our operations consist of the development of comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain
stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&rsquo;s disease, dystonia, essential tremors, and
other brain related disorders. Our cortical strip technology under development has only been used by Mayo in five patients for
research purposes and has not been tested in any clinical trials. We are based in Eden Prairie, Minnesota.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Acquisition was accounted for as a capital transaction, or reverse recapitalization. As a result, the financial information contained
in the Report reflect solely the operations of NeuroOne, Inc. (&ldquo;NeuroOne&rdquo;) and its predecessor NeuroOne LLC (the &ldquo;LLC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had very limited resources prior to our convertible promissory note (the &ldquo;Convertible Notes&rdquo;) and warrant financings
commencing in November 2016. To date, our primary activities have been limited to, and our limited resources have been dedicated
to, performing business and financial planning, raising capital, recruiting personnel, negotiating with business partners and
the licensors of our intellectual property and conducting development activities. Our cortical strip, grid electrode and depth
electrode technology is still under development, we do not yet have regulatory approval in any jurisdiction to sell any products
and, to date, we have not generated any revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred losses since inception.
As of September 30 2017, we had an accumulated deficit of $3,699,438, primarily as a result of expenses incurred in connection
with our research and development programs and from general and administrative expenses associated with our operations. The LLC,
prior to the merger with NeuroOne, also incurred losses since its inception and had cumulative losses of $49,930 as of the date
of the October 26, 2016 merger. We expect to continue to incur significant expenses and increasing operating and net losses for
the foreseeable future.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to generate revenue from product sales unless and until we obtain marketing authorization to sell our cortical strip,
grid electrode and depth electrode technology from applicable regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
primary source of cash has been proceeds from the issuances of short-term promissory notes (the &ldquo;Short-Term Notes&rdquo;),
Convertible Notes and common stock purchase warrants (the &ldquo;Warrants&rdquo;). From November 2016 to September 2017, we issued
Short-Term Notes (in aggregate principal amount of $253,000) and Warrants resulting in net proceeds of $249,970, and Convertible
Notes (in aggregate principal amount of $1,625,120) and Warrants, for aggregate net proceeds of $1,511,510 to fund our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2017, we entered into a Subscription Agreement (the &ldquo;Subscription Agreement&rdquo;) with certain accredited investors
(the &ldquo;Subscribers&rdquo;), pursuant to which we, in a private placement (the &ldquo;Private Placement&rdquo;), agreed to
issue and sell to the Subscribers 8% convertible promissory notes (each, a &ldquo;Note&rdquo; and collectively, (the &ldquo;2017
Convertible Notes&rdquo;) and warrants (the &ldquo;New Warrants&rdquo;) to purchase shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial closing of the Private Placement
was consummated on October 4, 2017, and, on that date, we issued Notes (in an aggregate principal amount of $150,000) to the Subscribers.
Between November 2, 2017 and November 7, 2017, the Company entered into Subscription Agreements under the Private Placement with
additional Subscribers, and issued Notes (in an aggregate principal amount of $215,000) to those Subscribers. We may conduct any
number of additional closings so long as the final closing occurs on or before the five-month anniversary of the initial closing
date and the amount does not exceed $1,000,000 or a higher amount determined by our Board of Directors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
need to obtain substantial additional funding in connection with our continuing operations through public or private equity or
debt financings or other sources, which may include collaborations with third parties. However, we may be unable to raise additional
funds when needed on favorable terms or at all. Our failure to raise such capital as and when needed would have a negative impact
on our financial condition and our ability to develop and commercialize our cortical strip, grid electrode and depth electrode
technology and future products and our ability to pursue our business strategy. See &ldquo;&ndash;Liquidity and Capital Requirements&rdquo;
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Acquisition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 20, 2017, we entered into a merger agreement with NeuroOne and OSOK Acquisition Company to acquire NeuroOne. The transactions
contemplated by the merger agreement were consummated on July 20, 2017 and, pursuant to the terms of the merger agreement, (i)&nbsp;all
outstanding NeuroOne Shares were exchanged for Company Shares based on the Exchange Ratio of 17.0103706 Company Shares for every
one NeuroOne Share, (ii)&nbsp;all NeuroOne Options were replaced with options (&ldquo;Company Options&rdquo;) based on the Exchange
Ratio, with corresponding adjustments to their respective exercise prices, (iii) all NeuroOne Warrants were replaced with Company
Warrants and (iv) we assumed the outstanding Convertible Notes of NeuroOne. Accordingly, we acquired 100% of NeuroOne, Inc. in
exchange for the issuance of shares of our common stock and NeuroOne became our wholly-owned subsidiary. Our sole business is
the business of NeuroOne. Our management&rsquo;s discussion and analysis below is based on the financial results of NeuroOne. Except
as otherwise indicated herein, all share and per share information in this &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; section gives retroactive effect to the exchange of NeuroOne Shares, NeuroOne Options
and NeuroOne Warrants for Company Shares, Company Options and Company Warrants, respectively, in the Acquisition, as well as the
corresponding exercise price adjustments for such Company Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Predecessor
NeuroOne, Inc. and NeuroOne LLC </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLC was formed on December 12, 2013 and operated as a limited liability company until it was merged with and into NeuroOne on
October 27, 2016 with NeuroOne as the surviving entity of the merger. NeuroOne was formed on October 7, 2016 under different ownership
than the LLC. As a result of the merger, all of the properties, rights, privileges, powers and franchises of the LLC vested in
NeuroOne, and all debts, liabilities and duties of the LLC became the debts, liabilities and duties of NeuroOne with the exception
of the Company&rsquo;s license agreement with Wisconsin Alumni Research Foundation (&ldquo;WARF&rdquo;) which required WARF&rsquo;s
approval for transfer. The purpose of the merger was to change the jurisdiction of NeuroOne&rsquo;s incorporation from Minnesota
to Delaware, change the ownership of the LLC&rsquo;s underlying assets, and to convert from a limited liability company to a corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
and the LLC were not entities under common control. As the LLC did not have an integrated set of activities that contained the
required complement of inputs, processes and outputs to be considered a business, the Merger was accounted for as an asset acquisition
as prescribed under ASC 805 &ndash; <I>Business Combinations</I>. As such, the activities of NeuroOne and the LLC were not combined
and are shown separately in the accompanying financial statements included in this Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue. We do not expect to generate revenue unless or until we develop, obtain regulatory approval
for and commercialize our cortical strip, grid electrode and depth electrode technology. If we fail to complete the development
of our cortical strip, grid electrode and depth electrode technology, or any other product candidate we may pursue in the future,
in a timely manner, or fail to obtain regulatory approval, we may never be able to generate any revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
and Administrative</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of personnel-related costs including stock-based compensation for personnel in functions
not directly associated with research and development activities. Other significant costs include legal fees relating to corporate
matters, intellectual property costs, professional fees for consultants assisting with regulatory, clinical, product development
and financial matters, and product costs. We anticipate that our general and administrative expenses will significantly increase
in the future to support our continued research and development activities, potential commercialization of our cortical strip,
grid electrode and depth electrode technology, if approved, and the increased costs of operating as a public company. These increases
will include increased costs related to the hiring of additional personnel and fees for legal and professional services, as well
as other public-company related costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist of expenses incurred in performing research and development activities in developing our cortical
strip, grid electrode and depth electrode technology. Research and development expenses include compensation and benefits for
research and development employees including stock-based compensation, overhead expenses, cost of laboratory supplies, clinical
trial and related clinical manufacturing expenses, costs related to regulatory operations, fees paid to consultants, and other
outside expenses. Research and development costs are expensed as incurred and costs incurred by third parties are expensed as
the contracted work is performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to significantly increase over the next several years as we develop our cortical
strip, grid electrode and depth electrode technology and conduct preclinical testing and clinical trials and will depend on the
duration, costs and timing to complete our preclinical programs and clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interest
Expense</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense primarily consists of amortized discount costs related to our Short-Term Notes and Convertible Notes and interest costs
related to the Convertible Notes we issued between November 2016 and September 2017. The Convertible Notes bear interest at a
fixed rate of 8% per annum, compounding annually.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense also includes the change in the fair value of warrant liability and the premium conversion derivative during the particular
period. The change in fair value of the warrant liability and premium conversion derivative results from the marking to market
at the end of every reporting period of the fair value related to the warrants and premium conversion derivative to purchase shares
of common stock issued in connection with the issuance of the Convertible Notes. The fair value of the warrant liability will
fluctuate based on the change in the price of our common stock in the public markets until these warrants are exercised or expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
comparison purposes, the results of operations for NeuroOne for the three and nine month periods ended September 30, 2017 is compared
to the operating results for the LLC for the three and nine month periods ended September 30, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of the Three Months Ended September 30, 2017 and 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the results of operations of NeuroOne and the LLC for the three-months ended September 30, 2017 and
2016, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LLC</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2016</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period-to-&nbsp;Period
    Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: 0in; padding-left: 0.125in">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">622,141</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,941</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">620,200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">271,651</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">271,651</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Operating Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(893,792</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,941</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(891,851</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Other expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(515,377</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,635</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(511,742</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,409,169</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,576</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,403,593</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and administrative expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$622,141 for the three months ended September 30, 2017, compared to $1,941 for the three months ended September 30, 2016. The increase
was primarily due to an increase in salary-related expenses of $331,539 for additional staffing to support the increased level
of commercialization and development activities and legal and accounting expenses of $290,602 primarily related to the Acquisition.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and development expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $271,651 for the three months ended September 30, 2017, compared to $0 for the three months ended
September 30, 2016. The increase was primarily due to an increase in salary-related expenses, inclusive of stock-based compensation
expense of $ 64,945, and development materials and supplies to support the increased level of development activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;Interest
expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense, for the three months ended September 30, 2017 was $515,377 consisting of interest expense of $32,503, fair market value
adjustments of the warrant and derivative liabilities of $21,953, and amortization of debt discount costs of $460,921 related
to the Short-Term Notes and Convertible Notes. There were no outstanding Short-Term Notes and Convertible Notes in the prior year.
The interest expense in the comparable prior year period related to interest on the Mayo intellectual milestone payments owed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of the Nine Months Ended September 30, 2017 and 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the results of operations of NeuroOne, and the LLC for the nine months ended September 30, 2017 and
2016, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LLC</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2016</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period-to-&nbsp;Period Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: 0in; padding-left: 0.125in">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,798,131</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,009</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,792,122</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,408</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,408</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Operating Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,298,539</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,009</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,292,530</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0in; padding-left: 0in">Other expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0.125in">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,134,529</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,698</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,123,831</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Net loss and comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,433,068</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(16,707</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,416,361</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and administrative expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$1,798,131 for the nine months ended September 30, 2017, compared to $6,009 for the nine months ended September 30, 2016. The increase
was primarily due to an increase in salary-related expenses of $927,587 for additional staffing, inclusive of stock-based compensation
of $2,065, to support the increased level of commercialization and development activities, legal and accounting expenses of $820,544
and investment banker fees of $50,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and development expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses were $500,408 for the nine months ended September 30, 2017, compared to $0 for the nine months ended
September 30, 2016. The increase was primarily due to an increase in salary-related expenses, inclusive of stock-based compensation
of $74,729, and development materials and supplies to support the increased level of development activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Interest
expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense for the nine months ended September 30, 2017 was $1,134,529, consisting of interest expense of $76,359, fair market value
adjustments of the warrant and derivative liabilities of $77,505, amortization of debt discount costs of $943,427 and warrant
issuance costs of $38,119 related to the Short-Term Notes and Convertible Notes offset by an $881 interest credit adjustment related
to Mayo intellectual milestone payments. There were no outstanding Short-Term Notes and Convertible Notes in the prior year. The
interest expense in the comparable prior year period related to interest on the Mayo intellectual milestone payments owed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Capital
Resources</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2017, our principal source of liquidity consisted of cash deposits of $70,029. We have not generated any revenue,
and we anticipate that we will continue to incur losses for the foreseeable future. We anticipate that our expenses will increase
substantially as we develop our cortical strip, grid electrode and depth electrode technology and pursue pre-clinical testing
and clinical trials, seek regulatory approvals, contract to manufacture any products, establish our own sales, marketing and distribution
infrastructure to commercialize our cortical strip, grid electrode and depth electrode technology under development, if approved,
hire additional staff, add operational, financial and management systems and operate as a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary sources of cash, since inception,
have been short-term financing instruments and associated warrants in the amount of $303,000, and proceeds from the issuance of
the Convertible Notes and Warrants. From November 2016 to June 2017, we issued Convertible Notes (in aggregate principal amount
of $1,625,120) and warrants for aggregate net proceeds of $1,511,510.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Convertible Notes bear interest at
a fixed rate of 8% per annum and require us to repay the principal and accrued and unpaid interest thereon at the earlier of November
21, 2017 or the consummation of the next equity or equity-linked round of financing resulting in more than $3 million in gross
proceeds. If such a financing occurs before November 21, 2017, the outstanding principal and accrued and unpaid interest on the
Convertible Notes shall automatically convert into the securities issued by us in such financing based on the greater number of
such securities resulting from either (i) the outstanding principal and accrued interest on the Convertible Notes divided by $1.80
or (ii) the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per
security in such financing. If a change of control transaction or initial public offering occurs prior to such a financing, the
Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the Convertible Notes, either
become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately
prior to such transaction at a price per share equal to the lesser of (i) the per share value as determined by our Board of Directors
as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms&rsquo; length
transaction or (ii) at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation
with another entity in which our stockholders do not own more than 50% of the outstanding voting power of the surviving entity
or the disposition of all or substantially all of our assets. The Convertible Notes are unsecured. If we fail to complete a qualified
equity financing by November 21, 2017, the Convertible Notes will be immediately due and payable on such date. We may seek to amend
the Convertible Notes in order to extend the maturity date of the Convertible Notes, however, we may be unable to enter into such
amendments.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Warrant grants the holder the option to purchase the number of shares issuable upon the conversion of the Note held by such holder.
The terms of the Warrants were amended in June 2017 to be exercisable only in the event of conversion of the outstanding principal
and accrued interest on the related Convertible Notes. Prior to such amendment, the Warrants were immediately exercisable into
common stock and the number of shares were not fixed and determinable at the issuance date. No Warrants were exercised prior to
the amendment. The Warrants have been accounted for as a liability at fair value. Following such amendment, the amount of warrant
shares to be issued are now fixed to the number of shares of common stock to be received by the holder upon conversion of such
holder&rsquo;s Convertible Note, and to an exercise price equal to the price at which the Convertible Notes convert into common
shares. However, the warrants still have price protections that result in the accounting for these Warrants as a liability at
fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the private placement of Convertible Notes and Warrants, we paid the placement agent a cash fee of $113,610 (8%
of the gross proceeds received to date from certain Note and Warrant investors) and are obligated to issue to the placement agent
a Warrant to purchase shares of common stock (or common stock equivalents) in an amount equal to 8% of the common stock purchased
by certain investors in the private placement, which Warrant is expected to have an exercise price of $2.00 per share of Company
common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants (other than the placement agent Warrant), after the amendment in June 2017, are exercisable following the conversion
of the Convertible Notes and expire on November 21, 2021. The exercise price and number of the shares of our common stock issuable
upon exercising the Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split,
recapitalization, reorganization, business combination or similar transaction, as described therein. In addition, the exercise
price of the Warrants (but not those issued to the placement agent) is subject to reduction of the exercise price if we subsequently
issue common stock or equivalents at an effective price less than the current exercise price of such Warrants. The placement agent
Warrants will be immediately exercisable and expire five years from the date of issuance. The placement agent Warrant is issuable
upon the closing of the Convertible Note and Warrant financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also received cash gross proceeds from short-term financings consisting of an unsecured loan for $50,000 in November 2016 and
$253,000 upon issuance of the Short-Term Notes in August 2017. We incurred no fees or interest costs related to the unsecured
loan and repaid it in full in February 2017. With regard to the Short-Term Notes, additional warrants in the amount of 126,500
warrant shares will be issuable upon maturity in February 2018, and no additional interest costs or fees are expected to be incurred
in connection with the Short-Term Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 4, 2017, we entered into the Subscription Agreement and executed a Private Placement agreeing to issue and sell to the
Subscribers, 8% convertible promissory notes and warrants to purchase shares of our common stock (2017 Convertible Notes).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The initial closing of the Private Placement
was consummated on October 4, 2017, and, on that date, we issued Notes in an aggregate principal amount of $150,000 to the Subscribers.
Between November 2, 2017 and November 7, 2017, the Company entered into Subscription Agreements with additional Subscribers, and
issued Notes in a principal amount of $215,000 to those Subscribers. We may conduct any number of additional closings so long as
the final closing occurs on or before the five-month anniversary of the initial closing date and the amount does not exceed $1,000,000
or a higher amount determined by our Board of Directors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
placement agent under the Private Placement is also entitled to receive a warrant to purchase common stock in an amount equal
to 10 percent of the common stock (common stock equivalents) purchased by the Subscribers. Such warrant, if issued will have an
exercise price determined in relation to the pricing of the subsequent financing and will be immediately exercisable once issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Funding
Requirements and Outlook</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no current source of revenue to sustain our present activities, and we do not expect to generate revenue until, and unless,
the FDA or other regulatory authorities approve our cortical strip, grid electrode and depth electrode technology under development
and we successfully commercialize our cortical strip, grid electrode and depth electrode technology. Until such time, if ever,
as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity and debt financings
as well as collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest
of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring
dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third-party
partners, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that
may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or through collaborations,
strategic alliances or licensing arrangements when needed, we may be required to delay, limit, reduce or terminate our product
development, future commercialization efforts, or grant rights to develop and market our cortical strip, grid electrode and depth
electrode technology that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
independent registered public accounting firm included an explanatory paragraph in its report on NeuroOne&rsquo;s financial statements
as of and for the years ended December 31, 2015 and 2016, noting the existence of substantial doubt about our ability to continue
as a going concern. This uncertainty arose from management&rsquo;s review of our results of operations and financial condition and its
conclusion that, based on our operating plans, we did not have sufficient existing working capital to sustain operations through
December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2017, the outstanding
principal and accrued and unpaid interest on the Convertible Notes totaled $1,705,834 and the outstanding principal on the Short-Term
Notes was $253,000. If we fail to complete an equity financing by November 21, 2017, the Convertible Notes will be immediately
due and payable on such date and we will not have sufficient cash to pay the principal and accrued and unpaid interest thereon.
In addition, the Short-Term Notes mature on February 18, 2018 and we may not have sufficient cash to pay the principal thereon.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreements with WARF and Mayo that require us to make certain milestone and royalty payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into an Exclusive Start-Up Company License Agreement with WARF (the &ldquo;WARF License&rdquo;) pursuant to which
WARF has granted us an exclusive license, or the WARF License, to make, use and sell, in the United States only, products that
employ certain licensed patents for a neural probe array or thin-film micro electrode array and method. In exchange for the license,
we have agreed to pay WARF a one-time fee of $120,000 (representing a license fee and reimbursement for costs incurred by WARF
in maintaining the licensed patents) upon the earliest to occur of certain events related to the Company raising a minimum amount
of financing, a change of control or our revenue reaching a threshold amount. We have also agreed to pay WARF a royalty equal
to a single-digit percentage of our product sales pursuant to the WARF License, with a minimum annual royalty payment of $50,000
for 2019, $100,000 for 2020 and $150,000 for 2021 and each calendar year thereafter that the WARF License is in effect. If we
or any of our sublicenses contest the validity of any licensed patent, the royalty rate will be doubled during the pendency of
such contest and, if the contested patent is found to be valid and would be infringed by us if not for the WARF License, the royalty
rate will be tripled for the remaining term of the WARF License.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to diligently develop, manufacture, market and sell products under the WARF License in the United States during the
term of the agreement and, specifically, that we will submit a business plan to WARF by February 1, 2018 and file an application
for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate this license in the event that we fail to
meet these milestones on 30 days&rsquo; written notice, if we default on the payments of amounts due to WARF or fail to timely
submit development reports, actively pursue our development plan or breach any other covenant in the WARF License and fail to
remedy such default in 90 days or in the event of certain bankruptcy events involving us. WARF may also terminate this license
(i) on 90 days&rsquo; notice if we fail to have commercial sales of one or more FDA-approved products under the WARF License by
March 31, 2019 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four calendar
quarters. The WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder
remain. We expect the latest expiration of a licensed patent to occur in 2030.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, WARF reserves the right to grant non-profit research institutions and government agencies non-exclusive licenses to
practice and use the inventions of the licensed patents for non-commercial research purposes, and we grant WARF a non-exclusive,
sub licensable, royalty-free right and license for non-commercial research purposes to use improvements to the licensed patents.
In the event that we discontinue use or commercialization of the licensed patents or improvements thereon, we must grant WARF
an option to obtain a non-exclusive, sub-licensable royalty-bearing license to use the improvements for commercial purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a license and development agreement (the &ldquo;Mayo Development Agreement&rdquo;) with the Mayo Foundation
for Medical Education and Research (&ldquo;Mayo&rdquo;) with to license worldwide (i) certain know how for the development and
commercialization of products, methods and processes related to flexible circuit thin film technology for the recording of tissue
and (ii) the products developed therefrom, and to partner with Mayo to assist the Company in the investigation, research application,
development and improvement of such technology. Mayo has agreed to assist us by providing access to certain individuals at Mayo,
or the Mayo Principal Investigators, in developing our cortical thin film flexible circuit technology, including prototype development,
animal testing, protocol development for human and animal use, abstract development and presentation and access to and license
of any intellectual property that the Mayo Principal Investigators develop relating to the procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not any such technology, product, method, process, device or delivery system is developed, we agreed, in consideration for
Mayo&rsquo;s efforts under the Mayo Development Agreement, as amended, to pay Mayo a cash payment of approximately $92,000 on
the earlier of December 31, 2017 or the date we raise a minimum amount of financing, and on May 25, 2017, prior to the closing
of the Acquisition, NeuroOne, Inc. issued Mayo 50,556 shares of NeuroOne, Inc. common stock pursuant to a Subscription Agreement.
Finally, we have agreed to pay Mayo a royalty equal to a single-digit percentage of our product sales pursuant to the Mayo Development
Agreement. Mayo may purchase any developed products licensed under the Mayo Development Agreement at the best price offered by
us to the end user in the prior year. The Mayo Development Agreement generally will expire in October 2034, unless the Mayo know-how
and improvements under the Mayo Development Agreement remain in use, and the Mayo Development Agreement may be terminated by Mayo
for cause or under certain circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of our past breach of each of the WARF License and the Mayo Development Agreement, WARF and Mayo may be less likely to waive future
defaults or breaches or further amend the agreements in the future, to the extent we request any waiver or amendment. For more
information, see &ldquo;Risk Factors&mdash;Risks Relating to our Business&rdquo;&mdash; in Part II, Item 1A in this Report. We
depend on intellectual property licensed from Wisconsin Alumni Research Foundation for our technology under development, and the
termination of this license would harm our business and we depend on our partnership with Mayo Foundation for Medical Education
and Research to license certain know how for the development and commercialization of our technology. Termination of this partnership
would harm our business, and even if this partnership continues, it may not be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our existing cash and cash equivalents
will not be sufficient to fund our operating expenses throughout fiscal 2017. To continue to fund operations, we will need to
secure additional funding and modify terms of some of our existing debt. We may obtain additional financing in the future through
the issuance of our common stock, through other equity or debt financings or through collaborations or partnerships with other
companies. We may not be able to raise additional capital on terms acceptable to us, or at all. Further, we may not be able to
modify terms of some of our existing debt that may come due, and any failure to raise capital or to amend existing debt that may
be due as and when needed could compromise our ability to execute on our business plan.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of our cortical strip, grid electrode and depth electrode technology is subject to numerous uncertainties, and we
have based these estimates on assumptions that may prove to be substantially different than we currently anticipate and could
use our cash resources sooner than we expect. Additionally, the process of developing medical devices is costly, and the timing
of progress in pre-clinical tests and clinical trials is uncertain. Our ability to successfully transition to profitability will
be dependent upon achieving a level of product sales adequate to support our cost structure. We cannot assure you that we will
ever be profitable or generate positive cash flow from operating activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash flows for each of the periods set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For&nbsp;the&nbsp;Nine Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne,&nbsp;Inc.</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2017</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeuroOne&nbsp;LLC</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2016</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0in; padding-left: 0in">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,509,669</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0in; padding-left: 0in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,057,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0in; padding-left: 0in">Net decrease in cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(452,188</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
cash used in operating activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities was
$1,509,669 for the nine months ended September 30, 2017, which consisted of a net loss of $3,433,068 partially offset primarily
by non-cash interest, stock-based compensation, discount amortization, warrant issuance costs and revaluation of premium debt conversion
derivative on the Convertible Notes totaling $1,234,623 in the aggregate, accrued expenses of $642,099, and prepaid expenses of
$46,677.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $0 for the nine months ended September 30, 2016. There was limited activity during the nine
month period ended September 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
cash provided by financing activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $1,057,481 for the nine months ended September 30, 2017, which consisted of $1,107,481
in net proceeds received upon the issuance of the Short-Term Notes, Convertible Notes and Warrants during the nine month period
partially offset by the $50,000 repayment of a short-term unsecured loan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had no cash provided by financing activities in the nine months ended September 30, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Critical
Accounting Policies</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&rsquo;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial
statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America,
or GAAP. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that
affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities as of the dates of the
balance sheets and the reported amounts of revenue and expenses during the reporting periods. In accordance with GAAP, we base
our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances
at the time such estimates are made. Actual results may differ materially from our estimates and judgments under different assumptions
or conditions. We periodically review our estimates in light of changes in circumstances, facts and experience. The effects of
material revisions in estimates are reflected in our consolidated financial statements prospectively from the date of the change
in estimate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our significant accounting policies are more fully described in the notes to our consolidated financial statements appearing elsewhere
in this Report, we believe the following are the critical accounting policies used in the preparation of our consolidated financial
statements that require significant estimates and judgments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
Value of Financial Instruments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the financial
statements on a recurring or nonrecurring basis adhering to the Financial Accounting Standards Board (FASB) fair value hierarchy
that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted
quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements
involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 41pt; text-align: justify; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 Inputs:
    Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement
    date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 Inputs:
    Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly,
    for substantially the full term of the asset or liability.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 Inputs:
    Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available,
    thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement
    date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0 0in 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2017 and December 31, 2016, the fair values of cash, other assets, accounts payable, accrued expenses and the
unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated
fair value of the short-term promissory notes and convertible promissory notes was based on amortized cost which was deemed to
approximate fair value. The fair value of the warrant liability and the premium conversion derivative associated with the convertible
promissory notes was based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions
representing expected returns by market participants for similar instruments which were based on Level&nbsp;3 inputs. There were
no transfers between fair value hierarchy levels during the nine-month period ended September 30, 2017, or during the year ended
December 31, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Intellectual
Property</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into two licensing agreements with major research institutions, which allow for access to certain patented technology
and know-how. Milestone payments under those agreements are capitalized and amortized to general and administrative expense over
the expected useful life of the acquired technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Impairment
of Long-Lived Assets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes
in circumstances indicate that the carrying value of these assets may not be recoverable. We assess the recoverability of long-lived
assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future
cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the
carrying value and the fair value of the impaired asset. Through September 30, 2017, we had not impaired any long-lived assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Debt
Issuance Costs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt
issuance costs are recorded as a reduction of the short-term promissory notes and convertible promissory notes. Amortization of
debt issuance costs is calculated using the straight-line method over the term of the short-term promissory notes and convertible
promissory notes, which approximates the effective interest method, and is recorded in interest expense in the statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Costs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are charged to expense as incurred. Research and development expenses may comprise costs incurred in performing
research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials
as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services
that will be used in future research and development activities are expensed when the activity is performed or when the goods
have been received, rather than when payment is made, in accordance with ASC 730,&nbsp;<I>Research and Development</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Warrant
Liability</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
issued warrants to purchase equity securities in connection with the issuance of the convertible promissory notes. We account
for these warrants as a liability at fair value for each reporting period as the number of shares were not fixed and determinable
at the issuance date for the warrants associated with the convertible promissory notes. Additionally, issuance costs associated
with the warrants are expensed as incurred and reflected as interest expense in the accompanying consolidated statement of operations.
We will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise or expiration of
the warrants, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will
be classified in stockholders&rsquo; (deficit) equity provided that there are sufficient authorized and unissued shares of common
stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future
change in fair value of the warrant liability will be recognized as a component of interest expense in the consolidated statement
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Premium
Debt Conversion Derivative</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives
that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its
host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded
to interest expense over the term of the host debt instrument using the straight line method which approximates the effective
interest method. The separated embedded derivative is accounted for separately on a fair market value basis. We record the fair
value changes of a separated embedded derivative to interest expense at each reporting period. We issued Convertible Notes that
contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.25 per common share. We
also issued 2017 Convertible Notes that contained a 125% conversion premium in the event that a qualified financing occurs at
a price under $2.8125 per common share. We determined that the redemption feature under the respective notes qualified as an embedded
derivative and was separated from its debt host.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Income
Taxes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For NeuroOne, income taxes are accounted
for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base
and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred
tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset
will not be realized.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne, Inc. on October 27,
2016. As such, it was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included
in the financial statements for the period from January 1, 2016 through October 26, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Loss Per Share</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings or loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common
stock outstanding during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted
earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average
shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive.
Our stock options, Convertible Notes and warrants are considered common stock equivalents for this purpose. Diluted earnings is
computed utilizing the treasury method for the stock options and warrants. Diluted earnings with respect to the Convertible Notes
utilizing the if-converted method was not applicable during the three and nine month periods ended September 30, 2017 as no conditions
required for conversion had occurred during this period. No incremental common stock equivalents were included in calculating
diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and nine month
periods ended September 30, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLC was a single-member LLC for which no units were outstanding. Accordingly, earnings per share is not presented for the LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fair
Value of Common Stock on Grant Dates</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to the Acquisition, we were a private company with no active public market for our common stock. Therefore, we have historically
periodically determined for financial reporting purposes the estimated per share fair value of our common stock at various dates
using contemporaneous valuations performed in accordance with the guidance outlined in the American Institute of Certified Public
Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, also known as the Practice
Aid. We performed these contemporaneous valuations on an as-needed basis. In conducting the contemporaneous valuations, we considered
all objective and subjective factors that we believed to be relevant for each valuation conducted, including our best estimate
of our business condition, prospects and operating performance at each valuation date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Common
Stock Valuation Methodology</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
contemporaneous valuations that we conducted were prepared in accordance with the guidelines in the Practice Aid, which prescribes
several valuation approaches for setting the value of an enterprise, such as the asset, market and income approaches, and various
methodologies for allocating the value of an enterprise to its common stock. In determining the fair value of the common stock
underlying the stock options granted, our Board of Directors has historically considered, among other things, the most recent
estimate of fair value provided by an independent third-party valuation specialist and our assessment of additional objective
and subjective factors to determine the common stock fair market value each valuation date. The following factors, among others,
were considered:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our financial condition and operating results,
    including our projected results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our stage of development and business strategy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the financial condition and operating results
    of comparable publicly owned companies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">worldwide economic conditions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our recent securities transactions; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the likelihood of a liquidity event such as
    an initial public offering, a merger or the sale of our company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are significant judgments and estimates inherent in the determination of fair value of our common stock, including the contemporaneous
valuations. These judgments and estimates include assumptions regarding our future operating performance, and the determination
of the appropriate valuation methods. If we had made different assumptions, our stock-based compensation expense, net loss and
net loss per common share could have been significantly different.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
each of our contemporaneous valuations, we generally used the asset and market approaches to derive an estimated enterprise value.
The asset approach establishes value based on the cost of reproducing or replacing the property, less economic depreciation due
to physical deterioration, and functional or economic obsolescence, if present and measurable. The particular market approach
utilizes the option pricing method, or OPM, backsolve method to determine our enterprise value. Under this method, an implied
equity value of the company is derived from recent transactions involving the Company&rsquo;s securities in arms-length transactions.
Under the option pricing method, shares are valued by creating a series of hypothetical call options using exercise prices based
on the liquidation preferences and conversion terms of each equity class. The values of the multiple classes of equity are inferred
by analyzing these options and determining the option value attributable to each respective security. We applied a discount to
the valuations due to the lack of marketability of the ordinary shares at the time of issuance. We calculated the discount for
lack of marketability and applied it as appropriate to each allocation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2016, the FASB issued ASU No.&nbsp;2016-01,&nbsp;<I>Financial Instruments&nbsp;&mdash; Overall: Recognition and Measurement
of Financial Assets and Financial Liabilities.</I>&nbsp;The guidance affects the accounting for equity investments, financial
liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance
is effective in the first quarter of fiscal 2018 for public entities and for all other entities in the first quarter of fiscal
2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. We are currently
evaluating the impact of the new guidance on our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2017, the FASB issued ASU 2017-09, <I>Compensation - Stock Compensation (Topic 718):&nbsp;Scope of Modification Accounting
(ASU 2016-09)</I>,&nbsp;which provides guidance about which changes to the terms or conditions of a share-based payment award
require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods
beginning after December 15, 2017. Early adoption is permitted. We are currently evaluating the requirements of this new guidance
and has not yet determined its impact on our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2017, the FASB issued ASU No. 2017-11 (&ldquo;ASU 2017-11&rdquo;), <I>Earnings Per Share, Distinguishing Liabilities from
Equity and Derivatives and Hedging</I>, which changes the accounting and earnings per share for certain instruments with down
round features. The amendments in ASU 2017-11 should be applied using a cumulative-effect adjustment as of the beginning of the
fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&nbsp;15,
2018 for public business entities and after December 15, 2019 for all other entities, including interim periods within those fiscal
years. Early adoption is permitted. We are currently evaluating the requirements of this new guidance and has not yet determined
its impact on our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Off
Balance Sheet Arrangements</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
3. Quantitative and Qualitative Disclosures About Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable for smaller reporting companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
4. Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three months ended September 30, 2017, there were no changes in our internal controls over financial reporting (as defined
in Rule 13a- 15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Evaluation
of Disclosure Controls and Procedures</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of our management, including our chief executive officer and principal financial officer,
we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and Rule 15d-15(e)
promulgated under the Securities Exchange Act of 1934, as amended, as of&nbsp;September 30, 2017. Based on this evaluation, our
chief executive officer and principal financial officer have concluded such controls and procedures to be ineffective as of September
30, 2017&nbsp;to ensure that information required to be disclosed by the issuer in the reports that it files or submits under
the Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and
forms and to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act
is accumulated and communicated to the issuer&rsquo;s management, including its principal executive and principal financial officers,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2017, disclosure controls
and procedures were not effective due to the previously identified material weaknesses disclosed in the risk factors within the
Current Report on Form 8-K filed on July 20, 2017, described below. The material weaknesses related to ineffective internal controls
over the accounting closing and financial reporting process pertaining to certain stock transactions and complicated convertible
debt instruments; insufficient internal personnel resources and technical accounting and reporting expertise within the Company&rsquo;s
financial closing and reporting functions; and due to our small size, the Company&rsquo;s inability to maintain effective internal
controls to assure proper segregation of duties as the same employee was responsible for initiating and recording transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to recruit additional professionals
with the requisite experience and skillset to address these material weaknesses, as our business conditions warrant. However, we
do not currently have adequate cash resources to invest in these additional resources. Accordingly, our remediation plans may be
delayed. Although we believe that these corrective steps, when taken, will enable management to conclude that the internal controls
over our financial reporting are effective when the staff is in place and trained, we cannot provide assurance that these steps
will be sufficient. We may be required to expend additional resources to identify, assess and correct any additional weaknesses
in internal control.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II - OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1. &nbsp;Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we are subject to litigation and claims arising in the ordinary course of business. Other than the letter received
by NeuroOne, Inc. in May 2017 from the former employer of Mark Christianson and Wade Fredrickson claiming, among other things,
certain breaches of non-competition obligations and confidentiality and non-disclosure obligations to such prior employer and
federal and state law by virtue of such officers&rsquo; work for NeuroOne, Inc., we are not currently a party to any material
legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material
adverse effect on our business, operating results or financial condition. See our Current Report on Form 8-K, filed on July 20
(the &ldquo;Acquisition 8-K&rdquo;) and our Current Report on Form 8-K, filed on August 14, 2017 for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1A. &nbsp;Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 45.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Factors
that could cause our actual results to differ materially from those in this Quarterly Report on Form 10-Q are any of the risks
described in our Acquisition 8-K. Any of these factors could result in a significant or material adverse effect on our results
of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may
also impair our business or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material
changes to the risk factors disclosed in our Acquisition 8-K.&nbsp; We may disclose changes to such factors or disclose additional
factors from time to time in our future filings with the SEC.</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the disclosures under &ldquo;Item 3.02 Unregistered Sales of Equity Securities&rdquo; in our Acquisition 8-K and in our Current
Report on Form 8-K, filed on August 23, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
3. &nbsp;Defaults Upon Senior Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 45.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
4. &nbsp;Mine Safety Disclosures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 45.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable to our Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
5. &nbsp;Other Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; text-align: center; margin-bottom: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
6. &nbsp;Exhibits </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 11%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    2.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 88%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex2-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreement
    and Plan of Merger and Reorganization by and among NeuroOne Medical Technologies Corporation, OSOK Acquisition Company and
    NeuroOne, Inc. dated as of July 20, 2017 (incorporated by reference to Exhibit 2.1 on the Registrant&rsquo;s Current Report
    on Form 8-K filed on July 20, 2017).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 10.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417040898/v472061_ex10-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
    Agreement by and between NeuroOne Medical Technologies Corporation and David A. Rosa dated August 4, 2017 (incorporated by
    reference to Exhibit 10.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on August 7, 2017).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 10.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit 10.5 on the Registrant&rsquo;s
    Current Report on Form 8-K filed on July 20, 2017).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 10.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-6.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Promissory Note issued pursuant to Promissory Note and Warrant Subscription Agreement (incorporated by reference to Exhibit
    10.6 on the Registrant&rsquo;s Current Report on Form 8-K filed on July 20, 2017).</FONT></A></TD></TR>

<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 10.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417044643/v473725_ex4-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Amendment to Promissory Note issued pursuant to Promissory Note and Warrant Subscription Agreement (incorporated by reference
    to Exhibit 4.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on August 23, 2017).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    10.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0in; text-indent: 0in"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417044643/v473725_ex4-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Capital Stock Purchase Warrant issued pursuant to Promissory Note and Warrant Subscription Agreement (incorporated by reference
    to Exhibit 4.2 on the Registrant&rsquo;s Current Report on Form 8-K filed on August 23, 2017).</FONT></A></TD></TR>

<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 10.6</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417037533/v468812_ex10-22.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Resignation
    Letter of Amer Samad (incorporated by reference to Exhibit 10.22 on the Registrant&rsquo;s Current Report on Form 8-K filed
    on July 20, 2017).</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 31</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10q0917ex31_neuroone.htm">Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 32</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="f10q0917ex32_neuroone.htm">Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; width: 11%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    101.INS</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 88%; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance Document.</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 101.SCH</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Schema Document.</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 101.CAL</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Calculation Linkbase Document.</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 101.DEF</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Definition Linkbase Document.</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 101.LAB</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Label Linkbase Document.</FONT></TD></TR>
<TR STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD NOWRAP STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 101.PRE</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Presentation Linkbase Document.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt; padding: 0pt 0pt 3pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; text-align: center; margin-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
10-Q</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; text-align: center; margin-bottom: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf
by the undersigned thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: November 14, 2017</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeuroOne
Medical Technologies Corporation&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Dave Rosa</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dave Rosa</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0in; margin-bottom: 0in"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0in 0; text-align: right"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>f10q0917ex31_neuroone.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NEUROONE
MEDICAL TECHNOLOGIES CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXCHANGE
ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SARBANES-OXLEY
ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Dave Rosa, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
I have reviewed this Quarterly Report on Form 10-Q of NeuroOne Medical Technologies Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.
The registrant&rsquo;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)&nbsp;Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report, our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)&nbsp;Disclosed
in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over
financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.
The registrant&rsquo;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.35in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
November 14, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Dave Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dave
    Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
    Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
    Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>f10q0917ex32_neuroone.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT><B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>18
U.S.C. SECTION 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Quarterly Report of NeuroOne Medical Technologies Corporation. (the &ldquo;Company&rdquo;) on Form 10-Q for
the quarter ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
I, Dave Rosa, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; text-align: justify; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; text-align: justify; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
    of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
November 14, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Dave Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dave
    Rosa</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
    Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
    Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>nmtc-20170930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 8.0.1.0 [11/15/2017 01:32:42 AM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:nmtc="http://www.originalsourcemusic.com/20170930"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31"
 xmlns:us-types="http://fasb.org/us-types/2017-01-31"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:utr="http://www.xbrl.org/2009/utr"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="nmtc-20170930.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_Custom_30_Sep_2014T00_00_00_TO_01_Oct_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-30
</xbrli:startDate>
<xbrli:endDate>
2014-10-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementScenarioAxis_PredecessorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_27_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-01
</xbrli:startDate>
<xbrli:endDate>
2016-10-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_07_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-07
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_07_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-07
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_28_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-28
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-06-01
</xbrli:startDate>
<xbrli:endDate>
2017-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-07-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-07-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-08-01
</xbrli:startDate>
<xbrli:endDate>
2017-08-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementScenarioAxis_PredecessorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nmtc:DebtConversionDerivativeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">nmtc:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nmtc:TwoThousandSixteenAndSeventeenPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-10-04
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nmtc:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-10-04
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-01
</xbrli:startDate>
<xbrli:endDate>
2017-10-04
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-10-01
</xbrli:startDate>
<xbrli:endDate>
2017-10-04
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06_Nov_2017T00_00_00_TO_06_Nov_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_10_Nov_2017T00_00_00_TO_10_Nov_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-11-10
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw<8c444c555cT{h>:H4F5HI71;<6J1866H1E5E81;E6FIE=<5:F8 -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">NEUROONE MEDICAL TECHNOLOGIES Corp</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">0001500198</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">false</dei:AmendmentFlag>
<dei:TradingSymbol contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">NMTC</dei:TradingSymbol>
<dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">10-Q</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">2017-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">2017</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Q3</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_10_Nov_2017T00_00_00_TO_10_Nov_2017T00_00_00" unitRef="shares" decimals="INF">7864994</dei:EntityCommonStockSharesOutstanding>
<us-gaap:Cash contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">522217</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">70029</us-gaap:Cash>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">53823</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">7146</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">576040</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">77175</us-gaap:AssetsCurrent>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">180890</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">190637</us-gaap:IntangibleAssetsNetExcludingGoodwill>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">756930</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">267812</us-gaap:Assets>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">264343</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">916734</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:ShortTermBorrowings contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">50000</us-gaap:ShortTermBorrowings>
<us-gaap:ShortTermBorrowings contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">204074</us-gaap:ShortTermBorrowings>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">225197</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1459841</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">137650</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">137650</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">137650</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">441823</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">441823</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">441823</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:DebtInstrumentUnamortizedPremiumCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedPremiumCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">677190</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">3022472</us-gaap:LiabilitiesCurrent>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">345960</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">345960</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">345960</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">774172</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">774172</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">774172</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:WarrantsAndRightsOutstanding>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">1023150</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">3796644</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">31</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">7865</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">119</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">162741</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-266370</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-3699438</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-266220</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-3528832</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">756930</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">267812</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">45000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">5216565</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">7864994</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">5216565</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">7864994</us-gaap:CommonStockSharesOutstanding>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">1941</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">6009</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">622141</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">1798131</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">271651</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">500408</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">8600</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">1941</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">33056</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">6009</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">893792</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">893792</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1918208</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">2298539</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-8600</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">-1941</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">33056</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">-6009</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-893792</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-893792</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-1918208</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-2298539</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-3635</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">-3635</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">10698</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">-10698</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-515377</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-515377</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-1134529</us-gaap:InterestIncomeExpenseNet>
<us-gaap:InterestIncomeExpenseNet contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-1134529</us-gaap:InterestIncomeExpenseNet>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">-12235</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">-5576</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">43754</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">-16707</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-1409169</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-1409169</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">-3052737</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-3433068</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD_per_Share" decimals="2">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD_per_Share" decimals="2">-0.19</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD_per_Share" decimals="2">-0.55</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="0">1658051</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="0">1658051</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">7864994</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="0">7540135</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="0">7369457</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="0">6217076</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:AdjustmentForAmortization contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">5823</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">13368</us-gaap:AdjustmentForAmortization>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">76794</us-gaap:ShareBasedCompensation>
<nmtc:ForgivenessOfShareSubscriptionAgreementForFoundersShares contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</nmtc:ForgivenessOfShareSubscriptionAgreementForFoundersShares>
<nmtc:ForgivenessOfShareSubscriptionAgreementForFoundersShares contextRef="Context_Custom_01_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">9051</nmtc:ForgivenessOfShareSubscriptionAgreementForFoundersShares>
<nmtc:ForgivenessOfShareSubscriptionAgreementForFoundersShares contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">9051</nmtc:ForgivenessOfShareSubscriptionAgreementForFoundersShares>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">284637</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">601794</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">76359</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_07_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">37469</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_3ME_07_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">137564</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">39781</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">213961</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">943427</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">38119</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<nmtc:RevaluationOfPremiumDebtConversionDerivative contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</nmtc:RevaluationOfPremiumDebtConversionDerivative>
<nmtc:RevaluationOfPremiumDebtConversionDerivative contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">90212</nmtc:RevaluationOfPremiumDebtConversionDerivative>
<nmtc:RevaluationOfWarrantLiability contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</nmtc:RevaluationOfWarrantLiability>
<nmtc:RevaluationOfWarrantLiability contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-12707</nmtc:RevaluationOfWarrantLiability>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-46677</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">10884</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">642099</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-1509669</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">253000</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:ProceedsFromShortTermDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">675705</us-gaap:ProceedsFromShortTermDebt>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ProceedsFromIssuanceOfWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">502415</us-gaap:ProceedsFromIssuanceOfWarrants>
<us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
<us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-50000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">38719</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">31920</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">1057481</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">-452188</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">522217</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">70029</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">213961</nmtc:ConversionDerivativeRelatedToConvertiblePromissoryNotes>
<nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes>
<nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">42811</nmtc:AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes>
<nmtc:AccruedIssuanceCostsAttributedToWarrantLiability contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</nmtc:AccruedIssuanceCostsAttributedToWarrantLiability>
<nmtc:AccruedIssuanceCostsAttributedToWarrantLiability contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">38119</nmtc:AccruedIssuanceCostsAttributedToWarrantLiability>
<us-gaap:StockIssued1 contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:StockIssued1>
<us-gaap:StockIssued1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">23115</us-gaap:StockIssued1>
<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 1 &amp;#8211; Organization and Basis of Presentation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On July 20, 2017, NeuroOne Medical Technologies Corporation , a Delaware Corporation, (the &amp;#8220;Company&amp;#8221;), through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&amp;#8220;NeuroOne&amp;#8221;) in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &amp;#8220;Acquisition&amp;#8221;). The Acquisition was accounted for as a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in this transaction. As such, the historical financial statements of NeuroOne and its predecessor NeuroOne LLC (the &amp;#8220;LLC&amp;#8221;) reflect operations of the Company for all periods presented prior to the date of Acquisition. NeuroOne, Inc. was formed on October 7, 2016 and acquired the LLC on October 27, 2016 (the &amp;#8220;Merger&amp;#8221;) as described more fully below. The accompanying condensed consolidated financial statements subsequent to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Subsequent to the Acquisition, the Company&amp;#8217;s operating activities are the same as those of NeuroOne, an early-stage medical technology company, engaged in the development of comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&amp;#8217;s disease, dystonia, essential tremors, and other brain related disorders. The Company is based in Eden Prairie, Minnesota.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Acquisition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The transactions contemplated by the agreement were consummated on July 20, 2017 (the &amp;#8220;Closing&amp;#8221;) and, pursuant to the terms of the agreement, (i) all outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the &amp;#8220;NeuroOne Shares&amp;#8221;) were exchanged for shares of the Company&amp;#8217;s common stock, par value $0.001 per share (the &amp;#8220;Company Shares&amp;#8221;) based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the &amp;#8220;Exchange Ratio&amp;#8221;), resulting in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options, (iii) all warrants of NeuroOne, Inc. were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible promissory notes of NeuroOne. NeuroOne options had been issued pursuant to the NeuroOne 2016 Equity Incentive Plan. Pursuant to the agreement, the Company assumed the NeuroOne 2016 Equity Incentive Plan upon the Closing.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Pursuant to the Acquisition, the Company acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became the Company&amp;#8217;s wholly-owned subsidiary. Also at the Closing, Mr. Samad (the majority owner of the
 Company prior to the Acquisition) tendered for cancellation 3,500,000 Company Shares held by him as part of the conditions to Closing.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;At the time of Acquisition, the Company had authorized 100,000,000 shares of common stock with a par value of $0.001 and 10,000,000 shares of preferred stock with a par value of $0.001.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;All issued and outstanding common stock share amounts, options for common stock and per share amounts contained in the condensed consolidated financial statements were retroactively adjusted to reflect the Exchange Ratio for all periods presented. The number of authorized shares for common and preferred stock and their respective par values per share as of December 31, 2016 reflect those of the Company prior to the Acquisition.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Merger&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The LLC was formed on December 12, 2013 and operated as a limited liability company until it was merged with and into NeuroOne on October 27, 2016 with NeuroOne as the surviving entity of the &amp;#8220;Merger&amp;#8221;. NeuroOne was formed on October 7, 2016 under different ownership than the LLC. As a result of the Merger, all of the properties, rights, privileges, powers and franchises of the LLC vested in NeuroOne, and all debts, liabilities and duties of the LLC became the debts, liabilities and duties of NeuroOne with the exception of the LLC&amp;#8217;s license agreement with Wisconsin Alumni Research Foundation (&amp;#8220;WARF&amp;#8221;) which required WARF&amp;#8217;s approval for transfer (See Note 4 &amp;#8211; Commitments and Contingencies). The purpose of the Merger was to change the jurisdiction of NeuroOne&amp;#8217;s incorporation from Minnesota to Delaware, change the ownership of the LLC&amp;#8217;s underlying assets, and to convert from a limited liability company to a corporation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NeuroOne and the LLC were not entities under common control. As the LLC did not have an integrated set of activities that contained the required complement of inputs, processes and outputs to be considered a business, the Merger was accounted for as an asset acquisition as prescribed under Accounting Standards Codification (ASC) 805 &amp;#8211;&amp;#160;&lt;i&gt;Business Combinations&lt;/i&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The accompanying condensed consolidated financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements may not include all disclosures required by U.S. GAAP; however, the
 Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto for the fiscal year ended December 31, 2016 included in the NeuroOne Current Report on Form 8-K filed on July 20, 2017. The condensed balance sheet at December 31, 2016 was derived from the audited financial statements of NeuroOne.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
<us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 2 &amp;#8211; Going Concern&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception and had an accumulated deficit of $3,699,438 as of September 30, 2017. Prior to the Merger, the LLC also incurred losses since its inception and had cumulative losses of $49,930 as of the date of the Merger. The Company does not have adequate liquidity to fund its operations throughout fiscal 2018 without raising additional funds. These factors raise substantial doubt about its ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this condition. Management intends to seek additional financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Through September 30, 2017, the Company has completed both a $253,000 short-term promissory note financing and a $1,625,120 convertible promissory note financing of a planned $2.5 million subscription. The Company does not have adequate liquidity to fund its operations throughout fiscal 2017 without raising additional funds. Management believes that the currently available resources from the short-term promissory note and convertible promissory note financings combined with funds expected to be raised in the last quarter of fiscal 2017 will be sufficient to enable the Company to meet its operating plan through at least September 30, 2018. However, if the Company is unable to raise additional funds, or the Company&amp;#8217;s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company&amp;#8217;s operations. If management is unable to obtain the necessary capital, it may have to cease operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 3 &amp;#8211; Summary of Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Management&amp;#8217;s Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&amp;#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of September 30, 2017, the Company did not have deposits in excess of federally insured amounts.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Prior to October 27, 2016, the LLC did not maintain a bank account. Any expenses incurred while the LLC was organized as a limited liability company were paid by the sole member of the LLC.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 18pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company&amp;#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px;
 white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As of September 30, 2017 and December 31, 2016, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term promissory notes and the convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and premium conversion derivative associated with the convertible promissory notes was based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments which were based on Level&amp;#160;3 inputs. There were no transfers between fair value hierarchy levels during the three and nine month periods ended September 30, 2017.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space:
 normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of September 30,&amp;#160;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;774,172&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;774,172&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,215,995&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,215,995&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman',
 times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1;
 font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;137,650&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;137,650&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;483,610&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;483,610&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman',
 times, serif; font-size: 10pt;"&gt;The following table provides a roll-forward of the warrant liability and premium conversion derivative measured at fair value on a recurring basis using unobservable level&amp;#160;3 inputs for the nine months ended
 September 30, 2017:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Nine months ended&amp;#160;&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-indent: 0in; padding-left: 0in;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Issuance of warrants in connection with convertible promissory notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;440,919&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(12,707&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;774,172&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Nine months ended&amp;#160;&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-indent: 0in; padding-left: 0in;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Value assigned to the underlying derivative in connection with convertible notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;213,961&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Change in fair value of premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;90,212&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;There
 were no financial instruments measured on a fair value recurring basis during the nine month period ended September 30, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NeuroOne and the LLC have entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Milestone payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company evaluates their long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2017, the Company has not impaired any long-lived assets.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Debt Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Debt issuance costs are recorded as a reduction of the short-term promissory notes and convertible promissory notes. Amortization of debt issuance costs is calculated using the straight-line method over the term of respective short-term and convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses may comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in
 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company issued warrants to purchase equity securities in connection with the issuance of the convertible promissory notes (see Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value as the number of shares were not fixed and determinable at the issuance date. Additionally, issuance costs associated with the warrants are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&amp;#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability will be recognized as a component of interest expense in the condensed consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Premium Debt Conversion Derivative&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&amp;#160; The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative to interest expense at each reporting period. The Company issued convertible promissory notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.25 per common share (see Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). We also issued 2017 Convertible Notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.8125 per common share (see Note 13 &amp;#8211; Subsequent Events). The Company determined that the redemption feature under the convertible promissory notes qualified as an embedded derivative and was separated from its debt host.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;For NeuroOne, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size:
 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;"&gt;The LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne on October 27, 2016. As such, it was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included in the financial statements for the period from January 1, 2016 through October 26, 2016.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The LLC was a single-member LLC for which no units were outstanding. Accordingly, earnings per share is not presented for the LLC.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For NeuroOne, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&amp;#8217;s stock options, convertible promissory notes and warrants are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the stock options and warrants. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the three and nine months ended September 30, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and nine months ended September 30, 2017.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and nine month periods ended September 30, 2017:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1395px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times,
 serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 125px; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;"&gt;1,074,181&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;365,716&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In January 2016, the FASB issued ASU No.&amp;#160;2016-01,&amp;#160;&lt;i&gt;Financial Instruments&amp;#160;&amp;#8212; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2018 for public entities and for all other entities in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In May 2017, the FASB issued ASU 2017-09,&amp;#160;&lt;i&gt;Compensation - Stock Compensation (Topic 718):&amp;#160;Scope of Modification Accounting (ASU 2016-09)&lt;/i&gt;,&amp;#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In July 2017, the FASB issued ASU No. 2017-11,&amp;#160;&lt;i&gt;Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging&lt;/i&gt;, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&amp;#160;15, 2018 for public business entities and after December 15, 2019 for all other entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 4 &amp;#8211; Commitments and Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;WARF License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On October 1, 2014, the LLC entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (&amp;#8220;WARF&amp;#8221;) for WARF&amp;#8217;s neural probe array and thin film electrode technology (the &amp;#8220;2014 WARF Agreement&amp;#8221;). The LLC was to make $110,000 in milestone payments depending on achievement of certain development and approval milestones or within twelve months of signing the 2014 WARF Agreement. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC was to pay royalties to WARF on a percentage of net sales of products of the licensed technology. Under the terms of the 2014 WARF Agreement, amounts that remained unpaid more than 30 days after they were due, accrued interest at 1 percent per month. Milestone payments due in 2015 were not made to WARF. From October 27, 2016 until the 2014 WARF Agreement was amended as described below, the LLC was in default under the 2014 WARF Agreement. In addition, the LLC was not able to transfer the rights and obligations under the 2014 WARF Agreement to NeuroOne at the time of the Merger (October 27, 2016) without the consent of WARF, which was received when the 2014 WARF Agreement was amended in February 2017 as described below. In connection with the Merger and in accordance with ASC 805-50, NeuroOne estimated the fair value of consideration payable to WARF and recorded an intangible asset of $90,000 with a corresponding accrued expense.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;This agreement was subsequently amended in February 2017 (as so amended, the &amp;#8220;2017 WARF Agreement&amp;#8221;) whereby WARF consented to the transfer of the rights and obligations under the license agreement from the LLC to NeuroOne (which are now the Company&amp;#8217;s rights and obligations, following the Acquisition). In the 2017 WARF Agreement, a contingent payment amount of $120,000 is due in the event that the Company completes a qualified financing. The Company is also obligated to pay royalties to WARF based on a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for calendar years 2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the 2017 WARF Agreement. Subject to earlier termination, the WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder remain. The Company expects the latest expiration of a licensed patent to occur in 2030. The 2017 WARF Agreement is also subject to certain cancellation provisions with 90 days&amp;#8217; notice should the Company elect not to continue to use the licensed technology.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company has agreed to diligently develop, manufacture, market and sell products under the WARF License in the United States during the term of the agreement and, specifically, that the Company will submit a business plan to WARF by February 1, 2018 and file an application for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate the 2017 WARF Agreement in the event that the Company fails to meet these milestones on 30 days&amp;#8217; written notice, if the
 Company defaults on the payments of amounts due to WARF or fails to timely submit development reports, actively pursue the development plan or breaches any other covenant in the 2017 WARF Agreement and fails to remedy such default in 90 days or in the event of certain bankruptcy events involving the Company. WARF may also terminate this license (i) on 90 days&amp;#8217; notice if the Company fails to have commercial sales of one or more FDA-approved products under the 2017 WARF Agreement by March 31, 2019 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four calendar quarters.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Mayo Agreement&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On October 3, 2014, the LLC entered into an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&amp;#8220;Mayo&amp;#8221;) related to certain intellectual property and development services for thin film electrode technology (&amp;#8220;2014 Mayo Agreement&amp;#8221;). The LLC was to make milestone payments depending on achievement of certain development and approval milestones and sales targets, none of which were met as of December 31, 2015. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC was to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of the 2014 Mayo Agreement, set to expire May 25, 2037. Also, the LLC was obligated to issue common stock to Mayo if certain events occurred. Upon the LLC&amp;#8217;s Merger with NeuroOne on October 27, 2016, the rights under the 2014 Mayo Agreement transferred to NeuroOne, and certain milestones were attained. Therefore, NeuroOne recorded $300 related to 10,000 shares of common stock issued to Mayo and $91,709 for the intellectual property. Milestone payments due under the 2014 Mayo Agreement and accrued were $91,709 as of September 30, 2017 and December 31, 2016. Under the terms of the 2014 Mayo Agreement, amounts that remained unpaid accrued interest at 2 percent above the prime rate. Milestone payments due in 2016 were not made to Mayo. As such, prior to the amendment of the 2014 Mayo Agreement in May 2017), NeuroOne was in default under the 2014 Mayo Agreement. Mayo and NeuroOne amended and restated the 2014 Mayo Agreement in May 2017 (as so amended and restated, the &amp;#8220;2017 Mayo Agreement&amp;#8221;). Pursuant to the 2017 Mayo Agreement, NeuroOne issued 50,556 shares of common stock to Mayo to settle the amount of common stock NeuroOne was previously obligated to issue under the 2014 Mayo Agreement and to amend the terms of the 2014 Mayo Agreement. NeuroOne recorded an additional $23,115 to intangible assets related to the fair value of the 2017 stock issuance to Mayo. As a part of the 2017 Mayo Agreement, as amended in November 2017, the $91,709 milestone payment is to be paid upon the earlier of a qualified financing or December 31, 2017.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NeuroOne received a letter in May 2017 from the former employer of certain employees of NeuroOne, claiming that NeuroOne and those individuals have wrongfully used or disclosed alleged trade secrets of the former employer and that the individuals breached non-competition or non-solicitation agreements with such party. The Company and the individuals intend to vigorously defend against these claims, if litigation results.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 5 &amp;#8211; Intangibles&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Intangible assets consisted of the following at September 30, 2017:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: center; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Useful Life&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: center; text-indent: 0in; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1191px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;License agreement, October 27, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 173px; text-align: center; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;12-13 years&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 141px; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;182,159&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Less: amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch:
 normal;"&gt;&lt;font style="font-family:
 'times new roman', times, serif; font-size: 10pt;"&gt;(1,269&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Net Intangibles, December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;180,890&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;License agreement amendment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;23,115&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Less: amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(13,368&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Net Intangibles, September 30, 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font:
 10pt/normal 'times new roman', times, serif; padding: 0in; text-align:
 right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;190,637&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Amortization expense was $4,264 and $13,368 for NeuroOne and the Company for the three and nine months ended September 30, 2017, respectively, and $1,941 and $5,823 for the LLC for the three and nine months ended September 30, 2016.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 6 &amp;#8211; Accrued Expenses&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Accrued expenses consisted of the following at September 30, 2017 and December 31, 2016:&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September&amp;#160;30,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Accrued license fees&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;182,009&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;182,009&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Accrued services&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;531,607&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;31,186&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Accrued issuance costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;32,306&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;22,015&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Accrued compensation and payroll related costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;170,812&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;28,252&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;881&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;916,734&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;264,343&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:ShortTermDebtTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 7 &amp;#8211; Short-Term Promissory Notes and Unsecured Loan&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Short-Term Promissory Notes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2017, the Company&amp;#8217;s Board of Directors authorized and the Company issued short-term unsecured promissory notes (the &amp;#8220;Short-Term Notes&amp;#8221;) for aggregate gross proceeds of $253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and are being amortized ratably to interest expense over the term of the Short-Term Notes. For the three and nine month period ended September 30, 2017, discount amortization charged to interest expense related to the issuance costs was $733. The Short-Term Notes do not bear interest on principal and require the Company to repay the principal upon maturity on February&amp;#160;18, 2018.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In addition, upon maturity, under the provisions of the Short-Term Notes, the holders will receive 126,500 common stock purchase warrants upon maturity with a term of 5 years at an exercise price of $1.80 which will be immediately exercisable upon issue. A portion of the proceeds from the Short-Term Notes was allocated to the warrants based on their relative fair value to the underlying Short-Term Notes. The proceeds allocated to the warrants were recorded as additional paid in capital in the accompanying condensed consolidated balance sheets and were discounted from the Short-Term Notes in the amount of $61,496. The relative fair value of the warrants was based on the Black-Scholes method with the following assumptions: risk-free interest rate 1.77 percent; expected volatility 48 percent; expected life 5.5 years; and expected dividend yield 0 percent. The underlying stock price used in the analysis is on a non-marketable basis and is according to a separate 409A valuation analysis. The discount related to the warrants is being amortized to interest expense ratably over the term of the Short-Term Notes which amounted to $14,868 during the three and nine month period ended September 30, 2017.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Unsecured Loan&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NeuroOne received a $50,000 short-term unsecured loan in November 2016 from the placement agent for its convertible promissory note financing (see Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). NeuroOne incurred no fees or interest costs for this temporary loan and it was repaid in full in February 2017.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Convertible Promissory Notes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In November 2016 and then amended in June 2017, the Company&amp;#8217;s Board of Directors authorized the Company to issue convertible promissory notes (the &amp;#8220;Convertible Notes&amp;#8221;) and common stock purchase warrants for aggregate gross proceeds of up to $2.5 million.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As of September 30, 2017, the Company has issued $1,625,120 of Convertible Notes and common stock purchase warrants to investors. The Convertible Notes are unsecured. The Convertible Notes bear interest at a fixed rate of 8 percent per annum and require the Company to repay the principal and accrued and unpaid interest thereon at the earlier of November 21, 2017 or the consummation of the next equity or equity-linked round of financing resulting in more than $3.0 million in gross proceeds (a &amp;#8220;Qualified Financing&amp;#8221;). If a Qualified Financing occurs before November 21, 2017, the outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by November 21, 2017, the Convertible Notes will be immediately due and payable on such date.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;If a change of control transaction or initial public offering occurs prior to a Qualified Financing, the Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the Convertible Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of the per share value as determined by the Company&amp;#8217;s Board of Directors as if in connection with the granting of stock based compensation, or in a private sale to a third party in an arms&amp;#8217; length transaction, or at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&amp;#8217;s stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The warrants granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number of shares issuable upon the conversion of the Convertible Notes, or (ii) if exercised prior to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued interest on the Convertible Note held by such warrant holder divided by $1.80. The warrants were immediately exercisable on the date of
 issuance and expire on November 21, 2021. In June 2017, however, the Company amended the terms of the common stock purchase warrants under the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the related Convertible Notes. The amount of warrant shares to be issued are now fixed to the number of shares of common stock received by the holder of the Convertible Notes upon conversion of such holder&amp;#8217;s Convertible Notes, and to an exercise price equal to the price at which the Convertible Notes convert into common shares.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The warrants were accounted for as a liability because there is no set exercise price. A Monte Carlo simulation model was used to estimate the aggregate fair value of the warrants as of September 30, 2017. Input assumptions used were as follows: risk-free interest rate 1.79 percent; expected volatility 50 percent; expected life 4.14 years; and expected dividend yield 0 percent. The underlying stock price used in the analysis is on a non-marketable basis and is according to a separate 409A valuation analysis.&amp;#160;The convertible promissory note proceeds assigned to the warrants were $440,919 and $345,640 during the nine months ended September 30, 2017 and for the period from October 7, 2016 to December 31, 2016, respectively, which represented their fair value at issuance, and were discounted from the Convertible Notes and reflected as a warrant liability. The discount is being amortized to interest expense over the term of the Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $284,637 and $601,794 for the three and nine months ended September 30, 2017, respectively. The Company recorded the fair value changes of the warrant liability associated with the Convertible Notes to interest expense which amounted to $6,546 and $(12,707) for the three and nine months ended September 30, 2017, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;At the time of their issuance, the Convertible Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes in the amount of $213,961 and $137,564 during the nine months ended September 30, 2017 and during the period from October 7, 2016 to December 31, 2016, respectively. The discount is being amortized to interest expense over the term of the Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $133,367 and $266,848 for the three and nine month period ended September 30, 2017, respectively. The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Convertible Notes to interest expense which amounted to $15,406 and $90,212 for the three and nine months ended September&amp;#160;30, 2017, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &amp;#8220;placement agent warrant&amp;#8221;) which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855 at September 30, 2017 and (iii) legal expenses of $33,450. The placement agent warrant is issuable at the time the private placement transaction closes. The placement agent warrant will be immediately exercisable on the date of issuance and will expire five years following the date of issuance. The placement agent is to receive a placement agent warrant to purchase shares of common stock in an amount equal to 8 percent of the common stock (or common stock equivalents) purchased by investors in the private placement transaction. As of September 30, 2017 and December 31, 2016, the Company has an obligation to issue a placement agent warrant for the purchase of approximately 63,000 and 29,000 shares of common stock, respectively. The Company recorded an issuance cost discount to the Convertible Notes in the amount of $39,781 and $37,469 for the nine months ended September 30, 2017 and for the period from October 7, 2016 to December 31, 2016, respectively, of which $27,317 and $59,184 was amortized to interest expense during the three and nine
 months ended September 30, 2017, respectively. The balance of the issuance costs in the amount of zero and $38,119 was attributed to the common stock purchase warrants and was immediately recorded as interest expense upon issuance during the three and nine months ended September 30, 2017, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The placement agent is also entitled to receive warrants to purchase common stock in an amount equal to 10 percent of the common stock (common stock equivalents) purchased by certain investors in subsequent equity financing rounds (see Note 13 &amp;#8211; Subsequent Events). Such warrants if issued will have an exercise price determined in relation to the pricing of the subsequent financing rounds and will be immediately exercisable once issued.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<nmtc:InvestmentBankerFeeTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 9 &amp;#8211; Investment Banker Fee&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Investment Banker Fee&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NeuroOne paid a $50,000 non-refundable fee to an investment banker in December 2016 to raise equity financing. This fee is reflected in NeuroOne&amp;#8217;s December 31, 2016 balance sheet as a prepaid expense. NeuroOne subsequently concluded that the investment banker was not expected to raise any equity and therefore expensed the fee in March 2017.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</nmtc:InvestmentBankerFeeTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 10 &amp;#8211; Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;NeuroOne formally adopted an equity incentive plan (&amp;#8220;the 2016 Plan&amp;#8221;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition. In addition, the Company adopted a 2017 Equity Incentive Plan (the &amp;#8220;2017 Plan&amp;#8221;) on April 17, 2017. The 2016 and 2017 Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards in the second quarter of 2017. During the three and nine-month period ended September 30, 2017, zero and 365,716 stock options for shares of common stock were granted, respectively, to directors and consultants at a weighted average exercise price of $0.035 per share. The stock options granted during the nine month period ended September 30, 2017 had a weighted average grant date fair value of $0.014 per share with various vesting periods and expire in ten years. In addition, the Company issued zero and 215,453 shares of restricted common stock with performance vesting conditions from the 2016 Plan during the three and nine month period ended September 30, 2017, respectively. All performance vesting conditions for the restricted common stock were met as of September 30, 2017. Compensation expense associated with restricted common stock shares was $7,220.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying condensed statements of operations:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="6"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="6"&gt;Nine Months Ended&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;September&amp;#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;2,065&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;
 text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;64,945&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;74,729&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;64,945&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;76,794&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine month periods ended September 30, 2017:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Three Months&amp;#160;&lt;br /&gt;Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Nine Months&amp;#160;&lt;br /&gt;Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;47.8&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left:
 0in;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align:
 left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;During the three and nine months ended September 30, 2017, 42,525 and 365,716 stock options vested, respectively, and zero and 215,453 restricted stock awards vested, respectively. The weighted average fair value per share of options vesting during the three and nine months ended September 30, 2017 was $0.014. No stock options were forfeited during the three and nine months ended September 30, 2017. As of September 30, 2017, 1,711,096 shares were available for future issuance on a combined basis under the 2016 and 2017 Plans.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;There was no unrecognized stock-based compensation cost for stock options and restricted common stock as of September 30, 2017.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 11 &amp;#8211; Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The effective tax rate for the three and nine months ended September 30, 2017 was zero percent. As a result of the analysis of all available evidence as of&amp;#160;September 30, 2017&amp;#160;and&amp;#160;December&amp;#160;31, 2016, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported&amp;#160;no&amp;#160;income tax benefit during the&amp;#160;three and nine month periods ended&amp;#160;September 30, 2017. If the Company&amp;#8217;s assumptions change and the Company believes that it will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be recognized as a reduction of future income tax expense.&amp;#160;&amp;#160;If the assumptions do not change, each period the Company could record an additional valuation allowance on any increases in the deferred tax assets.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne on October 27, 2016. As such, the LLC was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included in the financial statements for the three or nine month periods ended September 30, 2016.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 12 &amp;#8211; Stockholders&amp;#8217;/Member Deficit&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In June 2017, the purchase price owed by the seven individuals for the founders&amp;#8217; shares of NeuroOne under their respective subscription agreements totaling $9,051 was forgiven by NeuroOne prior to the Acquisition.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;NOTE 13 &amp;#8211; Subsequent Events&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On October 4, 2017, the Company entered into a Subscription Agreement (the &amp;#8220;Subscription Agreement&amp;#8221;) with certain accredited investors (the &amp;#8220;Subscribers&amp;#8221;), pursuant to which the Company, in a private placement (the &amp;#8220;Private Placement&amp;#8221;), agreed to issue and sell to the Subscribers 8% convertible promissory notes (each, a &amp;#8220;Note&amp;#8221; and collectively, the &amp;#8220;2017 Convertible Notes&amp;#8221;) and warrants (the &amp;#8220;New Warrants&amp;#8221;) to purchase shares of the Company&amp;#8217;s capital stock.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The initial closing of the Private Placement was consummated on October 4, 2017, and, on that date, the Company issued Notes in an aggregate principal amount of $150,000 to the Subscribers. Between November 2, 2017 and November 7, 2017, the Company entered into Subscription Agreements with additional Subscribers, and issued Notes in a principal amount of $215,000 to those Subscribers. The Company may conduct any number of additional closings so long as the final closing occurs on or before the five-month anniversary of the initial closing date and the amount does not exceed $1,000,000 or a higher amount determined by the Board of Directors.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The 2017 Convertible Notes bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on October 4, 2022 (the &amp;#8220;Maturity Date&amp;#8221;). If the Company raises more than $3,000,000 in an equity financing before the Maturity Date (the &amp;#8220;Qualified Financing&amp;#8221;), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the Notes multiplied by 1.25, divided by the price paid per security in such financing. If a change of control transaction occurs prior to the earlier of a Qualified Financing or the Maturity Date, the 2017 Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by our Board of Directors as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms&amp;#8217; length transaction or (ii) at the per share consideration to be paid in such transaction (the date of any such conversion of the 2017 Convertible Notes pursuant to this paragraph, is referred to herein as the &amp;#8220;Conversion Date&amp;#8221;). Change of control means a merger or consolidation with another entity in which our stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&amp;#8217;s assets.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Each New Warrant grants the holder the option to purchase the number of shares of capital stock of the Company issuable upon the conversion of the 2017 Convertible Notes held by such holder at a per share exercise price equal to the price at which the 2017 Convertible Notes converted. The New Warrants are
 exercisable
 commencing on the Conversion Date and expire on the five year anniversary of the Conversion Date. The exercise price and number of the shares of our common stock issuable upon exercising the New Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The placement agent is also entitled to receive a warrant to purchase common stock in an amount equal to 10 percent of the common stock (common stock equivalents) purchased by certain investors in subsequent equity financing rounds. Such warrant, if issued will have an exercise price determined in relation to the pricing of the subsequent financing and will be immediately exercisable once issued.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In such subsequent equity financing rounds, the placement agent is also entitled to receive a cash fee equal to 10 percent of the total amount of capital received by the Company, as well as a cash amount representing a non-accountable expense allowance equal to 3% of the aggregate gross proceeds raised in such financing.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Subscription Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Pursuant to the Subscription Agreements, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the 2017 Convertible Notes or New Warrants, and the right to purchase the 2017 Convertible Notes or New Warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the Subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the Subscription Agreements.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Management&amp;#8217;s Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:ConcentrationRiskCreditRisk contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&amp;#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of September 30, 2017, the Company did not have deposits in excess of federally insured amounts.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Prior to October 27, 2016, the LLC did not maintain a bank account. Any expenses incurred while the LLC was organized as a limited liability company were paid by the sole member of the LLC.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company&amp;#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;As of September 30, 2017 and December 31, 2016, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the
 short-term promissory notes and the convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and premium conversion derivative associated with the convertible promissory notes was based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments which were based on Level&amp;#160;3 inputs. There were no transfers between fair value hierarchy levels during the three and nine month periods ended September 30, 2017.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The fair value of financial instruments measured on a recurring basis is as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of September 30,&amp;#160;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;774,172&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;774,172&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,215,995&lt;/td&gt;&lt;td
 style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,215,995&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;137,650&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;137,650&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;483,610&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align:
 left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;483,610&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The following table provides a roll-forward of the warrant liability and premium conversion derivative measured at fair value on a recurring basis using unobservable level&amp;#160;3 inputs for the nine months ended September 30, 2017:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Nine months ended&amp;#160;&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-indent: 0in; padding-left: 0in;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Issuance of warrants in connection with convertible promissory notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;440,919&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(12,707&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;774,172&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Nine months ended&amp;#160;&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-indent: 0in; padding-left: 0in;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Value assigned to the underlying derivative in connection with convertible notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;213,961&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Change in fair value of premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;"&gt;90,212&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;There were no financial instruments measured on a fair value recurring basis during the nine month period ended September 30, 2016.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<nmtc:IntellectualPropertyPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Intellectual Property&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;NeuroOne and the LLC have entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Milestone payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</nmtc:IntellectualPropertyPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company evaluates their long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2017, the Company has not impaired any long-lived assets.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:DebtPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Debt Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Debt issuance costs are recorded as a reduction of the short-term promissory notes and convertible promissory notes. Amortization of debt issuance costs is calculated using the straight-line method over the term of respective short-term and convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Research and development costs are charged to expense as incurred. Research and development expenses may comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&amp;#160;&lt;i&gt;Research and Development&lt;/i&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<nmtc:WarrantLiabilityPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company issued warrants to purchase equity securities in connection with the issuance of the convertible promissory notes (see Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value as the number of shares were not fixed and determinable at the issuance date. Additionally, issuance costs associated with the warrants are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&amp;#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability will be recognized as a component of interest expense in the condensed consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</nmtc:WarrantLiabilityPolicyTextBlock>
<nmtc:PremiumDebtConversionDerivativePolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Premium Debt Conversion Derivative&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&amp;#160; The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative to interest expense at each reporting period. The Company issued convertible promissory notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.25 per common share (see Note 8 &amp;#8211; Convertible Promissory Notes and Warrant Agreements). We also issued 2017 Convertible Notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.8125 per common share (see Note 13 &amp;#8211; Subsequent Events). The Company determined that the redemption feature under the convertible promissory notes qualified as an embedded derivative and was separated from its debt host.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</nmtc:PremiumDebtConversionDerivativePolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;For NeuroOne, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne on October 27, 2016. As such, it was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included in the financial statements for the period from January 1, 2016 through October 26, 2016.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The LLC was a single-member LLC for which no units were outstanding. Accordingly, earnings per share is not presented for the LLC.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;For NeuroOne, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&amp;#8217;s stock options, convertible promissory notes and warrants are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the stock options and warrants. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the three and nine months ended September 30, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and nine months ended September 30, 2017.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and nine month periods ended September 30, 2017:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1395px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 125px; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,074,181&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;365,716&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In January 2016, the FASB issued ASU No.&amp;#160;2016-01,&amp;#160;&lt;i&gt;Financial Instruments&amp;#160;&amp;#8212; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/i&gt;. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2018 for public entities and for all other entities in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In May 2017, the FASB issued ASU 2017-09,&amp;#160;&lt;i&gt;Compensation - Stock Compensation (Topic 718):&amp;#160;Scope of Modification Accounting (ASU 2016-09)&lt;/i&gt;,&amp;#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In July 2017, the FASB issued ASU No. 2017-11,&amp;#160;&lt;i&gt;Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging&lt;/i&gt;, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&amp;#160;15, 2018 for public business entities and after December 15, 2019 for all other entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="6"&gt;September 30,&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;" colspan="6"&gt;September 30,&lt;/td&gt;&lt;td style="font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Nine months ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; padding-bottom: 1.5pt;"&gt;Total operating expenses&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;893,792&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;8,600&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,918,208&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;33,056&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(893,792&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(8,600&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,918,208&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(33,056&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Interest expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(515,377&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,635&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,134,529&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(10,698&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(1,409,169&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(12,235&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(3,052,737&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(43,754&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Net loss per share:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.18&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.01&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.41&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(0.03&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Number of shares used in per share calculations:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,864,994&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,658,051&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;7,369,457&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,658,051&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCondensedFinancialStatementsTableTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of September 30,&amp;#160;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;774,172&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;774,172&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,215,995&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,215,995&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold;
 border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14"&gt;As of December&amp;#160;31,&amp;#160;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Level&amp;#160;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;137,650&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;137,650&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total liabilities at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;483,610&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;483,610&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Nine months ended&amp;#160;&lt;br /&gt;September&amp;#160;30,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-indent: 0in; padding-left: 0in;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;345,960&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Issuance of warrants in connection with convertible promissory notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;440,919&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(12,707&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;774,172&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Nine months ended&amp;#160;&lt;br /&gt;September&amp;#160;30, 2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px;"&gt;Balance as of beginning of period&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;137,650&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Value assigned to the underlying derivative in connection with convertible notes&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;213,961&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Change in fair value of premium conversion derivative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;90,212&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 10pt;"&gt;Balance as of end of period&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;441,823&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px;"&gt;Warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1,074,181&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;365,716&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: center; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Useful Life&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: center; text-indent: 0in; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1191px; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;License agreement, October 27, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 173px; text-align: center; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;12-13 years&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 141px; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;182,159&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Less: amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(1,269&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Net Intangibles, December 31, 2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman',
 times, serif; font-size:
 10pt;"&gt;180,890&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;License agreement amendment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;23,115&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Less: amortization&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(13,368&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Net Intangibles, September 30, 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;190,637&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;September&amp;#160;30,&lt;br /&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Accrued license fees&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;182,009&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;182,009&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Accrued services&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;531,607&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;31,186&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Accrued issuance costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;32,306&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;22,015&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-left: 0in;"&gt;Accrued compensation and payroll related costs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;170,812&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;28,252&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;"&gt;Accrued interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;881&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;916,734&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;264,343&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="6"&gt;Three Months Ended&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="6"&gt;Nine Months Ended&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;September&amp;#160;30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 540.66px; text-align: left;"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 10.66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 94px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 94px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 93.33px; text-align: right;"&gt;2,065&lt;/td&gt;&lt;td style="width: 10px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 93.33px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 10px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;64,945&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;74,729&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;64,945&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;76,794&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#8212;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Three Months&amp;#160;&lt;br /&gt;Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Nine Months&amp;#160;&lt;br /&gt;Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 790px; text-align: left;"&gt;Expected stock price volatility&lt;/td&gt;&lt;td style="width: 10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 93.33px; text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="width: 11.33px; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 10px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 93.33px; text-align: right;"&gt;47.8&lt;/td&gt;&lt;td style="width: 11.33px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life of options (years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#8212;&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.9&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="pure" decimals="2">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
<us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00">(i) All outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the "NeuroOne Shares") were exchanged for shares of the Company's common stock, par value $0.001 per share (the "Company Shares") based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the "Exchange Ratio"), resulting in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
<us-gaap:BusinessAcquisitionSharePrice contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:BusinessAcquisitionSharePrice>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:SharesIssuedPricePerShare>
<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="pure" decimals="7">17.0103706</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">6291994</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_20_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">992265</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">2292265</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember" unitRef="shares" decimals="INF">1711096</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_20_Jul_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="shares" decimals="INF">3500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">-49930</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:ShortTermBankLoansAndNotesPayable contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">253000</us-gaap:ShortTermBankLoansAndNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1625120</us-gaap:ConvertibleNotesPayable>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">1625120</us-gaap:ConvertibleNotesPayable>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="-5">2500000</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="-5">2500000</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">483610</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">483610</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">1215995</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">1215995</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="0">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">440919</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">-12707</us-gaap:FairValueAdjustmentOfWarrants>
<nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">213961</nmtc:ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes>
<nmtc:ChangeInFairValueOfPremiumConversionDerivative contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_DebtInstrumentAxis_DebtConversionDerivativeMember" unitRef="USD" decimals="0">90212</nmtc:ChangeInFairValueOfPremiumConversionDerivative>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">365716</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="shares" decimals="0">1074181</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:DebtConversionDescription contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">The Company issued convertible promissory notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.25 per common share (see Note 8 Convertible Promissory Notes and Warrant Agreements). We also issued 2017 Convertible Notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.8125 per common share (see Note 13 Subsequent Events).</us-gaap:DebtConversionDescription>
<us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings>
<us-gaap:LongTermPurchaseCommitmentAmount contextRef="Context_Custom_30_Sep_2014T00_00_00_TO_01_Oct_2014T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">110000</us-gaap:LongTermPurchaseCommitmentAmount>
<us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">90000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
<nmtc:ContingentPaymentDueInEventOfCompletionOfFinancing contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">120000</nmtc:ContingentPaymentDueInEventOfCompletionOfFinancing>
<us-gaap:OtherCommitmentDueInThirdYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">50000</us-gaap:OtherCommitmentDueInThirdYear>
<us-gaap:OtherCommitmentDueInFourthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">100000</us-gaap:OtherCommitmentDueInFourthYear>
<nmtc:OtherCommitmentDueAfterFourthYear contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="USD" decimals="0">150000</nmtc:OtherCommitmentDueAfterFourthYear>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">300</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="shares" decimals="INF">10000</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="shares" decimals="INF">50556</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">23115</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">23115</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
<nmtc:AmountRecordedForIntellectualProperty contextRef="Context_Custom_01_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">91709</nmtc:AmountRecordedForIntellectualProperty>
<us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">91709</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" unitRef="USD" decimals="0">91709</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
<nmtc:PercentageOfAccruedInterest contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_TechnologyBasedIntangibleAssetsMember" unitRef="pure" decimals="2">0.01</nmtc:PercentageOfAccruedInterest>
<us-gaap:DebtInstrumentIssuanceDate1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">2037-05-25</us-gaap:DebtInstrumentIssuanceDate1>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember_RangeAxis_MinimumMember">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember_RangeAxis_MaximumMember">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_27_Oct_2016T00_00_00_TO_27_Oct_2016T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">180890</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">190637</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="Context_Custom_28_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">182159</us-gaap:FinitelivedIntangibleAssetsAcquired1>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">1941</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">5823</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_Custom_28_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">-1269</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">4264</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_FairValueByAssetClassAxis_FiniteLivedIntangibleAssetsMember" unitRef="USD" decimals="0">-13368</us-gaap:AmortizationOfIntangibleAssets>
<us-gaap:AmortizationOfIntangibleAssets contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">13368</us-gaap:AmortizationOfIntangibleAssets>
<nmtc:AccruedLicenseFees contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">182009</nmtc:AccruedLicenseFees>
<nmtc:AccruedLicenseFees contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">182009</nmtc:AccruedLicenseFees>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">31186</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">531607</us-gaap:AccruedProfessionalFeesCurrent>
<nmtc:AccruedIssuanceCosts contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">22015</nmtc:AccruedIssuanceCosts>
<nmtc:AccruedIssuanceCosts contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">32306</nmtc:AccruedIssuanceCosts>
<nmtc:AccruedCompensationAndPayrollRelatedCosts contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">28252</nmtc:AccruedCompensationAndPayrollRelatedCosts>
<nmtc:AccruedCompensationAndPayrollRelatedCosts contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">170812</nmtc:AccruedCompensationAndPayrollRelatedCosts>
<nmtc:AccruedInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">881</nmtc:AccruedInterest>
<nmtc:AccruedInterest contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">0</nmtc:AccruedInterest>
<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">3030</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
<us-gaap:InterestExpenseDebt contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">27317</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">6546</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">733</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">59184</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">-12707</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">733</us-gaap:InterestExpenseDebt>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">2018-02-18</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">2017-11-21</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember">2022-10-04</us-gaap:DebtInstrumentMaturityDate>
<nmtc:CommonStockPurchaseOfWarrants contextRef="Context_3ME_07_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="shares" decimals="0">29000</nmtc:CommonStockPurchaseOfWarrants>
<nmtc:CommonStockPurchaseOfWarrants contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="shares" decimals="INF">126500</nmtc:CommonStockPurchaseOfWarrants>
<nmtc:CommonStockPurchaseOfWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="shares" decimals="0">63000</nmtc:CommonStockPurchaseOfWarrants>
<nmtc:WarrantsMaturityTerm contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">P5Y</nmtc:WarrantsMaturityTerm>
<nmtc:WarrantsMaturityTerm contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">P5Y</nmtc:WarrantsMaturityTerm>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD_per_Share" decimals="2">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">61496</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="4">0.0177</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="4">0.0179</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="2">0.48</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember">P5Y6M</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">P4Y1M20D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_Custom_01_Aug_2017T00_00_00_TO_31_Aug_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
<nmtc:DiscountRelatedToWarrantsAmortizedToInterestExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">14868</nmtc:DiscountRelatedToWarrantsAmortizedToInterestExpense>
<nmtc:DiscountRelatedToWarrantsAmortizedToInterestExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ExtinguishmentOfDebtAxis_ShortTermDebtMember" unitRef="USD" decimals="0">14868</nmtc:DiscountRelatedToWarrantsAmortizedToInterestExpense>
<us-gaap:UnsecuredDebtCurrent contextRef="Context_As_Of_30_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="USD" decimals="0">50000</us-gaap:UnsecuredDebtCurrent>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="-5">3000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:DebtInstrumentInterestRateTerms contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">If a Qualified Financing occurs before November 21, 2017, the outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by November 21, 2017, the Convertible Notes will be immediately due and payable on such date.</us-gaap:DebtInstrumentInterestRateTerms>
<nmtc:DescriptionOfMaximumVotingPowerOfSurvivingEntity contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.</nmtc:DescriptionOfMaximumVotingPowerOfSurvivingEntity>
<nmtc:AmountOfConvertibleNoteHeldByWarrantHolder contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="2">1.80</nmtc:AmountOfConvertibleNoteHeldByWarrantHolder>
<us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember">2021-11-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
<nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants contextRef="Context_3ME_07_Oct_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">345640</nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants>
<nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">440919</nmtc:ConvertiblePromissoryNoteProceedsAssignedToWarrants>
<us-gaap:DebtConversionConvertedInstrumentRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">1.25</us-gaap:DebtConversionConvertedInstrumentRate>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD_per_Share" decimals="2">2.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<nmtc:ConvertibleNotesOfConversionPremiumAmortizationExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">133367</nmtc:ConvertibleNotesOfConversionPremiumAmortizationExpense>
<nmtc:ConvertibleNotesOfConversionPremiumAmortizationExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">266848</nmtc:ConvertibleNotesOfConversionPremiumAmortizationExpense>
<nmtc:PremiumDebtConversionDerivativeInterestExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">15406</nmtc:PremiumDebtConversionDerivativeInterestExpense>
<nmtc:PremiumDebtConversionDerivativeInterestExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="USD" decimals="0">90212</nmtc:PremiumDebtConversionDerivativeInterestExpense>
<us-gaap:DeferredFinanceCostsNet contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">151915</us-gaap:DeferredFinanceCostsNet>
<us-gaap:DebtInstrumentFee contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the "placement agent warrant") which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855 at September 30, 2017 and (iii) legal expenses of $33,450.</us-gaap:DebtInstrumentFee>
<nmtc:PercentageOfCommonStockPurchaseWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="pure" decimals="2">0.08</nmtc:PercentageOfCommonStockPurchaseWarrants>
<nmtc:PercentageOfCommonStockPurchaseWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember" unitRef="pure" decimals="2">0.10</nmtc:PercentageOfCommonStockPurchaseWarrants>
<nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">0</nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants>
<nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ShortTermDebtTypeAxis_ConvertibleNotesPayableMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">38119</nmtc:IssuanceCostsAttributedToCommonStockPurchaseWarrants>
<nmtc:NonRefundableFeeToInvestmentBanker contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">50000</nmtc:NonRefundableFeeToInvestmentBanker>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">64945</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">64945</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">76794</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">2065</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">74729</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="3">0.478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="3">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">365716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD_per_Share" decimals="3">0.035</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.014</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD_per_Share" decimals="3">0.014</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.014</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="USD_per_Share" decimals="3">0.014</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenAndSeventeenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">215453</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_PlanNameAxis_TwoThousandSixteenPlanMember_TitleOfIndividualAxis_EmployeesDirectorsAndConsultantsMember" unitRef="shares" decimals="INF">215453</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">42525</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">365716</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="Context_As_Of_30_Sep_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
<us-gaap:RestrictedStockExpense contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="USD" decimals="0">7220</us-gaap:RestrictedStockExpense>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2016T00_00_00_TO_30_Sep_2016T00_00_00_StatementScenarioAxis_PredecessorMember" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2017T00_00_00_TO_30_Sep_2017T00_00_00_ConsolidatedEntitiesAxis_SubsidiariesMember" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="pure" decimals="2">0.08</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_SubsidiarySaleOfStockAxis_PlacementAgentMember" unitRef="pure" decimals="2">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_04_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">150000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_06_Nov_2017T00_00_00_TO_06_Nov_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">115000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:SubsequentEventDescription contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember">The Company may conduct any number of additional closings so long as the final closing occurs on or before the five-month anniversary of the initial closing date and the amount does not exceed $1,000,000 or a higher amount determined by the Board of Directors.</us-gaap:SubsequentEventDescription>
<us-gaap:SubsequentEventDescription contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">If the Company raises more than $3,000,000 in an equity financing before the Maturity Date (the "Qualified Financing"), the outstanding principal and accrued and unpaid interest on the Notes shall automatically convert into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the Notes multiplied by 1.25, divided by the price paid per security in such financing. If a change of control transaction occurs prior to the earlier of a Qualified Financing or the Maturity Date, the Notes would, at the election of the holders of a majority of the outstanding principal of the Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by our Board of Directors as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms' length transaction or (ii) at the per share consideration to be paid in such transaction (the date of any such conversion of the Notes pursuant to this paragraph, is referred to herein as the "Conversion Date"). Change of control means a merger or consolidation with another entity in which our stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.</us-gaap:SubsequentEventDescription>
<nmtc:PercentageOfCapitalReceived contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="pure" decimals="2">0.10</nmtc:PercentageOfCapitalReceived>
<nmtc:PercentageOfNonaccountableExpense contextRef="Context_Custom_01_Oct_2017T00_00_00_TO_04_Oct_2017T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="pure" decimals="2">0.03</nmtc:PercentageOfNonaccountableExpense>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nmtc-20170930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://www.originalsourcemusic.com/20170930" elementFormDefault="qualified"
xmlns:nmtc="http://www.originalsourcemusic.com/20170930"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:us-types="http://fasb.org/us-types/2017-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
>
<annotation><appinfo>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" id="CondensedConsolidatedStatementsOfOperationsUnaudited">
<link:definition>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<link:definition>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentation" id="OrganizationAndBasisOfPresentation">
<link:definition>006 - Disclosure - Organization and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/GoingConcern" id="GoingConcern">
<link:definition>007 - Disclosure - Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>009 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/Intangibles" id="Intangibles">
<link:definition>010 - Disclosure - Intangibles</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>011 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan" id="ShortTermPromissoryNotesAndUnsecuredLoan">
<link:definition>012 - Disclosure - Short-Term Promissory Notes and Unsecured Loan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements" id="ConvertiblePromissoryNotesAndWarrantAgreements">
<link:definition>013 - Disclosure - Convertible Promissory Notes and Warrant Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/InvestmentBankerFee" id="InvestmentBankerFee">
<link:definition>014 - Disclosure - Investment Banker Fee</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>015 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>016 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockholdersmemberDeficit" id="StockholdersmemberDeficit">
<link:definition>017 - Disclosure - Stockholders'/Member Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>018 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>019 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/OrganizationandBasisofPresentationTables" id="OrganizationandBasisofPresentationTables">
<link:definition>020 - Disclosure - Organization and Basis of Presentation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables" id="SummaryofSignificantAccountingPoliciesTables">
<link:definition>021 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesTables" id="IntangiblesTables">
<link:definition>022 - Disclosure - Intangibles (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>023 - Disclosure - Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
<link:definition>024 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentationDetails" id="OrganizationAndBasisOfPresentationDetails">
<link:definition>025 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/GoingConcernDetails" id="GoingConcernDetails">
<link:definition>026 - Disclosure - Going Concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails" id="SummaryofSignificantAccountingPoliciesDetails">
<link:definition>027 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1" id="SummaryofSignificantAccountingPoliciesDetails1">
<link:definition>028 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2" id="SummaryofSignificantAccountingPoliciesDetails2">
<link:definition>029 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3" id="SummaryofSignificantAccountingPoliciesDetails3">
<link:definition>030 - Disclosure - Summary of Significant Accounting Policies (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>031 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
<link:definition>032 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails" id="IntangiblesDetails">
<link:definition>033 - Disclosure - Intangibles (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual" id="IntangiblesDetailsTextual">
<link:definition>034 - Disclosure - Intangibles (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
<link:definition>035 - Disclosure - Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails" id="ShortTermPromissoryNotesAndUnsecuredLoanDetails">
<link:definition>036 - Disclosure - Short-Term Promissory Notes and Unsecured Loan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails" id="ConvertiblePromissoryNotesandWarrantAgreementsDetails">
<link:definition>037 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/InvestmentBankerFeeDetails" id="InvestmentBankerFeeDetails">
<link:definition>038 - Disclosure - Investment Banker Fee (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails" id="StockBasedCompensationDetails">
<link:definition>039 - Disclosure - Stock-Based Compensation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1" id="StockBasedCompensationDetails1">
<link:definition>040 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2" id="StockBasedCompensationDetails2">
<link:definition>041 - Disclosure - Stock-Based Compensation (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>042 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/StockholdersmemberDeficitDetails" id="StockholdersmemberDeficitDetails">
<link:definition>043 - Disclosure - Stockholders'/Member Deficit (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>044 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="nmtc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ForgivenessOfShareSubscriptionAgreementForFoundersShares" id="nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RevaluationOfPremiumDebtConversionDerivative" id="nmtc_RevaluationOfPremiumDebtConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RevaluationOfWarrantLiability" id="nmtc_RevaluationOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionDerivativeRelatedToConvertiblePromissoryNotes" id="nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" id="nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedIssuanceCostsAttributedToWarrantLiability" id="nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoingConcernAbstract" id="nmtc_GoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InvestmentBankerFeeAbstract" id="nmtc_InvestmentBankerFeeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InvestmentBankerFeeTextBlock" id="nmtc_InvestmentBankerFeeTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IntellectualPropertyPolicyTextBlock" id="nmtc_IntellectualPropertyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantLiabilityPolicyTextBlock" id="nmtc_WarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumDebtConversionDerivativePolicyTextBlock" id="nmtc_PremiumDebtConversionDerivativePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OrganizationAndBasisOfPresentationTextualAbstract" id="nmtc_OrganizationAndBasisOfPresentationTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoingConcernTextualAbstract" id="nmtc_GoingConcernTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfWarrantLiabilityAbstract" id="nmtc_ScheduleOfWarrantLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtConversionDerivativeMember" id="nmtc_DebtConversionDerivativeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPremiumConversionDerivativeAbstract" id="nmtc_ScheduleOfPremiumConversionDerivativeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" id="nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ChangeInFairValueOfPremiumConversionDerivative" id="nmtc_ChangeInFairValueOfPremiumConversionDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTextualAbstract" id="nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTextualAbstract" id="nmtc_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ContingentPaymentDueInEventOfCompletionOfFinancing" id="nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="OtherCommitmentDueAfterFourthYear" id="nmtc_OtherCommitmentDueAfterFourthYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountRecordedForIntellectualProperty" id="nmtc_AmountRecordedForIntellectualProperty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfAccruedInterest" id="nmtc_PercentageOfAccruedInterest" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="GoodwilAndIntangibleAssetsTextualAbstract" id="nmtc_GoodwilAndIntangibleAssetsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedExpensesTable" id="nmtc_AccruedExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccruedExpensesLineItems" id="nmtc_AccruedExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedLicenseFees" id="nmtc_AccruedLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedIssuanceCosts" id="nmtc_AccruedIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedCompensationAndPayrollRelatedCosts" id="nmtc_AccruedCompensationAndPayrollRelatedCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedInterest" id="nmtc_AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" id="nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockPurchaseOfWarrants" id="nmtc_CommonStockPurchaseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsMaturityTerm" id="nmtc_WarrantsMaturityTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DiscountRelatedToWarrantsAmortizedToInterestExpense" id="nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" id="nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DescriptionOfMaximumVotingPowerOfSurvivingEntity" id="nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AmountOfConvertibleNoteHeldByWarrantHolder" id="nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNoteProceedsAssignedToWarrants" id="nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConvertibleNotesOfConversionPremiumAmortizationExpense" id="nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PremiumDebtConversionDerivativeInterestExpense" id="nmtc_PremiumDebtConversionDerivativeInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfCommonStockPurchaseWarrants" id="nmtc_PercentageOfCommonStockPurchaseWarrants" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceCostsAttributedToCommonStockPurchaseWarrants" id="nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="InvestmentBankerFeeTextualAbstract" id="nmtc_InvestmentBankerFeeTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NonRefundableFeeToInvestmentBanker" id="nmtc_NonRefundableFeeToInvestmentBanker" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandSixteenPlanMember" id="nmtc_TwoThousandSixteenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoThousandSixteenAndSeventeenPlanMember" id="nmtc_TwoThousandSixteenAndSeventeenPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeesDirectorsAndConsultantsMember" id="nmtc_EmployeesDirectorsAndConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockBasedCompensationTextualAbstract" id="nmtc_StockBasedCompensationTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxesTextualAbstract" id="nmtc_IncomeTaxesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockholdersMemberDeficitTextualAbstract" id="nmtc_StockholdersMemberDeficitTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlacementAgentMember" id="nmtc_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubsequentEventsTextualAbstract" id="nmtc_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfCapitalReceived" id="nmtc_PercentageOfCapitalReceived" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfNonaccountableExpense" id="nmtc_PercentageOfNonaccountableExpense" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nmtc-20170930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ShortTermBorrowings" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InterestIncomeExpenseNet" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentForAmortization" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xlink:label="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_nmtc_RevaluationOfWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_nmtc_RevaluationOfWarrantLiability" order="90" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="100" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="110" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="50" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#AccruedExpensesDetails" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_nmtc_AccruedLicenseFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedLicenseFees" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_nmtc_AccruedIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedIssuanceCosts" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedCompensationAndPayrollRelatedCosts" xlink:label="loc_nmtc_AccruedCompensationAndPayrollRelatedCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedCompensationAndPayrollRelatedCosts" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedInterest" xlink:label="loc_nmtc_AccruedInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_nmtc_AccruedInterest" order="50" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nmtc-20170930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" >
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#OrganizationAndBasisOfPresentationDetails" roleURI="http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentationDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#GoingConcernDetails" roleURI="http://www.originalsourcemusic.com/role/GoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesDetails1" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesDetails2" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesDetails3" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CommitmentsandContingenciesDetails" roleURI="http://www.originalsourcemusic.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#IntangiblesDetails" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#IntangiblesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#AccruedExpensesDetails" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#ShortTermPromissoryNotesAndUnsecuredLoanDetails" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#ConvertiblePromissoryNotesandWarrantAgreementsDetails" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockBasedCompensationDetails" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockBasedCompensationDetails2" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#IncomeTaxesDetails" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockholdersmemberDeficitDetails" roleURI="http://www.originalsourcemusic.com/role/StockholdersmemberDeficitDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SubsequentEventsDetails" roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_Cash_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_AssetsCurrent_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5" xlink:to="loc_us-gaap_Assets_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_13" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_13" xlink:to="loc_us-gaap_ShortTermBorrowings_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_13" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_16" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_13" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_17" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_18" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_13" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_19" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_Liabilities_20" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_StockholdersEquityAbstract_22" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_PreferredStockValue_23" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_CommonStockValue_24" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AdditionalPaidInCapital_25" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquity_27" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_28" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_12" order="80" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6" xlink:to="loc_us-gaap_PredecessorMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8" xlink:to="loc_us-gaap_OperatingExpenses_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_15" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_17" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_17" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_18" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6" xlink:to="loc_us-gaap_PredecessorMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_NetIncomeLoss_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" xlink:to="loc_us-gaap_AdjustmentForAmortization_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensation_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xlink:label="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" xlink:to="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares_13" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_14" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_15" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_16" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" xlink:to="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative_17" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_nmtc_RevaluationOfWarrantLiability_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_10" xlink:to="loc_nmtc_RevaluationOfWarrantLiability_18" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_20" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_21" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_22" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_24" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_25" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_26" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_27" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_28" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_30" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_33" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:label="loc_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes_34" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:label="loc_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability_35" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_us-gaap_StockIssued1_36" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xlink:label="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0" xlink:to="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_12" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_13" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_14" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_15" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_16" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_17" order="110" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/GoingConcernDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_3" xlink:to="loc_us-gaap_PredecessorMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoingConcernTextualAbstract" xlink:label="loc_nmtc_GoingConcernTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_nmtc_GoingConcernTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_ConvertibleNotesPayable_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoingConcernTextualAbstract_5" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_10" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_10" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_10" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_13" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_5" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_8" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_nmtc_DebtConversionDerivativeMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_nmtc_DebtConversionDerivativeMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ChangeInFairValueOfPremiumConversionDerivative" xlink:label="loc_nmtc_ChangeInFairValueOfPremiumConversionDerivative_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_5" xlink:to="loc_nmtc_ChangeInFairValueOfPremiumConversionDerivative_8" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_0" xlink:to="loc_us-gaap_LossContingenciesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6" xlink:to="loc_us-gaap_IntellectualPropertyMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_0" xlink:to="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" xlink:label="loc_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_OtherCommitmentDueAfterFourthYear" xlink:label="loc_nmtc_OtherCommitmentDueAfterFourthYear_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_OtherCommitmentDueAfterFourthYear_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_16" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_17" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_18" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AmountRecordedForIntellectualProperty" xlink:label="loc_nmtc_AmountRecordedForIntellectualProperty_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_AmountRecordedForIntellectualProperty_19" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_20" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfAccruedInterest" xlink:label="loc_nmtc_PercentageOfAccruedInterest_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_nmtc_PercentageOfAccruedInterest_21" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_22" order="120" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_14" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_ParentCompanyMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_6" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_6" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7" xlink:to="loc_us-gaap_PredecessorMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:label="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0" xlink:to="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_10" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedExpensesLineItems" xlink:label="loc_nmtc_AccruedExpensesLineItems_0" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedExpensesTable" xlink:label="loc_nmtc_AccruedExpensesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nmtc_AccruedExpensesLineItems_0" xlink:to="loc_nmtc_AccruedExpensesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nmtc_AccruedExpensesTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_AccruedExpensesLineItems_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_nmtc_AccruedLicenseFees_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_nmtc_AccruedLicenseFees_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_nmtc_AccruedIssuanceCosts_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_nmtc_AccruedIssuanceCosts_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedCompensationAndPayrollRelatedCosts" xlink:label="loc_nmtc_AccruedCompensationAndPayrollRelatedCosts_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_nmtc_AccruedCompensationAndPayrollRelatedCosts_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedInterest" xlink:label="loc_nmtc_AccruedInterest_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_nmtc_AccruedInterest_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_11" order="50" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_us-gaap_ShortTermDebtMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6" xlink:to="loc_us-gaap_UnsecuredDebtMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_InterestExpenseDebt_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_nmtc_CommonStockPurchaseOfWarrants_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_nmtc_CommonStockPurchaseOfWarrants_13" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_nmtc_WarrantsMaturityTerm_14" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_16" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_17" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_18" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_19" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_20" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" xlink:label="loc_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense_21" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaap_UnsecuredDebtCurrent_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_8" xlink:to="loc_us-gaap_UnsecuredDebtCurrent_22" order="130" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_ConvertibleNotesPayable_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_13" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_14" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_15" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_16" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_17" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_18" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_19" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_20" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_21" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_22" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_23" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_InterestExpenseDebt_24" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_25" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_26" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_27" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_28" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_29" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_30" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_us-gaap_DebtInstrumentFee_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentFee_31" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_WarrantsMaturityTerm_32" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_nmtc_CommonStockPurchaseOfWarrants_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_CommonStockPurchaseOfWarrants_33" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_34" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_8" xlink:to="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_35" order="260" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenPlanMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenPlanMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_nmtc_StockBasedCompensationTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_nmtc_StockBasedCompensationTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_16" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_17" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_18" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_19" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_9" xlink:to="loc_us-gaap_RestrictedStockExpense_20" order="100" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6" xlink:to="loc_us-gaap_PredecessorMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_IncomeTaxesTextualAbstract" xlink:label="loc_nmtc_IncomeTaxesTextualAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0" xlink:to="loc_nmtc_IncomeTaxesTextualAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_10" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersmemberDeficitDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_nmtc_StockholdersMemberDeficitTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_nmtc_StockholdersMemberDeficitTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xlink:label="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_5" xlink:to="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares_6" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PlacementAgentMember" xlink:label="loc_nmtc_PlacementAgentMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_nmtc_PlacementAgentMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_nmtc_SubsequentEventsTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_nmtc_SubsequentEventsTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_SubsequentEventDescription_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfCapitalReceived" xlink:label="loc_nmtc_PercentageOfCapitalReceived_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_9" xlink:to="loc_nmtc_PercentageOfCapitalReceived_16" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfNonaccountableExpense" xlink:label="loc_nmtc_PercentageOfNonaccountableExpense_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_9" xlink:to="loc_nmtc_PercentageOfNonaccountableExpense_17" order="70" use="optional"  />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nmtc-20170930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DocumentAndEntityInformationAbstract" xlink:label="loc_2F7GJF4361G9_nmtc_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_DocumentAndEntityInformationAbstract" xlink:to="lab_4H9ILH6583I1_nmtc_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_1I5G6IJ8237K977IF6F9_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_dei_EntityRegistrantName" xlink:to="lab_3K7I8KL0459M199KH8H1_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_2F7GJF4361G9_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_dei_EntityCentralIndexKey" xlink:to="lab_4H9ILH6583I1_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_1I5G6IJ8237K977IF6F9_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_dei_AmendmentFlag" xlink:to="lab_3K7I8KL0459M199KH8H1_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_2F7GJF4361G9_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_dei_TradingSymbol" xlink:to="lab_4H9ILH6583I1_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_1I5G6IJ8237K977IF6F9_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_dei_CurrentFiscalYearEndDate" xlink:to="lab_3K7I8KL0459M199KH8H1_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_2F7GJF4361G9_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_dei_DocumentType" xlink:to="lab_4H9ILH6583I1_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_1I5G6IJ8237K977IF6F9_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_dei_DocumentPeriodEndDate" xlink:to="lab_3K7I8KL0459M199KH8H1_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_2F7GJF4361G9_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_dei_DocumentFiscalYearFocus" xlink:to="lab_4H9ILH6583I1_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_1I5G6IJ8237K977IF6F9_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_dei_DocumentFiscalPeriodFocus" xlink:to="lab_3K7I8KL0459M199KH8H1_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_2F7GJF4361G9_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_dei_EntityFilerCategory" xlink:to="lab_4H9ILH6583I1_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_1I5G6IJ8237K977IF6F9_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_3K7I8KL0459M199KH8H1_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StatementTable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_2F7GJF4361G9_us-gaap_ConsolidatedEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ConsolidatedEntitiesAxis" xlink:to="lab_4H9ILH6583I1_us-gaap_ConsolidatedEntitiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ConsolidatedEntitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ConsolidatedEntitiesDomain" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ConsolidatedEntitiesDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_2F7GJF4361G9_us-gaap_SubsidiariesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SubsidiariesMember" xml:lang="en-US">Subsidiaries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_SubsidiariesMember" xml:lang="en-US">NeuroOne, Inc. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_SubsidiariesMember" xml:lang="en-US">NeuroOne, Inc. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SubsidiariesMember" xlink:to="lab_4H9ILH6583I1_us-gaap_SubsidiariesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StatementLineItems" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AssetsAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AssetsCurrentAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_2F7GJF4361G9_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_Cash" xlink:to="lab_4H9ILH6583I1_us-gaap_Cash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_2F7GJF4361G9_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AssetsCurrent" xlink:to="lab_4H9ILH6583I1_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_2F7GJF4361G9_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_Assets" xlink:to="lab_4H9ILH6583I1_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_2F7GJF4361G9_us-gaap_ShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-term promissory notes and unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ShortTermBorrowings" xlink:to="lab_4H9ILH6583I1_us-gaap_ShortTermBorrowings"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ConvertibleNotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible promissory notes, net and accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ConvertibleNotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Balance as of end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xml:lang="en-US">Premium conversion derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentUnamortizedPremiumCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_LiabilitiesCurrent" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_2F7GJF4361G9_us-gaap_WarrantsAndRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Balance as of beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Balance as of end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_4H9ILH6583I1_us-gaap_WarrantsAndRightsOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_Liabilities" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_2F7GJF4361G9_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 4)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_CommitmentsAndContingencies" xlink:to="lab_4H9ILH6583I1_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockholdersEquityAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_2F7GJF4361G9_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 and 5,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; no shares issued or outstanding as of September 30, 2017 and December 31, 2016.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_PreferredStockValue" xlink:to="lab_4H9ILH6583I1_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value ; 100,000,000 and 45,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; and 7,864,994 and 5,216,565 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommonStockValue" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_2F7GJF4361G9_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AdditionalPaidInCapital" xlink:to="lab_4H9ILH6583I1_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_2F7GJF4361G9_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_StockholdersEquity" xml:lang="en-US">Balances</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_StockholdersEquity" xml:lang="en-US">Balances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_StockholdersEquity" xlink:to="lab_4H9ILH6583I1_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_2F7GJF4361G9_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_4H9ILH6583I1_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_2F7GJF4361G9_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_PreferredStockSharesIssued" xlink:to="lab_4H9ILH6583I1_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_2F7GJF4361G9_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_4H9ILH6583I1_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_2F7GJF4361G9_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_CommonStockSharesIssued" xlink:to="lab_4H9ILH6583I1_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balances (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Balances (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_IncomeStatementAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StatementScenarioAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StatementScenarioAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_2F7GJF4361G9_us-gaap_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_4H9ILH6583I1_us-gaap_ScenarioUnspecifiedDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_PredecessorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PredecessorMember" xml:lang="en-US">Predecessor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PredecessorMember" xml:lang="en-US">NeuroOne LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PredecessorMember" xml:lang="en-US">NeuroOne LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_PredecessorMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_PredecessorMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_OperatingExpensesAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_2F7GJF4361G9_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_4H9ILH6583I1_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_OperatingExpenses" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_2F7GJF4361G9_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income (Loss) from Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_OperatingIncomeLoss" xlink:to="lab_4H9ILH6583I1_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_InterestIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_InterestIncomeExpenseNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_2F7GJF4361G9_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_NetIncomeLoss" xlink:to="lab_4H9ILH6583I1_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net loss per share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_2F7GJF4361G9_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_4H9ILH6583I1_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Number of shares used in per share calculations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_2F7GJF4361G9_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_4H9ILH6583I1_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_2F7GJF4361G9_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AdjustmentForAmortization" xlink:to="lab_4H9ILH6583I1_us-gaap_AdjustmentForAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensation" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xlink:label="loc_2F7GJF4361G9_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xml:lang="en-US">Forgiveness Of Share Subscription Agreement For Founders Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xml:lang="en-US">Forgiveness of share subscription agreement for founders' shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xml:lang="en-US">Forgiveness of share subscription agreement for founders shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xlink:to="lab_4H9ILH6583I1_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Non-cash interest on convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_2F7GJF4361G9_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Discount to convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Non-cash discount amortization on short-term promissory notes and convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_4H9ILH6583I1_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Non-cash note issuance costs attributed to warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_2F7GJF4361G9_nmtc_RevaluationOfPremiumDebtConversionDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation Of Premium Debt Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation of premium debt conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_RevaluationOfPremiumDebtConversionDerivative" xml:lang="en-US">Revaluation of premium debt conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:to="lab_4H9ILH6583I1_nmtc_RevaluationOfPremiumDebtConversionDerivative"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_RevaluationOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_RevaluationOfWarrantLiability" xml:lang="en-US">Revaluation of warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_RevaluationOfWarrantLiability" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_RevaluationOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Change in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_2F7GJF4361G9_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_4H9ILH6583I1_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ProceedsFromShortTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from Short-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Proceeds from issuance of short-term promissory notes and convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromShortTermDebt" xml:lang="en-US">Aggregate gross proceeds of short-term unsecured promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromShortTermDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_2F7GJF4361G9_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Common stock purchase warrants for aggregate gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from issuance of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_4H9ILH6583I1_us-gaap_ProceedsFromIssuanceOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xml:lang="en-US">Proceeds from Issuance of Unsecured Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xml:lang="en-US">Repayment of short-term unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_2F7GJF4361G9_us-gaap_PaymentsOfDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Issuance costs related to short-term promissory notes and convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Issuance costs related to short-term promissory notes and convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_4H9ILH6583I1_us-gaap_PaymentsOfDebtIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Issuance costs related to warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Issuance costs related to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_2F7GJF4361G9_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_4H9ILH6583I1_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net decrease in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_2F7GJF4361G9_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_4H9ILH6583I1_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental non-cash investing and financing transactions:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_2F7GJF4361G9_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Conversion Derivative Related To Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Bifurcation of premium conversion derivative related to convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xml:lang="en-US">Bifurcation of premium conversion derivative related to convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:to="lab_4H9ILH6583I1_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued Issuance Costs Attributed To Short Term Promissory Notes And Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued issuance costs attributed to short term promissory notes and convertible promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xml:lang="en-US">Accrued issuance costs attributed to short term promissory notes and convertible promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:label="loc_2F7GJF4361G9_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued Issuance Costs Attributed To Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued issuance costs attributed to warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xml:lang="en-US">Accrued issuance costs attributed to warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:to="lab_4H9ILH6583I1_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssued1" xml:lang="en-US">Common stock issued in connection with purchase of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockIssued1" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization and Basis of Presentation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Operations and Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_2F7GJF4361G9_nmtc_GoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_GoingConcernAbstract" xml:lang="en-US">Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_GoingConcernAbstract" xlink:to="lab_4H9ILH6583I1_nmtc_GoingConcernAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xml:lang="en-US">Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Intangibles [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_IntangibleAssetsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Accrued Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_PayablesAndAccrualsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loan\Convertible Promissory Notes and Warrant Agreements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Description of convertible notes issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtDisclosureAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShortTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermDebtTextBlock" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShortTermDebtTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermDebtTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_InvestmentBankerFeeAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_InvestmentBankerFeeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_InvestmentBankerFeeAbstract" xml:lang="en-US">Investment Banker Fee [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_InvestmentBankerFeeAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_InvestmentBankerFeeAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_InvestmentBankerFeeTextBlock" xlink:label="loc_2F7GJF4361G9_nmtc_InvestmentBankerFeeTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_InvestmentBankerFeeTextBlock" xml:lang="en-US">Investment Banker Fee [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_InvestmentBankerFeeTextBlock" xml:lang="en-US">Investment Banker Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_InvestmentBankerFeeTextBlock" xml:lang="en-US">The entire disclosure for investment banker fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_InvestmentBankerFeeTextBlock" xlink:to="lab_4H9ILH6583I1_nmtc_InvestmentBankerFeeTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Stock-Based Compensation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders'/Member Deficit [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders'/Member Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventsAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_UseOfEstimates" xml:lang="en-US">Management's Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_UseOfEstimates" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_2F7GJF4361G9_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_4H9ILH6583I1_us-gaap_ConcentrationRiskCreditRisk"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_IntellectualPropertyPolicyTextBlock" xlink:label="loc_2F7GJF4361G9_nmtc_IntellectualPropertyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Intellectual Property [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Intellectual Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_IntellectualPropertyPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy fori ntellectual property.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_IntellectualPropertyPolicyTextBlock" xlink:to="lab_4H9ILH6583I1_nmtc_IntellectualPropertyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtPolicyTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_WarrantLiabilityPolicyTextBlock" xlink:label="loc_2F7GJF4361G9_nmtc_WarrantLiabilityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Warrant Liability [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_WarrantLiabilityPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for warrant liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_WarrantLiabilityPolicyTextBlock" xlink:to="lab_4H9ILH6583I1_nmtc_WarrantLiabilityPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Premium Debt Conversion Derivative [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Premium Debt Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for premium debt conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_PremiumDebtConversionDerivativePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" xml:lang="en-US">Schedule of unaudited pro forma consolidated statements of operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_2F7GJF4361G9_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_4H9ILH6583I1_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_2F7GJF4361G9_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_4H9ILH6583I1_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_2F7GJF4361G9_us-gaap_DefinedBenefitPlanDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DefinedBenefitPlanDisclosureLineItems" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_4H9ILH6583I1_us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of fair value of financial instruments measured on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of warrant liability and premium conversion derivative measured at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of computation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_2F7GJF4361G9_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Schedule of stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_4H9ILH6583I1_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of weighted-average assumptions used Black-Scholes option-pricing model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_2F7GJF4361G9_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_4H9ILH6583I1_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xlink:label="loc_2F7GJF4361G9_nmtc_OrganizationAndBasisOfPresentationTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xml:lang="en-US">Organization And Basis Of Presentation Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xml:lang="en-US">Organization and Basis of Presentation (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xlink:to="lab_4H9ILH6583I1_nmtc_OrganizationAndBasisOfPresentationTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Common stock, ownership percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Common stock, ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_2F7GJF4361G9_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xml:lang="en-US">Business Acquisition, Description of Acquired Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xml:lang="en-US">Description of acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="lab_4H9ILH6583I1_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_BusinessAcquisitionSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Par value of outstanding shares of common stock of NeuroOne</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_BusinessAcquisitionSharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_2F7GJF4361G9_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Par value of Company's common stock issued in lieu of exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_4H9ILH6583I1_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US">Common shares exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_2F7GJF4361G9_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Aggregate shares issued of the then-outstanding NeuroOne Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Aggregate of outstanding NeuroOne shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_4H9ILH6583I1_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Reserved shares of common stock for issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Reserved for future issuance shares exercise of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_2F7GJF4361G9_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Cancellation of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_4H9ILH6583I1_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfShortTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfShortTermDebtTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_2F7GJF4361G9_us-gaap_ShortTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ShortTermDebtLineItems" xlink:to="lab_4H9ILH6583I1_us-gaap_ShortTermDebtLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoingConcernTextualAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_GoingConcernTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_GoingConcernTextualAbstract" xml:lang="en-US">Going Concern (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_GoingConcernTextualAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_GoingConcernTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_2F7GJF4361G9_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Cumulative losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_4H9ILH6583I1_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShortTermBankLoansAndNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermBankLoansAndNotesPayable" xml:lang="en-US">Short-term Bank Loans and Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermBankLoansAndNotesPayable" xml:lang="en-US">Short-term promissory note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermBankLoansAndNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_2F7GJF4361G9_us-gaap_ConvertibleNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible promissory note financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible notes and common stock purchase warrants to investors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ConvertibleNotesPayable" xlink:to="lab_4H9ILH6583I1_us-gaap_ConvertibleNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Convertible promissory notes and common stock purchase warrants for aggregate gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from subscription</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_2F7GJF4361G9_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_4H9ILH6583I1_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_2F7GJF4361G9_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_4H9ILH6583I1_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_2F7GJF4361G9_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_4H9ILH6583I1_us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_2F7GJF4361G9_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_4H9ILH6583I1_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_EquityComponentDomain" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_2F7GJF4361G9_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_WarrantMember" xlink:to="lab_4H9ILH6583I1_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_ScheduleOfWarrantLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ScheduleOfWarrantLiabilityAbstract" xml:lang="en-US">Schedule Of Warrant Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ScheduleOfWarrantLiabilityAbstract" xml:lang="en-US">Schedule of warrant liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_ScheduleOfWarrantLiabilityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_2F7GJF4361G9_us-gaap_ProceedsFromWarrantExercises" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Issuance of warrants in connection with convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_4H9ILH6583I1_us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentAxis" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtInstrumentNameDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_2F7GJF4361G9_nmtc_DebtConversionDerivativeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Debt Conversion Derivative [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Premium conversion derivative [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_DebtConversionDerivativeMember" xml:lang="en-US">Debt Conversion Derivative [Member].</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_DebtConversionDerivativeMember" xlink:to="lab_4H9ILH6583I1_nmtc_DebtConversionDerivativeMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xml:lang="en-US">Schedule Of Premium Conversion Derivative [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xml:lang="en-US">Schedule of Premium conversion derivative [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_ScheduleOfPremiumConversionDerivativeAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_2F7GJF4361G9_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value Assigned To Underlying Derivative In Connection With Convertible Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value assigned to the underlying derivative in connection with convertible notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xml:lang="en-US">Value assigned to the underlying derivative in connection with convertible notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:to="lab_4H9ILH6583I1_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ChangeInFairValueOfPremiumConversionDerivative" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_ChangeInFairValueOfPremiumConversionDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ChangeInFairValueOfPremiumConversionDerivative" xml:lang="en-US">Change In Fair Value Of Premium Conversion Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ChangeInFairValueOfPremiumConversionDerivative" xml:lang="en-US">Change in fair value of premium conversion derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ChangeInFairValueOfPremiumConversionDerivative" xml:lang="en-US">Change in fair value of premium conversion derivative.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_ChangeInFairValueOfPremiumConversionDerivative" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_ChangeInFairValueOfPremiumConversionDerivative"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_2F7GJF4361G9_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_4H9ILH6583I1_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_2F7GJF4361G9_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_4H9ILH6583I1_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_EmployeeStockOptionMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_2F7GJF4361G9_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_4H9ILH6583I1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Anti-dilutive computation of diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_2F7GJF4361G9_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_4H9ILH6583I1_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_DebtConversionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtConversionDescription" xml:lang="en-US">Debt Conversion, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtConversionDescription" xml:lang="en-US">Common share price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtConversionDescription" xml:lang="en-US">Debt conversion description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_DebtConversionDescription" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtConversionDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:label="loc_2F7GJF4361G9_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xml:lang="en-US">Financial instruments measured on a fair value recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:to="lab_4H9ILH6583I1_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_LossContingenciesTable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_LossContingenciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_2F7GJF4361G9_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Technology-Based Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">WARF License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_4H9ILH6583I1_us-gaap_TechnologyBasedIntangibleAssetsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_IntellectualPropertyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Intellectual Property [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IntellectualPropertyMember" xml:lang="en-US">Mayo Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_IntellectualPropertyMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_IntellectualPropertyMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_2F7GJF4361G9_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_LossContingenciesLineItems" xlink:to="lab_4H9ILH6583I1_us-gaap_LossContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_CommitmentsAndContingenciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments And Contingencies Textual [Abstract].</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_2F7GJF4361G9_us-gaap_LongTermPurchaseCommitmentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_LongTermPurchaseCommitmentAmount" xml:lang="en-US">Long-term Purchase Commitment, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_LongTermPurchaseCommitmentAmount" xml:lang="en-US">Milestone payments in connection with WARF License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_4H9ILH6583I1_us-gaap_LongTermPurchaseCommitmentAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US">Estimated the fair value of consideration payable to WARF recorded as an intangible asset with a corresponding accrued expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" xlink:label="loc_2F7GJF4361G9_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" xml:lang="en-US">Contingent Payment Due In Event Of Completion Of Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" xml:lang="en-US">Contingent payment due in the event of completion of financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" xml:lang="en-US">Contingent payment due in the event of completion of financing.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" xlink:to="lab_4H9ILH6583I1_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_OtherCommitmentDueInThirdYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_OtherCommitmentDueInThirdYear" xml:lang="en-US">Other Commitment, Due in Third Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_OtherCommitmentDueInThirdYear" xml:lang="en-US">Minimum royalties for the year 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_OtherCommitmentDueInThirdYear" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_OtherCommitmentDueInThirdYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_2F7GJF4361G9_us-gaap_OtherCommitmentDueInFourthYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_OtherCommitmentDueInFourthYear" xml:lang="en-US">Other Commitment, Due in Fourth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_OtherCommitmentDueInFourthYear" xml:lang="en-US">Minimum royalties for the year 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_OtherCommitmentDueInFourthYear" xlink:to="lab_4H9ILH6583I1_us-gaap_OtherCommitmentDueInFourthYear"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_OtherCommitmentDueAfterFourthYear" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_OtherCommitmentDueAfterFourthYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_OtherCommitmentDueAfterFourthYear" xml:lang="en-US">Other Commitment Due After Fourth Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_OtherCommitmentDueAfterFourthYear" xml:lang="en-US">Royalties per year beginning from 2021</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_OtherCommitmentDueAfterFourthYear" xml:lang="en-US">Other Commitment Due After Fourth Year.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_OtherCommitmentDueAfterFourthYear" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_OtherCommitmentDueAfterFourthYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_2F7GJF4361G9_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Value of share issued as royalty upon the achievement of milestone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_4H9ILH6583I1_us-gaap_StockIssuedDuringPeriodValueOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockIssuedDuringPeriodSharesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Share issued as royalty upon the achievment of milestone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssuedDuringPeriodSharesOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xml:lang="en-US">Additional amount of intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xml:lang="en-US">License agreement amendment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AmountRecordedForIntellectualProperty" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_AmountRecordedForIntellectualProperty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AmountRecordedForIntellectualProperty" xml:lang="en-US">Amount Recorded For Intellectual Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AmountRecordedForIntellectualProperty" xml:lang="en-US">Milestone amount recorded for intellectual property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AmountRecordedForIntellectualProperty" xml:lang="en-US">Amount Recorded For Intellectual Property.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_AmountRecordedForIntellectualProperty" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_AmountRecordedForIntellectualProperty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_2F7GJF4361G9_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Other Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Milestone payments accrued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_4H9ILH6583I1_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfAccruedInterest" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_PercentageOfAccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfAccruedInterest" xml:lang="en-US">Percentage Of Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfAccruedInterest" xml:lang="en-US">Accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfAccruedInterest" xml:lang="en-US">Percentage of accrued interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_PercentageOfAccruedInterest" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfAccruedInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentIssuanceDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentIssuanceDate1" xml:lang="en-US">Debt Instrument, Issuance Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentIssuanceDate1" xml:lang="en-US">Expiry date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentIssuanceDate1" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentIssuanceDate1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_2F7GJF4361G9_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_4H9ILH6583I1_us-gaap_FairValueByAssetClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsMember" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsMember" xml:lang="en-US">Intangible Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsMember" xlink:to="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_RangeAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_2F7GJF4361G9_us-gaap_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_RangeMember" xlink:to="lab_4H9ILH6583I1_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_MinimumMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_2F7GJF4361G9_us-gaap_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_MaximumMember" xlink:to="lab_4H9ILH6583I1_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsRollForward" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsRollForward" xml:lang="en-US">Schedule of Intangible Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">License agreement Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net Intangibles, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net Intangibles, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_4H9ILH6583I1_us-gaap_FiniteLivedIntangibleAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite-lived Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">License agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_2F7GJF4361G9_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Less: amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_4H9ILH6583I1_us-gaap_AmortizationOfIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ParentCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ParentCompanyMember" xml:lang="en-US">Parent Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ParentCompanyMember" xml:lang="en-US">NeuroOne Medical Technologies Corporation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ParentCompanyMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ParentCompanyMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:label="loc_2F7GJF4361G9_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Goodwil And Intangible Assets Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Intangibles (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xml:lang="en-US">Goodwil And Intangible Assets Textual [Abstract].</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:to="lab_4H9ILH6583I1_nmtc_GoodwilAndIntangibleAssetsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedExpensesTable" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_AccruedExpensesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedExpensesTable" xml:lang="en-US">Accrued Expenses [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedExpensesTable" xml:lang="en-US">Accrued Expenses [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_AccruedExpensesTable" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedExpensesTable"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedExpensesLineItems" xlink:label="loc_2F7GJF4361G9_nmtc_AccruedExpensesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedExpensesLineItems" xml:lang="en-US">Accrued Expenses [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedExpensesLineItems" xml:lang="en-US">Accrued Expenses [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_AccruedExpensesLineItems" xlink:to="lab_4H9ILH6583I1_nmtc_AccruedExpensesLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccruedLiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Schedule of Accrued expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedLiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_2F7GJF4361G9_nmtc_AccruedLicenseFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued License Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued license fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedLicenseFees" xml:lang="en-US">Accrued License Fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_AccruedLicenseFees" xlink:to="lab_4H9ILH6583I1_nmtc_AccruedLicenseFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AccruedProfessionalFeesCurrent"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_2F7GJF4361G9_nmtc_AccruedIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedIssuanceCosts" xml:lang="en-US">Accrued Issuance Costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_AccruedIssuanceCosts" xlink:to="lab_4H9ILH6583I1_nmtc_AccruedIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedCompensationAndPayrollRelatedCosts" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_AccruedCompensationAndPayrollRelatedCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedCompensationAndPayrollRelatedCosts" xml:lang="en-US">Accrued Compensation And Payroll Related Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedCompensationAndPayrollRelatedCosts" xml:lang="en-US">Accrued compensation and payroll related costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedCompensationAndPayrollRelatedCosts" xml:lang="en-US">Accrued Compensation And Payroll Related Costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_AccruedCompensationAndPayrollRelatedCosts" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_AccruedCompensationAndPayrollRelatedCosts"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedInterest" xlink:label="loc_2F7GJF4361G9_nmtc_AccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedInterest" xml:lang="en-US">Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedInterest" xml:lang="en-US">Accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_AccruedInterest" xml:lang="en-US">Accrued Interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_AccruedInterest" xlink:to="lab_4H9ILH6583I1_nmtc_AccruedInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ExtinguishmentOfDebtAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ExtinguishmentOfDebtAxis" xml:lang="en-US">Extinguishment of Debt [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ExtinguishmentOfDebtAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ExtinguishmentOfDebtAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_2F7GJF4361G9_us-gaap_ExtinguishmentOfDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ExtinguishmentOfDebtTypeDomain" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="lab_4H9ILH6583I1_us-gaap_ExtinguishmentOfDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShortTermDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermDebtMember" xml:lang="en-US">Short-term Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermDebtMember" xml:lang="en-US">Short-Term Promissory Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShortTermDebtMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermDebtMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_2F7GJF4361G9_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_4H9ILH6583I1_us-gaap_LongtermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_LongtermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_2F7GJF4361G9_us-gaap_UnsecuredDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_UnsecuredDebtMember" xlink:to="lab_4H9ILH6583I1_us-gaap_UnsecuredDebtMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xml:lang="en-US">Short Term Promissory Notes And Unsecured Loan Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xml:lang="en-US">Short-Term Promissory Notes and Unsecured Loan (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_2F7GJF4361G9_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Issuance costs discounted of short-term unsecured promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_4H9ILH6583I1_us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_InterestExpenseDebt" xml:lang="en-US">Discount amortization charged to interest expense related to issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_InterestExpenseDebt" xml:lang="en-US">Convertible notes to interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_InterestExpenseDebt" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_InterestExpenseDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Short-term unsecured promissory notes maturity date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Repay principal and accrued and unpaid interest earlier</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentMaturityDate"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_CommonStockPurchaseOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common Stock Purchase Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_CommonStockPurchaseOfWarrants" xml:lang="en-US">Common stock purchase of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_CommonStockPurchaseOfWarrants" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_CommonStockPurchaseOfWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_2F7GJF4361G9_nmtc_WarrantsMaturityTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants Maturity Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants maturity term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrant term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_WarrantsMaturityTerm" xml:lang="en-US">Warrants maturity term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_WarrantsMaturityTerm" xlink:to="lab_4H9ILH6583I1_nmtc_WarrantsMaturityTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_2F7GJF4361G9_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Warrants recorded as additional paid in capital and discounted from short-term notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_4H9ILH6583I1_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair value of warrants risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_2F7GJF4361G9_us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair value of warrants expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_4H9ILH6583I1_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAssumptionsExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair value of warrants expected life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_2F7GJF4361G9_us-gaap_FairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair value of warrants expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_4H9ILH6583I1_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" xml:lang="en-US">Discount Related To Warrants Amortized To Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" xml:lang="en-US">Discount related to warrants amortized to interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" xml:lang="en-US">Discount related to warrants amortized to interest expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_2F7GJF4361G9_us-gaap_UnsecuredDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_UnsecuredDebtCurrent" xml:lang="en-US">Unsecured Debt, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_UnsecuredDebtCurrent" xml:lang="en-US">Short-term unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_UnsecuredDebtCurrent" xlink:to="lab_4H9ILH6583I1_us-gaap_UnsecuredDebtCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_DebtInstrumentTable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtInstrumentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_2F7GJF4361G9_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_4H9ILH6583I1_us-gaap_ShortTermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShortTermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_2F7GJF4361G9_us-gaap_ConvertibleNotesPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Promissory Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_4H9ILH6583I1_us-gaap_ConvertibleNotesPayableMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_2F7GJF4361G9_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_4H9ILH6583I1_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private placement agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_PrivatePlacementMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentLineItems" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xml:lang="en-US">Convertible Promissory Notes And Warrant Agreements Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xml:lang="en-US">Convertible Promissory Notes and Warrant Agreements (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Convertible notes bear interest at fixed rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Percentage of convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Gross proceeds of equity qualified financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentInterestRateTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Debt Instrument, Interest Rate Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Description of outstanding principal and accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentInterestRateTerms" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentInterestRateTerms"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description Of Maximum Voting Power Of Surviving Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description of maximum voting power of surviving entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xml:lang="en-US">Description of maximum voting power of surviving entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_2F7GJF4361G9_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount Of Convertible Note Held By Warrant Holder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount of convertible note held by warrant holder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xml:lang="en-US">Amount of convertible note held by warrant holder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:to="lab_4H9ILH6583I1_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US">Warrants exercisable date of issuance and expire</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_2F7GJF4361G9_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible Promissory Note Proceeds Assigned To Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible promissory note proceeds assigned to warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xml:lang="en-US">Convertible promissory note proceeds assigned to warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:to="lab_4H9ILH6583I1_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_DebtConversionConvertedInstrumentRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtConversionConvertedInstrumentRate" xml:lang="en-US">Debt Conversion, Converted Instrument, Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtConversionConvertedInstrumentRate" xml:lang="en-US">Convertible notes conversion premium</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_DebtConversionConvertedInstrumentRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Convertible notes conversion price per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible Notes Of Conversion Premium Amortization Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible notes of conversion premium amortization expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xml:lang="en-US">Convertible notes of conversion premium amortization expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_2F7GJF4361G9_nmtc_PremiumDebtConversionDerivativeInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium Debt Conversion Derivative Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium debt conversion derivative interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_PremiumDebtConversionDerivativeInterestExpense" xml:lang="en-US">Premium debt conversion derivative interest expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:to="lab_4H9ILH6583I1_nmtc_PremiumDebtConversionDerivativeInterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Convertible notes incurred issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_DeferredFinanceCostsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentFee" xml:lang="en-US">Debt Instrument, Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentFee" xml:lang="en-US">Description of convertible notes issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentFee" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentFee"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_PercentageOfCommonStockPurchaseWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage Of Common Stock Purchase Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage of common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfCommonStockPurchaseWarrants" xml:lang="en-US">Percentage of common stock purchase warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfCommonStockPurchaseWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_2F7GJF4361G9_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance Costs Attributed To Common Stock Purchase Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance costs attributed to common stock purchase warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xml:lang="en-US">Issuance costs attributed to common stock purchase warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:to="lab_4H9ILH6583I1_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_InvestmentBankerFeeTextualAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_InvestmentBankerFeeTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_InvestmentBankerFeeTextualAbstract" xml:lang="en-US">Investment Banker Fee Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_InvestmentBankerFeeTextualAbstract" xml:lang="en-US">Investment Banker Fee (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_InvestmentBankerFeeTextualAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_InvestmentBankerFeeTextualAbstract"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_NonRefundableFeeToInvestmentBanker" xlink:label="loc_2F7GJF4361G9_nmtc_NonRefundableFeeToInvestmentBanker" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_NonRefundableFeeToInvestmentBanker" xml:lang="en-US">Non Refundable Fee To Investment Banker</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_NonRefundableFeeToInvestmentBanker" xml:lang="en-US">Non-refundable fee to investment banker</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_NonRefundableFeeToInvestmentBanker" xml:lang="en-US">The amount of non-refundable fee to investment banker.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_NonRefundableFeeToInvestmentBanker" xlink:to="lab_4H9ILH6583I1_nmtc_NonRefundableFeeToInvestmentBanker"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_2F7GJF4361G9_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_4H9ILH6583I1_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_2F7GJF4361G9_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_4H9ILH6583I1_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_2F7GJF4361G9_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_4H9ILH6583I1_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_2F7GJF4361G9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected life of options (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_2F7GJF4361G9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_2F7GJF4361G9_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_4H9ILH6583I1_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_PlanNameAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_2F7GJF4361G9_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_PlanNameDomain" xlink:to="lab_4H9ILH6583I1_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_TwoThousandSixteenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_TwoThousandSixteenPlanMember" xml:lang="en-US">Two Thousand Sixteen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_TwoThousandSixteenPlanMember" xml:lang="en-US">2016 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_TwoThousandSixteenPlanMember" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_TwoThousandSixteenPlanMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_2F7GJF4361G9_nmtc_TwoThousandSixteenAndSeventeenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xml:lang="en-US">Two Thousand Sixteen And Seventeen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xml:lang="en-US">2016 and 2017 Plans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:to="lab_4H9ILH6583I1_nmtc_TwoThousandSixteenAndSeventeenPlanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_TitleOfIndividualAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_2F7GJF4361G9_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_4H9ILH6583I1_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_EmployeesDirectorsAndConsultantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees Directors And Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_EmployeesDirectorsAndConsultantsMember" xml:lang="en-US">Employees, directors, and consultants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_EmployeesDirectorsAndConsultantsMember" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_EmployeesDirectorsAndConsultantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_2F7GJF4361G9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_StockBasedCompensationTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_StockBasedCompensationTextualAbstract" xml:lang="en-US">Stock Based Compensation Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_StockBasedCompensationTextualAbstract" xml:lang="en-US">Stock-Based Compensation (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_StockBasedCompensationTextualAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_StockBasedCompensationTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_2F7GJF4361G9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Stock options for shares of common stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_4H9ILH6583I1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Stock options weighted average exercise price for shares of common stock granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_2F7GJF4361G9_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Stock options granted weighted average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Stock options vesting periods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_2F7GJF4361G9_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Stock options expire</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Shares of restricted common stock vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_2F7GJF4361G9_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xml:lang="en-US">Stock options vested shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="lab_4H9ILH6583I1_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Stock options forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_2F7GJF4361G9_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized stock-based compensation cost for stock options and restricted common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_4H9ILH6583I1_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_RestrictedStockExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted Stock or Unit Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_RestrictedStockExpense" xml:lang="en-US">Compensation expense associated with restricted common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_RestrictedStockExpense" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_RestrictedStockExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_2F7GJF4361G9_us-gaap_IncomeTaxContingencyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeTaxContingencyTable" xml:lang="en-US">Income Tax Contingency [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_4H9ILH6583I1_us-gaap_IncomeTaxContingencyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_IncomeTaxContingencyLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_IncomeTaxContingencyLineItems" xml:lang="en-US">Income Tax Contingency [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_IncomeTaxContingencyLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_IncomeTaxesTextualAbstract" xlink:label="loc_2F7GJF4361G9_nmtc_IncomeTaxesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_IncomeTaxesTextualAbstract" xlink:to="lab_4H9ILH6583I1_nmtc_IncomeTaxesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_2F7GJF4361G9_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Provision for income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_4H9ILH6583I1_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_2F7GJF4361G9_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_ClassOfStockLineItems" xlink:to="lab_4H9ILH6583I1_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_StockholdersMemberDeficitTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_StockholdersMemberDeficitTextualAbstract" xml:lang="en-US">Stockholders Member Deficit Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_StockholdersMemberDeficitTextualAbstract" xml:lang="en-US">Stockholders'/Member Deficit (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_StockholdersMemberDeficitTextualAbstract" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_StockholdersMemberDeficitTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_2F7GJF4361G9_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SubsequentEventTable" xlink:to="lab_4H9ILH6583I1_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_2F7GJF4361G9_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_4H9ILH6583I1_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Events [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventMember" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PlacementAgentMember" xlink:label="loc_2F7GJF4361G9_nmtc_PlacementAgentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_PlacementAgentMember" xlink:to="lab_4H9ILH6583I1_nmtc_PlacementAgentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventLineItems" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_2F7GJF4361G9_nmtc_SubsequentEventsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_SubsequentEventsTextualAbstract" xlink:to="lab_4H9ILH6583I1_nmtc_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Exchange for the issuance of company shares acquisition percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_2F7GJF4361G9_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_4H9ILH6583I1_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventDescription" xml:lang="en-US">Subsequent Event, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventDescription" xml:lang="en-US">Subsequent event, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_us-gaap_SubsequentEventDescription" xlink:to="lab_3K7I8KL0459M199KH8H1_us-gaap_SubsequentEventDescription"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfCapitalReceived" xlink:label="loc_2F7GJF4361G9_nmtc_PercentageOfCapitalReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4H9ILH6583I1_nmtc_PercentageOfCapitalReceived" xml:lang="en-US">Percentage Of Capital Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4H9ILH6583I1_nmtc_PercentageOfCapitalReceived" xml:lang="en-US">Total amount of capital received, percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4H9ILH6583I1_nmtc_PercentageOfCapitalReceived" xml:lang="en-US">Percentage of capital received.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2F7GJF4361G9_nmtc_PercentageOfCapitalReceived" xlink:to="lab_4H9ILH6583I1_nmtc_PercentageOfCapitalReceived"/>
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfNonaccountableExpense" xlink:label="loc_1I5G6IJ8237K977IF6F9_nmtc_PercentageOfNonaccountableExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfNonaccountableExpense" xml:lang="en-US">Percentage Of Nonaccountable Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfNonaccountableExpense" xml:lang="en-US">Percentage of non-accountable expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfNonaccountableExpense" xml:lang="en-US">Percentage of nonaccountable expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_1I5G6IJ8237K977IF6F9_nmtc_PercentageOfNonaccountableExpense" xlink:to="lab_3K7I8KL0459M199KH8H1_nmtc_PercentageOfNonaccountableExpense"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nmtc-20170930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#DocumentAndEntityInformation" roleURI="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#OrganizationAndBasisOfPresentation" roleURI="http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentation"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#GoingConcern" roleURI="http://www.originalsourcemusic.com/role/GoingConcern"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CommitmentsAndContingencies" roleURI="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#Intangibles" roleURI="http://www.originalsourcemusic.com/role/Intangibles"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#AccruedExpenses" roleURI="http://www.originalsourcemusic.com/role/AccruedExpenses"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#ShortTermPromissoryNotesAndUnsecuredLoan" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#ConvertiblePromissoryNotesAndWarrantAgreements" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#InvestmentBankerFee" roleURI="http://www.originalsourcemusic.com/role/InvestmentBankerFee"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockBasedCompensation" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensation"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#IncomeTaxes" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockholdersmemberDeficit" roleURI="http://www.originalsourcemusic.com/role/StockholdersmemberDeficit"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SubsequentEvents" roleURI="http://www.originalsourcemusic.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#OrganizationandBasisofPresentationTables" roleURI="http://www.originalsourcemusic.com/role/OrganizationandBasisofPresentationTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#IntangiblesTables" roleURI="http://www.originalsourcemusic.com/role/IntangiblesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#AccruedExpensesTables" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockBasedCompensationTables" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationTables"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#OrganizationAndBasisOfPresentationDetails" roleURI="http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentationDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#GoingConcernDetails" roleURI="http://www.originalsourcemusic.com/role/GoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesDetails1" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesDetails2" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryofSignificantAccountingPoliciesDetails3" roleURI="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#CommitmentsandContingenciesDetails" roleURI="http://www.originalsourcemusic.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#IntangiblesDetails" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#IntangiblesDetailsTextual" roleURI="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#AccruedExpensesDetails" roleURI="http://www.originalsourcemusic.com/role/AccruedExpensesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#ShortTermPromissoryNotesAndUnsecuredLoanDetails" roleURI="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#ConvertiblePromissoryNotesandWarrantAgreementsDetails" roleURI="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#InvestmentBankerFeeDetails" roleURI="http://www.originalsourcemusic.com/role/InvestmentBankerFeeDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockBasedCompensationDetails" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockBasedCompensationDetails1" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockBasedCompensationDetails2" roleURI="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#IncomeTaxesDetails" roleURI="http://www.originalsourcemusic.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#StockholdersmemberDeficitDetails" roleURI="http://www.originalsourcemusic.com/role/StockholdersmemberDeficitDetails"/>
<roleRef xlink:type="simple" xlink:href="nmtc-20170930.xsd#SubsequentEventsDetails" roleURI="http://www.originalsourcemusic.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DocumentAndEntityInformationAbstract" xlink:label="loc_nmtc_DocumentAndEntityInformationAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_4" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="40" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_6" order="50" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="60" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_8" order="70" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" order="80" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_10" order="90" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_11" order="100" use="optional" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_AssetsAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_Cash_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_AssetsCurrent_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_Assets_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_ShortTermBorrowings_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrent_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_CommitmentsAndContingencies_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_PreferredStockValue_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_CommonStockValue_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AdditionalPaidInCapital_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_StockholdersEquity_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_CommonStockSharesIssued_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6" xlink:to="loc_us-gaap_PredecessorMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9" xlink:to="loc_us-gaap_OperatingExpenses_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OperatingIncomeLoss_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetIncomeLoss_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_16" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_18" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6" xlink:to="loc_us-gaap_PredecessorMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_NetIncomeLoss_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" xlink:to="loc_us-gaap_AdjustmentForAmortization_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" xlink:to="loc_us-gaap_ShareBasedCompensation_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xlink:label="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" xlink:to="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_RevaluationOfPremiumDebtConversionDerivative" xlink:label="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" xlink:to="loc_nmtc_RevaluationOfPremiumDebtConversionDerivative_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_RevaluationOfWarrantLiability" xlink:label="loc_nmtc_RevaluationOfWarrantLiability_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_11" xlink:to="loc_nmtc_RevaluationOfWarrantLiability_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_20" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes" xlink:label="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes" xlink:label="loc_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCostsAttributedToWarrantLiability" xlink:label="loc_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability_37" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_34" xlink:to="loc_us-gaap_StockIssued1_38" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/GoingConcern">
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_nmtc_GoingConcernAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernAbstract_0" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/Intangibles">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ShortTermDebtTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/InvestmentBankerFee">
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_InvestmentBankerFeeAbstract" xlink:label="loc_nmtc_InvestmentBankerFeeAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_InvestmentBankerFeeTextBlock" xlink:label="loc_nmtc_InvestmentBankerFeeTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_InvestmentBankerFeeAbstract_0" xlink:to="loc_nmtc_InvestmentBankerFeeTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersmemberDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_IntellectualPropertyPolicyTextBlock" xlink:label="loc_nmtc_IntellectualPropertyPolicyTextBlock_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_IntellectualPropertyPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DebtPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_WarrantLiabilityPolicyTextBlock" xlink:label="loc_nmtc_WarrantLiabilityPolicyTextBlock_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_WarrantLiabilityPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PremiumDebtConversionDerivativePolicyTextBlock" xlink:label="loc_nmtc_PremiumDebtConversionDerivativePolicyTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_PremiumDebtConversionDerivativePolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/OrganizationandBasisofPresentationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_OrganizationAndBasisOfPresentationTextualAbstract" xlink:label="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5" xlink:to="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_OrganizationAndBasisOfPresentationTextualAbstract_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/GoingConcernDetails">
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoingConcernAbstract" xlink:label="loc_nmtc_GoingConcernAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_3" xlink:to="loc_us-gaap_PredecessorMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoingConcernTextualAbstract" xlink:label="loc_nmtc_GoingConcernTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5" xlink:to="loc_nmtc_GoingConcernTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="loc_us-gaap_ShortTermBankLoansAndNotesPayable_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_ShortTermBankLoansAndNotesPayable_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_ConvertibleNotesPayable_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoingConcernTextualAbstract_6" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_10" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_11" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ScheduleOfWarrantLiabilityAbstract" xlink:label="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfWarrantLiabilityAbstract_6" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DebtConversionDerivativeMember" xlink:label="loc_nmtc_DebtConversionDerivativeMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_nmtc_DebtConversionDerivativeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ScheduleOfPremiumConversionDerivativeAbstract" xlink:label="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5" xlink:to="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes" xlink:label="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ChangeInFairValueOfPremiumConversionDerivative" xlink:label="loc_nmtc_ChangeInFairValueOfPremiumConversionDerivative_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_nmtc_ChangeInFairValueOfPremiumConversionDerivative_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremiumCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ScheduleOfPremiumConversionDerivativeAbstract_6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremiumCurrent_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionDescription" xlink:label="loc_us-gaap_DebtConversionDescription_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_DebtConversionDescription_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract_1" xlink:to="loc_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LossContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6" xlink:to="loc_us-gaap_IntellectualPropertyMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1" xlink:to="loc_us-gaap_LossContingenciesLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_9" xlink:to="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing" xlink:label="loc_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInThirdYear" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInFourthYear" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_OtherCommitmentDueAfterFourthYear" xlink:label="loc_nmtc_OtherCommitmentDueAfterFourthYear_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_OtherCommitmentDueAfterFourthYear_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AmountRecordedForIntellectualProperty" xlink:label="loc_nmtc_AmountRecordedForIntellectualProperty_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_AmountRecordedForIntellectualProperty_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfAccruedInterest" xlink:label="loc_nmtc_PercentageOfAccruedInterest_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_nmtc_PercentageOfAccruedInterest_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="loc_us-gaap_DebtInstrumentIssuanceDate1_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_CommitmentsAndContingenciesTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentIssuanceDate1_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_ParentCompanyMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_6" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_7" xlink:to="loc_us-gaap_PredecessorMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_GoodwilAndIntangibleAssetsTextualAbstract" xlink:label="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9" xlink:to="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_GoodwilAndIntangibleAssetsTextualAbstract_10" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedExpensesTable" xlink:label="loc_nmtc_AccruedExpensesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_nmtc_AccruedExpensesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_AccruedExpensesTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedExpensesLineItems" xlink:label="loc_nmtc_AccruedExpensesLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_AccruedExpensesTable_1" xlink:to="loc_nmtc_AccruedExpensesLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_AccruedExpensesLineItems_5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedLicenseFees" xlink:label="loc_nmtc_AccruedLicenseFees_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6" xlink:to="loc_nmtc_AccruedLicenseFees_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedIssuanceCosts" xlink:label="loc_nmtc_AccruedIssuanceCosts_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6" xlink:to="loc_nmtc_AccruedIssuanceCosts_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedCompensationAndPayrollRelatedCosts" xlink:label="loc_nmtc_AccruedCompensationAndPayrollRelatedCosts_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6" xlink:to="loc_nmtc_AccruedCompensationAndPayrollRelatedCosts_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AccruedInterest" xlink:label="loc_nmtc_AccruedInterest_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6" xlink:to="loc_nmtc_AccruedInterest_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAxis" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_3" xlink:to="loc_us-gaap_ShortTermDebtMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6" xlink:to="loc_us-gaap_UnsecuredDebtMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract" xlink:label="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_8" xlink:to="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_InterestExpenseDebt_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_nmtc_CommonStockPurchaseOfWarrants_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_nmtc_CommonStockPurchaseOfWarrants_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_nmtc_WarrantsMaturityTerm_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_21" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense" xlink:label="loc_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense_22" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnsecuredDebtCurrent" xlink:label="loc_us-gaap_UnsecuredDebtCurrent_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract_9" xlink:to="loc_us-gaap_UnsecuredDebtCurrent_23" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_2" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_3" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract" xlink:label="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8" xlink:to="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_ConvertibleNotesPayable_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity" xlink:label="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_AmountOfConvertibleNoteHeldByWarrantHolder" xlink:label="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_21" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_22" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants" xlink:label="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants_23" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_24" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_InterestExpenseDebt_25" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_26" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_27" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_28" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense" xlink:label="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense_29" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PremiumDebtConversionDerivativeInterestExpense" xlink:label="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_PremiumDebtConversionDerivativeInterestExpense_30" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_31" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFee" xlink:label="loc_us-gaap_DebtInstrumentFee_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentFee_32" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_WarrantsMaturityTerm" xlink:label="loc_nmtc_WarrantsMaturityTerm_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_WarrantsMaturityTerm_33" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_CommonStockPurchaseOfWarrants" xlink:label="loc_nmtc_CommonStockPurchaseOfWarrants_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_CommonStockPurchaseOfWarrants_34" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfCommonStockPurchaseWarrants" xlink:label="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_PercentageOfCommonStockPurchaseWarrants_35" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants" xlink:label="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract_9" xlink:to="loc_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants_36" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/InvestmentBankerFeeDetails">
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_InvestmentBankerFeeAbstract" xlink:label="loc_nmtc_InvestmentBankerFeeAbstract_0" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_InvestmentBankerFeeTextualAbstract" xlink:label="loc_nmtc_InvestmentBankerFeeTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_InvestmentBankerFeeAbstract_0" xlink:to="loc_nmtc_InvestmentBankerFeeTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_NonRefundableFeeToInvestmentBanker" xlink:label="loc_nmtc_NonRefundableFeeToInvestmentBanker_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_InvestmentBankerFeeTextualAbstract_1" xlink:to="loc_nmtc_NonRefundableFeeToInvestmentBanker_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2" xlink:to="loc_us-gaap_PlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_TwoThousandSixteenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenPlanMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenPlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_TwoThousandSixteenAndSeventeenPlanMember" xlink:label="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3" xlink:to="loc_nmtc_TwoThousandSixteenAndSeventeenPlanMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_EmployeesDirectorsAndConsultantsMember" xlink:label="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_nmtc_EmployeesDirectorsAndConsultantsMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_StockBasedCompensationTextualAbstract" xlink:label="loc_nmtc_StockBasedCompensationTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_nmtc_StockBasedCompensationTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockBasedCompensationTextualAbstract_10" xlink:to="loc_us-gaap_RestrictedStockExpense_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_5" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PredecessorMember" xlink:label="loc_us-gaap_PredecessorMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_6" xlink:to="loc_us-gaap_PredecessorMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_IncomeTaxesTextualAbstract" xlink:label="loc_nmtc_IncomeTaxesTextualAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_8" xlink:to="loc_nmtc_IncomeTaxesTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_IncomeTaxesTextualAbstract_9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/StockholdersmemberDeficitDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:label="loc_us-gaap_ConsolidatedEntitiesAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ConsolidatedEntitiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:label="loc_us-gaap_ConsolidatedEntitiesDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesAxis_2" xlink:to="loc_us-gaap_ConsolidatedEntitiesDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:label="loc_us-gaap_SubsidiariesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidatedEntitiesDomain_3" xlink:to="loc_us-gaap_SubsidiariesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_StockholdersMemberDeficitTextualAbstract" xlink:label="loc_nmtc_StockholdersMemberDeficitTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_nmtc_StockholdersMemberDeficitTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares" xlink:label="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_StockholdersMemberDeficitTextualAbstract_6" xlink:to="loc_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.originalsourcemusic.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_us-gaap_PrivatePlacementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PlacementAgentMember" xlink:label="loc_nmtc_PlacementAgentMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6" xlink:to="loc_nmtc_PlacementAgentMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_SubsequentEventsTextualAbstract" xlink:label="loc_nmtc_SubsequentEventsTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9" xlink:to="loc_nmtc_SubsequentEventsTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_10" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_10" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_10" xlink:to="loc_us-gaap_SubsequentEventDescription_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfCapitalReceived" xlink:label="loc_nmtc_PercentageOfCapitalReceived_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_10" xlink:to="loc_nmtc_PercentageOfCapitalReceived_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="nmtc-20170930.xsd#nmtc_PercentageOfNonaccountableExpense" xlink:label="loc_nmtc_PercentageOfNonaccountableExpense_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nmtc_SubsequentEventsTextualAbstract_10" xlink:to="loc_nmtc_PercentageOfNonaccountableExpense_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814569616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 10, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROONE MEDICAL TECHNOLOGIES Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001500198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,864,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820967040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 70,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">7,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">77,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">190,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">267,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">916,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term promissory notes and unsecured loan</a></td>
<td class="nump">204,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes, net and accrued interest</a></td>
<td class="nump">1,459,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium debt conversion derivative</a></td>
<td class="nump">441,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,022,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">774,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,796,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 and 5,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; no shares issued or outstanding as of September 30, 2017 and December 31, 2016.</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value ; 100,000,000 and 45,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; and 7,864,994 and 5,216,565 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively.</a></td>
<td class="nump">7,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">162,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,699,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(3,528,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 267,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,823<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term promissory notes and unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible promissory notes, net and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium debt conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,650<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">677,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,960<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,023,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 and 5,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; no shares issued or outstanding as of September 30, 2017 and December 31, 2016.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value ; 100,000,000 and 45,000,000 shares authorized as of September 30, 2017 and December 31, 2016, respectively; and 7,864,994 and 5,216,565 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(266,370)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(266,220)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt premium to be amortized within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814819152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,864,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">7,864,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,216,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,216,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814873024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 893,792<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="nump">$ 1,918,208<span></span>
</td>
<td class="nump">$ 33,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(893,792)<span></span>
</td>
<td class="num">(8,600)<span></span>
</td>
<td class="num">(1,918,208)<span></span>
</td>
<td class="nump">33,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="num">(515,377)<span></span>
</td>
<td class="num">(3,635)<span></span>
</td>
<td class="num">(1,134,529)<span></span>
</td>
<td class="nump">10,698<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (1,409,169)<span></span>
</td>
<td class="num">$ (12,235)<span></span>
</td>
<td class="num">$ (3,052,737)<span></span>
</td>
<td class="nump">$ 43,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">7,864,994<span></span>
</td>
<td class="nump">1,658,051<span></span>
</td>
<td class="nump">7,369,457<span></span>
</td>
<td class="nump">1,658,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember', window );">NeuroOne LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,009)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,698)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,707)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 622,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,798,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">271,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">893,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,298,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(893,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,298,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense</a></td>
<td class="num">(515,377)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,134,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (1,409,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,433,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">7,540,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821381984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,052,737)<span></span>
</td>
<td class="nump">$ 43,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember', window );">NeuroOne LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares', window );">Forgiveness of share subscription agreement for founders' shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Non-cash interest on convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash discount amortization on short-term promissory notes and convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Non-cash note issuance costs attributed to warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevaluationOfPremiumDebtConversionDerivative', window );">Revaluation of premium debt conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevaluationOfWarrantLiability', window );">Revaluation of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,884<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from issuance of short-term promissory notes and convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Repayment of short-term unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs related to short-term promissory notes and convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs related to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes', window );">Bifurcation of premium conversion derivative related to convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes', window );">Accrued issuance costs attributed to short term promissory notes and convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability', window );">Accrued issuance costs attributed to warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in connection with purchase of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,433,068)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">13,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">76,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares', window );">Forgiveness of share subscription agreement for founders' shares</a></td>
<td class="nump">9,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Non-cash interest on convertible promissory notes</a></td>
<td class="nump">76,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash discount amortization on short-term promissory notes and convertible promissory notes</a></td>
<td class="nump">943,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Non-cash note issuance costs attributed to warrant liability</a></td>
<td class="nump">38,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevaluationOfPremiumDebtConversionDerivative', window );">Revaluation of premium debt conversion derivative</a></td>
<td class="nump">90,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_RevaluationOfWarrantLiability', window );">Revaluation of warrant liability</a></td>
<td class="num">(12,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">46,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">642,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,509,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from issuance of short-term promissory notes and convertible promissory notes</a></td>
<td class="nump">675,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">502,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Repayment of short-term unsecured loan</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Issuance costs related to short-term promissory notes and convertible promissory notes</a></td>
<td class="num">(38,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs related to warrants</a></td>
<td class="num">(31,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,057,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
<td class="num">(452,188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
<td class="nump">522,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
<td class="nump">70,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes', window );">Bifurcation of premium conversion derivative related to convertible promissory notes</a></td>
<td class="nump">213,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes', window );">Accrued issuance costs attributed to short term promissory notes and convertible promissory notes</a></td>
<td class="nump">42,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability', window );">Accrued issuance costs attributed to warrant liability</a></td>
<td class="nump">38,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock issued in connection with purchase of intangible assets</a></td>
<td class="nump">$ 23,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued issuance costs attributed to short term promissory notes and convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCostsAttributedToShortTermPromissoryNotesAndConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCostsAttributedToWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued issuance costs attributed to warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCostsAttributedToWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bifurcation of premium conversion derivative related to convertible promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConversionDerivativeRelatedToConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of share subscription agreement for founders shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RevaluationOfPremiumDebtConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of premium debt conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RevaluationOfPremiumDebtConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_RevaluationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_RevaluationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811207072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 1 &#8211; Organization and Basis of Presentation</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On July 20, 2017, NeuroOne Medical Technologies Corporation , a Delaware Corporation, (the &#8220;Company&#8221;), through a wholly owned acquisition subsidiary, acquired 100% of the outstanding capital stock of NeuroOne, Inc. (&#8220;NeuroOne&#8221;) in a reverse triangular merger and reorganization pursuant to Section 368(a) of the Internal Revenue Code (the &#8220;Acquisition&#8221;). The Acquisition was accounted for as a capital transaction, or reverse recapitalization. NeuroOne was the accounting acquirer in this transaction. As such, the historical financial statements of NeuroOne and its predecessor NeuroOne LLC (the &#8220;LLC&#8221;) reflect operations of the Company for all periods presented prior to the date of Acquisition. NeuroOne, Inc. was formed on October 7, 2016 and acquired the LLC on October 27, 2016 (the &#8220;Merger&#8221;) as described more fully below. The accompanying condensed consolidated financial statements subsequent to the Acquisition include those of the Company, as well as those of its wholly owned subsidiary NeuroOne.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Subsequent to the Acquisition, the Company&#8217;s operating activities are the same as those of NeuroOne, an early-stage medical technology company, engaged in the development of comprehensive neuromodulation cEEG and sEEG monitoring, ablation, and brain stimulation solutions to diagnose and treat patients with epilepsy, Parkinson&#8217;s disease, dystonia, essential tremors, and other brain related disorders. The Company is based in Eden Prairie, Minnesota.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Acquisition</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The transactions contemplated by the agreement were consummated on July 20, 2017 (the &#8220;Closing&#8221;) and, pursuant to the terms of the agreement, (i) all outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the &#8220;NeuroOne Shares&#8221;) were exchanged for shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Company Shares&#8221;) based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the &#8220;Exchange Ratio&#8221;), resulting in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options, (iii) all warrants of NeuroOne, Inc. were replaced with warrants to purchase Company Shares and (iv) the Company assumed the outstanding convertible promissory notes of NeuroOne. NeuroOne options had been issued pursuant to the NeuroOne 2016 Equity Incentive Plan. Pursuant to the agreement, the Company assumed the NeuroOne 2016 Equity Incentive Plan upon the Closing.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Pursuant to the Acquisition, the Company acquired 100% of NeuroOne Shares in exchange for the issuance of Company Shares and NeuroOne became the Company&#8217;s wholly-owned subsidiary. Also at the Closing, Mr. Samad (the majority owner of the
 Company prior to the Acquisition) tendered for cancellation 3,500,000 Company Shares held by him as part of the conditions to Closing.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">At the time of Acquisition, the Company had authorized 100,000,000 shares of common stock with a par value of $0.001 and 10,000,000 shares of preferred stock with a par value of $0.001.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All issued and outstanding common stock share amounts, options for common stock and per share amounts contained in the condensed consolidated financial statements were retroactively adjusted to reflect the Exchange Ratio for all periods presented. The number of authorized shares for common and preferred stock and their respective par values per share as of December 31, 2016 reflect those of the Company prior to the Acquisition.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Merger</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The LLC was formed on December 12, 2013 and operated as a limited liability company until it was merged with and into NeuroOne on October 27, 2016 with NeuroOne as the surviving entity of the &#8220;Merger&#8221;. NeuroOne was formed on October 7, 2016 under different ownership than the LLC. As a result of the Merger, all of the properties, rights, privileges, powers and franchises of the LLC vested in NeuroOne, and all debts, liabilities and duties of the LLC became the debts, liabilities and duties of NeuroOne with the exception of the LLC&#8217;s license agreement with Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;) which required WARF&#8217;s approval for transfer (See Note 4 &#8211; Commitments and Contingencies). The purpose of the Merger was to change the jurisdiction of NeuroOne&#8217;s incorporation from Minnesota to Delaware, change the ownership of the LLC&#8217;s underlying assets, and to convert from a limited liability company to a corporation.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">NeuroOne and the LLC were not entities under common control. As the LLC did not have an integrated set of activities that contained the required complement of inputs, processes and outputs to be considered a business, the Merger was accounted for as an asset acquisition as prescribed under Accounting Standards Codification (ASC) 805 &#8211;&#160;<i>Business Combinations</i>.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Basis of presentation</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The accompanying condensed consolidated financial statements have been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements may not include all disclosures required by U.S. GAAP; however, the
 Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto for the fiscal year ended December 31, 2016 included in the NeuroOne Current Report on Form 8-K filed on July 20, 2017. The condensed balance sheet at December 31, 2016 was derived from the audited financial statements of NeuroOne.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617888208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoingConcernAbstract', window );"><strong>Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Going Concern</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 2 &#8211; Going Concern</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has incurred losses since inception and had an accumulated deficit of $3,699,438 as of September 30, 2017. Prior to the Merger, the LLC also incurred losses since its inception and had cumulative losses of $49,930 as of the date of the Merger. The Company does not have adequate liquidity to fund its operations throughout fiscal 2018 without raising additional funds. These factors raise substantial doubt about its ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this condition. Management intends to seek additional financing to fund operations. If the Company is not able to raise additional working capital, it will have a material adverse effect on the operations of the Company and the development of its technology.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Through September 30, 2017, the Company has completed both a $253,000 short-term promissory note financing and a $1,625,120 convertible promissory note financing of a planned $2.5 million subscription. The Company does not have adequate liquidity to fund its operations throughout fiscal 2017 without raising additional funds. Management believes that the currently available resources from the short-term promissory note and convertible promissory note financings combined with funds expected to be raised in the last quarter of fiscal 2017 will be sufficient to enable the Company to meet its operating plan through at least September 30, 2018. However, if the Company is unable to raise additional funds, or the Company&#8217;s anticipated operating results are not achieved, management believes planned expenditures may need to be reduced in order to extend the time period that existing resources can fund the Company&#8217;s operations. If management is unable to obtain the necessary capital, it may have to cease operations.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811248016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 3 &#8211; Summary of Significant Accounting Policies</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Management&#8217;s Use of Estimates</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Concentration of Credit Risk</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of September 30, 2017, the Company did not have deposits in excess of federally insured amounts.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Prior to October 27, 2016, the LLC did not maintain a bank account. Any expenses incurred while the LLC was organized as a limited liability company were paid by the sole member of the LLC.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 18pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><i>&#160;</i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Fair Value of Financial Instruments</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal;
 word-spacing: 0px;
 white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2017 and December 31, 2016, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the short-term promissory notes and the convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and premium conversion derivative associated with the convertible promissory notes was based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments which were based on Level&#160;3 inputs. There were no transfers between fair value hierarchy levels during the three and nine month periods ended September 30, 2017.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The fair value of financial instruments measured on a recurring basis is as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space:
 normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of September 30,&#160;2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">774,172</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">774,172</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">441,823</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">441,823</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,215,995</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,215,995</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman',
 times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1;
 font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">345,960</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">137,650</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">137,650</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">483,610</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">483,610</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman',
 times, serif; font-size: 10pt;">The following table provides a roll-forward of the warrant liability and premium conversion derivative measured at fair value on a recurring basis using unobservable level&#160;3 inputs for the nine months ended
 September 30, 2017:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-weight: bold;">Warrant liability</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Nine months ended&#160;<br />September&#160;30,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-indent: 0in; padding-left: 0in;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Issuance of warrants in connection with convertible promissory notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">440,919</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(12,707</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">774,172</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-weight: bold;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Nine months ended&#160;<br />September&#160;30,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-indent: 0in; padding-left: 0in;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">137,650</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Value assigned to the underlying derivative in connection with convertible notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">213,961</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Change in fair value of premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">90,212</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">441,823</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">There
 were no financial instruments measured on a fair value recurring basis during the nine month period ended September 30, 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Intellectual Property</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">NeuroOne and the LLC have entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Milestone payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Impairment of Long-Lived Assets</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company evaluates their long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2017, the Company has not impaired any long-lived assets.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><i>&#160;</i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Debt Issuance Costs</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Debt issuance costs are recorded as a reduction of the short-term promissory notes and convertible promissory notes. Amortization of debt issuance costs is calculated using the straight-line method over the term of respective short-term and convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed consolidated statements of operations.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><i>&#160;</i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Research and Development Costs</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Research and development costs are charged to expense as incurred. Research and development expenses may comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in
 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Warrant Liability</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company issued warrants to purchase equity securities in connection with the issuance of the convertible promissory notes (see Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value as the number of shares were not fixed and determinable at the issuance date. Additionally, issuance costs associated with the warrants are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability will be recognized as a component of interest expense in the condensed consolidated statements of operations.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Premium Debt Conversion Derivative</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&#160; The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative to interest expense at each reporting period. The Company issued convertible promissory notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.25 per common share (see Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). We also issued 2017 Convertible Notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.8125 per common share (see Note 13 &#8211; Subsequent Events). The Company determined that the redemption feature under the convertible promissory notes qualified as an embedded derivative and was separated from its debt host.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Income Taxes</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">For NeuroOne, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size:
 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;">The LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne on October 27, 2016. As such, it was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included in the financial statements for the period from January 1, 2016 through October 26, 2016.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Net Loss Per Share</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The LLC was a single-member LLC for which no units were outstanding. Accordingly, earnings per share is not presented for the LLC.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For NeuroOne, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s stock options, convertible promissory notes and warrants are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the stock options and warrants. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the three and nine months ended September 30, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and nine months ended September 30, 2017.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and nine month periods ended September 30, 2017:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1395px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Warrants</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times,
 serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 125px; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;">1,074,181</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Stock options</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">365,716</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Recent Accounting Pronouncements</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In January 2016, the FASB issued ASU No.&#160;2016-01,&#160;<i>Financial Instruments&#160;&#8212; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</i>. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2018 for public entities and for all other entities in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In May 2017, the FASB issued ASU 2017-09,&#160;<i>Compensation - Stock Compensation (Topic 718):&#160;Scope of Modification Accounting (ASU 2016-09)</i>,&#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#8217;s financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In July 2017, the FASB issued ASU No. 2017-11,&#160;<i>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</i>, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&#160;15, 2018 for public business entities and after December 15, 2019 for all other entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#8217;s financial statements.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618305680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 4 &#8211; Commitments and Contingencies</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><i>&#160;</i></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>WARF License Agreement</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On October 1, 2014, the LLC entered into an exclusive start-up company license agreement with the Wisconsin Alumni Research Foundation (&#8220;WARF&#8221;) for WARF&#8217;s neural probe array and thin film electrode technology (the &#8220;2014 WARF Agreement&#8221;). The LLC was to make $110,000 in milestone payments depending on achievement of certain development and approval milestones or within twelve months of signing the 2014 WARF Agreement. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC was to pay royalties to WARF on a percentage of net sales of products of the licensed technology. Under the terms of the 2014 WARF Agreement, amounts that remained unpaid more than 30 days after they were due, accrued interest at 1 percent per month. Milestone payments due in 2015 were not made to WARF. From October 27, 2016 until the 2014 WARF Agreement was amended as described below, the LLC was in default under the 2014 WARF Agreement. In addition, the LLC was not able to transfer the rights and obligations under the 2014 WARF Agreement to NeuroOne at the time of the Merger (October 27, 2016) without the consent of WARF, which was received when the 2014 WARF Agreement was amended in February 2017 as described below. In connection with the Merger and in accordance with ASC 805-50, NeuroOne estimated the fair value of consideration payable to WARF and recorded an intangible asset of $90,000 with a corresponding accrued expense.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">This agreement was subsequently amended in February 2017 (as so amended, the &#8220;2017 WARF Agreement&#8221;) whereby WARF consented to the transfer of the rights and obligations under the license agreement from the LLC to NeuroOne (which are now the Company&#8217;s rights and obligations, following the Acquisition). In the 2017 WARF Agreement, a contingent payment amount of $120,000 is due in the event that the Company completes a qualified financing. The Company is also obligated to pay royalties to WARF based on a percentage of net sales of products of licensed technology with minimum royalties of $50,000 and $100,000 for calendar years 2019 and 2020, respectively, and $150,000 per year beginning in 2021 through the duration of the 2017 WARF Agreement. Subject to earlier termination, the WARF License otherwise expires by its terms on the date that no valid claims on the patents licensed thereunder remain. The Company expects the latest expiration of a licensed patent to occur in 2030. The 2017 WARF Agreement is also subject to certain cancellation provisions with 90 days&#8217; notice should the Company elect not to continue to use the licensed technology.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company has agreed to diligently develop, manufacture, market and sell products under the WARF License in the United States during the term of the agreement and, specifically, that the Company will submit a business plan to WARF by February 1, 2018 and file an application for 510(k) marketing clearance with the FDA by February 1, 2019. WARF may terminate the 2017 WARF Agreement in the event that the Company fails to meet these milestones on 30 days&#8217; written notice, if the
 Company defaults on the payments of amounts due to WARF or fails to timely submit development reports, actively pursue the development plan or breaches any other covenant in the 2017 WARF Agreement and fails to remedy such default in 90 days or in the event of certain bankruptcy events involving the Company. WARF may also terminate this license (i) on 90 days&#8217; notice if the Company fails to have commercial sales of one or more FDA-approved products under the 2017 WARF Agreement by March 31, 2019 or (ii) if, after royalties earned on sales begin to be paid, such earned royalties cease for more than four calendar quarters.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Mayo Agreement</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On October 3, 2014, the LLC entered into an exclusive license and development agreement with the Mayo Foundation for Medical Education and Research (&#8220;Mayo&#8221;) related to certain intellectual property and development services for thin film electrode technology (&#8220;2014 Mayo Agreement&#8221;). The LLC was to make milestone payments depending on achievement of certain development and approval milestones and sales targets, none of which were met as of December 31, 2015. Additionally, if the LLC was successful in obtaining regulatory approval, the LLC was to pay royalties to Mayo based on a percentage of net sales of products of the licensed technology through the term of the 2014 Mayo Agreement, set to expire May 25, 2037. Also, the LLC was obligated to issue common stock to Mayo if certain events occurred. Upon the LLC&#8217;s Merger with NeuroOne on October 27, 2016, the rights under the 2014 Mayo Agreement transferred to NeuroOne, and certain milestones were attained. Therefore, NeuroOne recorded $300 related to 10,000 shares of common stock issued to Mayo and $91,709 for the intellectual property. Milestone payments due under the 2014 Mayo Agreement and accrued were $91,709 as of September 30, 2017 and December 31, 2016. Under the terms of the 2014 Mayo Agreement, amounts that remained unpaid accrued interest at 2 percent above the prime rate. Milestone payments due in 2016 were not made to Mayo. As such, prior to the amendment of the 2014 Mayo Agreement in May 2017), NeuroOne was in default under the 2014 Mayo Agreement. Mayo and NeuroOne amended and restated the 2014 Mayo Agreement in May 2017 (as so amended and restated, the &#8220;2017 Mayo Agreement&#8221;). Pursuant to the 2017 Mayo Agreement, NeuroOne issued 50,556 shares of common stock to Mayo to settle the amount of common stock NeuroOne was previously obligated to issue under the 2014 Mayo Agreement and to amend the terms of the 2014 Mayo Agreement. NeuroOne recorded an additional $23,115 to intangible assets related to the fair value of the 2017 stock issuance to Mayo. As a part of the 2017 Mayo Agreement, as amended in November 2017, the $91,709 milestone payment is to be paid upon the earlier of a qualified financing or December 31, 2017.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Other</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">NeuroOne received a letter in May 2017 from the former employer of certain employees of NeuroOne, claiming that NeuroOne and those individuals have wrongfully used or disclosed alleged trade secrets of the former employer and that the individuals breached non-competition or non-solicitation agreements with such party. The Company and the individuals intend to vigorously defend against these claims, if litigation results.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811209536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangibles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangibles</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 5 &#8211; Intangibles</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Intangible assets consisted of the following at September 30, 2017:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: center; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Useful Life</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: center; text-indent: 0in; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1191px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">License agreement, October 27, 2016</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 173px; text-align: center; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">12-13 years</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 141px; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">182,159</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Less: amortization</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch:
 normal;"><font style="font-family:
 'times new roman', times, serif; font-size: 10pt;">(1,269</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Net Intangibles, December 31, 2016</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">180,890</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">License agreement amendment</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">23,115</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Less: amortization</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(13,368</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Net Intangibles, September 30, 2017</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="font:
 10pt/normal 'times new roman', times, serif; padding: 0in; text-align:
 right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">190,637</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Amortization expense was $4,264 and $13,368 for NeuroOne and the Company for the three and nine months ended September 30, 2017, respectively, and $1,941 and $5,823 for the LLC for the three and nine months ended September 30, 2016.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618305680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 6 &#8211; Accrued Expenses</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Accrued expenses consisted of the following at September 30, 2017 and December 31, 2016:&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31,<br />2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left; text-indent: 0in; padding-left: 0in;">Accrued license fees</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">182,009</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">182,009</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Accrued services</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">531,607</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">31,186</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Accrued issuance costs</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">32,306</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">22,015</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Accrued compensation and payroll related costs</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">170,812</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">28,252</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Accrued interest</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">881</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;">Total accrued expenses</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">916,734</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">264,343</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803207408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Promissory Notes and Unsecured Loan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-Term Promissory Notes and Unsecured Loan</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 7 &#8211; Short-Term Promissory Notes and Unsecured Loan</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Short-Term Promissory Notes</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2017, the Company&#8217;s Board of Directors authorized and the Company issued short-term unsecured promissory notes (the &#8220;Short-Term Notes&#8221;) for aggregate gross proceeds of $253,000 prior to issuance costs of $3,030 which were discounted from the Short-Term Notes and are being amortized ratably to interest expense over the term of the Short-Term Notes. For the three and nine month period ended September 30, 2017, discount amortization charged to interest expense related to the issuance costs was $733. The Short-Term Notes do not bear interest on principal and require the Company to repay the principal upon maturity on February&#160;18, 2018.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In addition, upon maturity, under the provisions of the Short-Term Notes, the holders will receive 126,500 common stock purchase warrants upon maturity with a term of 5 years at an exercise price of $1.80 which will be immediately exercisable upon issue. A portion of the proceeds from the Short-Term Notes was allocated to the warrants based on their relative fair value to the underlying Short-Term Notes. The proceeds allocated to the warrants were recorded as additional paid in capital in the accompanying condensed consolidated balance sheets and were discounted from the Short-Term Notes in the amount of $61,496. The relative fair value of the warrants was based on the Black-Scholes method with the following assumptions: risk-free interest rate 1.77 percent; expected volatility 48 percent; expected life 5.5 years; and expected dividend yield 0 percent. The underlying stock price used in the analysis is on a non-marketable basis and is according to a separate 409A valuation analysis. The discount related to the warrants is being amortized to interest expense ratably over the term of the Short-Term Notes which amounted to $14,868 during the three and nine month period ended September 30, 2017.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Unsecured Loan</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">NeuroOne received a $50,000 short-term unsecured loan in November 2016 from the placement agent for its convertible promissory note financing (see Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). NeuroOne incurred no fees or interest costs for this temporary loan and it was repaid in full in February 2017.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811207072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan\Convertible Promissory Notes and Warrant Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Promissory Notes and Warrant Agreements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 8 &#8211; Convertible Promissory Notes and Warrant Agreements</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Convertible Promissory Notes</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In November 2016 and then amended in June 2017, the Company&#8217;s Board of Directors authorized the Company to issue convertible promissory notes (the &#8220;Convertible Notes&#8221;) and common stock purchase warrants for aggregate gross proceeds of up to $2.5 million.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2017, the Company has issued $1,625,120 of Convertible Notes and common stock purchase warrants to investors. The Convertible Notes are unsecured. The Convertible Notes bear interest at a fixed rate of 8 percent per annum and require the Company to repay the principal and accrued and unpaid interest thereon at the earlier of November 21, 2017 or the consummation of the next equity or equity-linked round of financing resulting in more than $3.0 million in gross proceeds (a &#8220;Qualified Financing&#8221;). If a Qualified Financing occurs before November 21, 2017, the outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by November 21, 2017, the Convertible Notes will be immediately due and payable on such date.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">If a change of control transaction or initial public offering occurs prior to a Qualified Financing, the Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the Convertible Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of the per share value as determined by the Company&#8217;s Board of Directors as if in connection with the granting of stock based compensation, or in a private sale to a third party in an arms&#8217; length transaction, or at the per share consideration to be paid in such transaction. Change of control means a merger or consolidation with another entity in which the Company&#8217;s stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The warrants granted holders the option to purchase either (i) if exercised after conversion of the Convertible Notes, the number of shares issuable upon the conversion of the Convertible Notes, or (ii) if exercised prior to conversion of the Convertible Notes, the number of shares of common stock equal to the outstanding principal and accrued interest on the Convertible Note held by such warrant holder divided by $1.80. The warrants were immediately exercisable on the date of
 issuance and expire on November 21, 2021. In June 2017, however, the Company amended the terms of the common stock purchase warrants under the Convertible Notes to be exercisable only in the event of conversion of the outstanding principal and accrued interest on the related Convertible Notes. The amount of warrant shares to be issued are now fixed to the number of shares of common stock received by the holder of the Convertible Notes upon conversion of such holder&#8217;s Convertible Notes, and to an exercise price equal to the price at which the Convertible Notes convert into common shares.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The warrants were accounted for as a liability because there is no set exercise price. A Monte Carlo simulation model was used to estimate the aggregate fair value of the warrants as of September 30, 2017. Input assumptions used were as follows: risk-free interest rate 1.79 percent; expected volatility 50 percent; expected life 4.14 years; and expected dividend yield 0 percent. The underlying stock price used in the analysis is on a non-marketable basis and is according to a separate 409A valuation analysis.&#160;The convertible promissory note proceeds assigned to the warrants were $440,919 and $345,640 during the nine months ended September 30, 2017 and for the period from October 7, 2016 to December 31, 2016, respectively, which represented their fair value at issuance, and were discounted from the Convertible Notes and reflected as a warrant liability. The discount is being amortized to interest expense over the term of the Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $284,637 and $601,794 for the three and nine months ended September 30, 2017, respectively. The Company recorded the fair value changes of the warrant liability associated with the Convertible Notes to interest expense which amounted to $6,546 and $(12,707) for the three and nine months ended September 30, 2017, respectively.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">At the time of their issuance, the Convertible Notes contained a 125% conversion premium in the event that a Qualified Financing occurs at a price under $2.25 per common share. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes in the amount of $213,961 and $137,564 during the nine months ended September 30, 2017 and during the period from October 7, 2016 to December 31, 2016, respectively. The discount is being amortized to interest expense over the term of the Convertible Notes using the straight-line method which approximates the effective interest method. The amortization expense was $133,367 and $266,848 for the three and nine month period ended September 30, 2017, respectively. The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium debt conversion derivative associated with the Convertible Notes to interest expense which amounted to $15,406 and $90,212 for the three and nine months ended September&#160;30, 2017, respectively.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the &#8220;placement agent warrant&#8221;) which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855 at September 30, 2017 and (iii) legal expenses of $33,450. The placement agent warrant is issuable at the time the private placement transaction closes. The placement agent warrant will be immediately exercisable on the date of issuance and will expire five years following the date of issuance. The placement agent is to receive a placement agent warrant to purchase shares of common stock in an amount equal to 8 percent of the common stock (or common stock equivalents) purchased by investors in the private placement transaction. As of September 30, 2017 and December 31, 2016, the Company has an obligation to issue a placement agent warrant for the purchase of approximately 63,000 and 29,000 shares of common stock, respectively. The Company recorded an issuance cost discount to the Convertible Notes in the amount of $39,781 and $37,469 for the nine months ended September 30, 2017 and for the period from October 7, 2016 to December 31, 2016, respectively, of which $27,317 and $59,184 was amortized to interest expense during the three and nine
 months ended September 30, 2017, respectively. The balance of the issuance costs in the amount of zero and $38,119 was attributed to the common stock purchase warrants and was immediately recorded as interest expense upon issuance during the three and nine months ended September 30, 2017, respectively.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The placement agent is also entitled to receive warrants to purchase common stock in an amount equal to 10 percent of the common stock (common stock equivalents) purchased by certain investors in subsequent equity financing rounds (see Note 13 &#8211; Subsequent Events). Such warrants if issued will have an exercise price determined in relation to the pricing of the subsequent financing rounds and will be immediately exercisable once issued.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617888208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Banker Fee<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InvestmentBankerFeeAbstract', window );"><strong>Investment Banker Fee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InvestmentBankerFeeTextBlock', window );">Investment Banker Fee</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 9 &#8211; Investment Banker Fee</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Investment Banker Fee</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">NeuroOne paid a $50,000 non-refundable fee to an investment banker in December 2016 to raise equity financing. This fee is reflected in NeuroOne&#8217;s December 31, 2016 balance sheet as a prepaid expense. NeuroOne subsequently concluded that the investment banker was not expected to raise any equity and therefore expensed the fee in March 2017.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InvestmentBankerFeeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InvestmentBankerFeeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InvestmentBankerFeeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment banker fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InvestmentBankerFeeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811245584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 10 &#8211; Stock-Based Compensation</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">NeuroOne formally adopted an equity incentive plan (&#8220;the 2016 Plan&#8221;) on October 27, 2016 which was subsequently adopted by the Company upon completion of the Acquisition. In addition, the Company adopted a 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) on April 17, 2017. The 2016 and 2017 Plans provide for the issuance of restricted shares and stock options to employees, directors, and consultants of the Company. The Company reserved 2,292,265 shares of common stock (as adjusted for the exchange ratio in connection with the Acquisition) for issuance under the 2016 and 2017 Plans on a combined basis. The Company began granting stock options and restricted stock awards in the second quarter of 2017. During the three and nine-month period ended September 30, 2017, zero and 365,716 stock options for shares of common stock were granted, respectively, to directors and consultants at a weighted average exercise price of $0.035 per share. The stock options granted during the nine month period ended September 30, 2017 had a weighted average grant date fair value of $0.014 per share with various vesting periods and expire in ten years. In addition, the Company issued zero and 215,453 shares of restricted common stock with performance vesting conditions from the 2016 Plan during the three and nine month period ended September 30, 2017, respectively. All performance vesting conditions for the restricted common stock were met as of September 30, 2017. Compensation expense associated with restricted common stock shares was $7,220.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying condensed statements of operations:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="6">Three Months Ended</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="6">Nine Months Ended</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">September 30,</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">September&#160;30,</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;">General and administrative</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">2,065</td><td style="width: 15px; text-align: left;">&#160;</td><td
 style="width: 15px;">&#160;</td><td style="width: 15px;
 text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Research and development</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">64,945</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">74,729</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;">Total stock-based compensation</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">64,945</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">76,794</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The weighted-average assumptions used in the Black-Scholes option-pricing model are as follows for the stock options granted during the three and nine month periods ended September 30, 2017:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Three Months&#160;<br />Ended</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Nine Months&#160;<br />Ended</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left; text-indent: 0in; padding-left: 0in;">Expected stock price volatility</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">%</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">47.8</td><td style="width: 15px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Expected life of options (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.0</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-left:
 0in;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align:
 left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.9</td><td style="text-align: left;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">During the three and nine months ended September 30, 2017, 42,525 and 365,716 stock options vested, respectively, and zero and 215,453 restricted stock awards vested, respectively. The weighted average fair value per share of options vesting during the three and nine months ended September 30, 2017 was $0.014. No stock options were forfeited during the three and nine months ended September 30, 2017. As of September 30, 2017, 1,711,096 shares were available for future issuance on a combined basis under the 2016 and 2017 Plans.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">There was no unrecognized stock-based compensation cost for stock options and restricted common stock as of September 30, 2017.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631682336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 11 &#8211; Income Taxes</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The effective tax rate for the three and nine months ended September 30, 2017 was zero percent. As a result of the analysis of all available evidence as of&#160;September 30, 2017&#160;and&#160;December&#160;31, 2016, the Company recorded a full valuation allowance on its net deferred tax assets. Consequently, the Company reported&#160;no&#160;income tax benefit during the&#160;three and nine month periods ended&#160;September 30, 2017. If the Company&#8217;s assumptions change and the Company believes that it will be able to realize these deferred tax assets, the tax benefits relating to any reversal of the valuation allowance on deferred tax assets will be recognized as a reduction of future income tax expense.&#160;&#160;If the assumptions do not change, each period the Company could record an additional valuation allowance on any increases in the deferred tax assets.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne on October 27, 2016. As such, the LLC was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included in the financial statements for the three or nine month periods ended September 30, 2016.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811189952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders'/Member Deficit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders'/Member Deficit [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders'/Member Deficit</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 12 &#8211; Stockholders&#8217;/Member Deficit</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In June 2017, the purchase price owed by the seven individuals for the founders&#8217; shares of NeuroOne under their respective subscription agreements totaling $9,051 was forgiven by NeuroOne prior to the Acquisition.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803498320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-top-color: black; border-bottom-color: black; border-top-width: 1pt; border-bottom-width: 2.25pt; border-top-style: solid; border-bottom-style: solid; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>NOTE 13 &#8211; Subsequent Events</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On October 4, 2017, the Company entered into a Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with certain accredited investors (the &#8220;Subscribers&#8221;), pursuant to which the Company, in a private placement (the &#8220;Private Placement&#8221;), agreed to issue and sell to the Subscribers 8% convertible promissory notes (each, a &#8220;Note&#8221; and collectively, the &#8220;2017 Convertible Notes&#8221;) and warrants (the &#8220;New Warrants&#8221;) to purchase shares of the Company&#8217;s capital stock.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The initial closing of the Private Placement was consummated on October 4, 2017, and, on that date, the Company issued Notes in an aggregate principal amount of $150,000 to the Subscribers. Between November 2, 2017 and November 7, 2017, the Company entered into Subscription Agreements with additional Subscribers, and issued Notes in a principal amount of $215,000 to those Subscribers. The Company may conduct any number of additional closings so long as the final closing occurs on or before the five-month anniversary of the initial closing date and the amount does not exceed $1,000,000 or a higher amount determined by the Board of Directors.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The 2017 Convertible Notes bear interest at a fixed rate of 8% per annum and require the Company to repay the principal and accrued and unpaid interest thereon on October 4, 2022 (the &#8220;Maturity Date&#8221;). If the Company raises more than $3,000,000 in an equity financing before the Maturity Date (the &#8220;Qualified Financing&#8221;), the outstanding principal and accrued and unpaid interest on the 2017 Convertible Notes shall automatically convert into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the 2017 Convertible Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the Notes multiplied by 1.25, divided by the price paid per security in such financing. If a change of control transaction occurs prior to the earlier of a Qualified Financing or the Maturity Date, the 2017 Convertible Notes would, at the election of the holders of a majority of the outstanding principal of the 2017 Convertible Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by our Board of Directors as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms&#8217; length transaction or (ii) at the per share consideration to be paid in such transaction (the date of any such conversion of the 2017 Convertible Notes pursuant to this paragraph, is referred to herein as the &#8220;Conversion Date&#8221;). Change of control means a merger or consolidation with another entity in which our stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company&#8217;s assets.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Each New Warrant grants the holder the option to purchase the number of shares of capital stock of the Company issuable upon the conversion of the 2017 Convertible Notes held by such holder at a per share exercise price equal to the price at which the 2017 Convertible Notes converted. The New Warrants are
 exercisable
 commencing on the Conversion Date and expire on the five year anniversary of the Conversion Date. The exercise price and number of the shares of our common stock issuable upon exercising the New Warrants will be subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described therein.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The placement agent is also entitled to receive a warrant to purchase common stock in an amount equal to 10 percent of the common stock (common stock equivalents) purchased by certain investors in subsequent equity financing rounds. Such warrant, if issued will have an exercise price determined in relation to the pricing of the subsequent financing and will be immediately exercisable once issued.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In such subsequent equity financing rounds, the placement agent is also entitled to receive a cash fee equal to 10 percent of the total amount of capital received by the Company, as well as a cash amount representing a non-accountable expense allowance equal to 3% of the aggregate gross proceeds raised in such financing.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Subscription Agreements</i></b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Pursuant to the Subscription Agreements, the Company is entitled to receive notice in the event a holder elects to sell or receives a bona fide offer for any portion of the 2017 Convertible Notes or New Warrants, and the right to purchase the 2017 Convertible Notes or New Warrants on the same terms as the proposed sale or bona fide offer, as applicable, as long as the Company exercises that right within 15 days of receiving written notice. The Company has granted the Subscribers indemnification rights with respect to its representations, warranties, covenants and agreements under the Subscription Agreements.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809361424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Management's Use of Estimates</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Management&#8217;s Use of Estimates</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Concentration of Credit Risk</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company&#8217;s cash is held by one financial institution in the United States. Amounts on deposit may at times exceed federally insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. As of September 30, 2017, the Company did not have deposits in excess of federally insured amounts.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Prior to October 27, 2016, the LLC did not maintain a bank account. Any expenses incurred while the LLC was organized as a limited liability company were paid by the sole member of the LLC.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Fair Value of Financial Instruments</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company&#8217;s accounting for fair value measurements of assets and liabilities that are recognized or disclosed at fair value in the condensed consolidated financial statements on a recurring or nonrecurring basis adheres to the Financial Accounting Standards Board (FASB) fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 79px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1488px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">As of September 30, 2017 and December 31, 2016, the fair values of cash, other assets, accrued expenses and the unsecured loan approximated their carrying values because of the short-term nature of these assets or liabilities. The estimated fair value of the
 short-term promissory notes and the convertible promissory notes of the Company was based on amortized cost which was deemed to approximate fair value. The fair value of the warrant liability and premium conversion derivative associated with the convertible promissory notes was based on cash flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments which were based on Level&#160;3 inputs. There were no transfers between fair value hierarchy levels during the three and nine month periods ended September 30, 2017.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The fair value of financial instruments measured on a recurring basis is as follows:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of September 30,&#160;2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">774,172</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">774,172</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">441,823</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">441,823</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,215,995</td><td
 style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,215,995</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0in; padding-left: 0in;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">345,960</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">137,650</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">137,650</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0in;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">483,610</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align:
 left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">483,610</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The following table provides a roll-forward of the warrant liability and premium conversion derivative measured at fair value on a recurring basis using unobservable level&#160;3 inputs for the nine months ended September 30, 2017:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-weight: bold;">Warrant liability</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Nine months ended&#160;<br />September&#160;30,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-indent: 0in; padding-left: 0in;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Issuance of warrants in connection with convertible promissory notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">440,919</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(12,707</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">774,172</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-weight: bold;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Nine months ended&#160;<br />September&#160;30,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-indent: 0in; padding-left: 0in;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">137,650</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Value assigned to the underlying derivative in connection with convertible notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">213,961</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Change in fair value of premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;">90,212</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">441,823</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px 0in 5pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">There were no financial instruments measured on a fair value recurring basis during the nine month period ended September 30, 2016.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IntellectualPropertyPolicyTextBlock', window );">Intellectual Property</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Intellectual Property</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">NeuroOne and the LLC have entered into two licensing agreements with major research institutions, which allows for access to certain patented technology and know-how. Milestone payments under those agreements are capitalized and amortized to general and administrative expense over the expected useful life of the acquired technology.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Impairment of Long-Lived Assets</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company evaluates their long-lived assets, which consists entirely of licensed intellectual property for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. The Company assesses the recoverability of long-lived assets by determining whether or not the carrying value of such assets will be recovered through undiscounted expected future cash flows. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. Through September 30, 2017, the Company has not impaired any long-lived assets.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Debt Issuance Costs</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Debt issuance costs are recorded as a reduction of the short-term promissory notes and convertible promissory notes. Amortization of debt issuance costs is calculated using the straight-line method over the term of respective short-term and convertible promissory notes, which approximates the effective interest method, and is recorded in interest expense in the accompanying condensed consolidated statements of operations.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0px; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Research and Development Costs</i></b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal; line-height: normal; margin: 0px; text-align: justify;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Research and development costs are charged to expense as incurred. Research and development expenses may comprise costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and pre-clinical materials as well as other contracted services, license fees, and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with ASC 730,&#160;<i>Research and Development</i>.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Warrant Liability</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company issued warrants to purchase equity securities in connection with the issuance of the convertible promissory notes (see Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). The Company accounts for these warrants as a liability at fair value as the number of shares were not fixed and determinable at the issuance date. Additionally, issuance costs associated with the warrants are expensed as incurred and reflected as interest expense in the accompanying condensed consolidated statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant, or until such time, if any, as the number of shares to be exercised becomes fixed, at which point the warrants will be classified in stockholders&#8217; (deficit) equity provided that there are sufficient authorized and unissued shares of common stock to settle the warrants and redeem any other contracts that may require settlement in shares of common stock. Any future change in fair value of the warrant liability will be recognized as a component of interest expense in the condensed consolidated statements of operations.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumDebtConversionDerivativePolicyTextBlock', window );">Premium Debt Conversion Derivative</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Premium Debt Conversion Derivative</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company evaluates all conversion and redemption features contained in a debt instrument to determine if there are any embedded derivatives that require separation from the host debt instrument. An embedded derivative that requires separation is bifurcated from its host debt instrument and a corresponding discount to the host debt instrument is recorded. The discount is amortized and recorded to interest expense over the term of the host debt instrument using the straight-line method which approximates the effective interest method.&#160; The separated embedded derivative is accounted for separately on a fair market value basis. The Company records the fair value changes of a separated embedded derivative to interest expense at each reporting period. The Company issued convertible promissory notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.25 per common share (see Note 8 &#8211; Convertible Promissory Notes and Warrant Agreements). We also issued 2017 Convertible Notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.8125 per common share (see Note 13 &#8211; Subsequent Events). The Company determined that the redemption feature under the convertible promissory notes qualified as an embedded derivative and was separated from its debt host.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Income Taxes</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">For NeuroOne, income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that some portion of all of the deferred tax asset will not be realized.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The LLC operated as a single-member LLC from formation on December 12, 2013 until it was merged into NeuroOne on October 27, 2016. As such, it was a disregarded legal entity for income tax purposes. Accordingly, no provision for income taxes was included in the financial statements for the period from January 1, 2016 through October 26, 2016.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Net Loss Per Share</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The LLC was a single-member LLC for which no units were outstanding. Accordingly, earnings per share is not presented for the LLC.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">For NeuroOne, basic loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#8217;s stock options, convertible promissory notes and warrants are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method for the stock options and warrants. Diluted earnings with respect to the convertible promissory notes utilizing the if-converted method was not applicable during the three and nine months ended September 30, 2017 as no conditions required for conversion had occurred during these periods. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the three and nine months ended September 30, 2017.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti-dilutive for the three and nine month periods ended September 30, 2017:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1395px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Warrants</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 125px; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,074,181</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Stock options</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font
 style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">365,716</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Recent Accounting Pronouncements</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In January 2016, the FASB issued ASU No.&#160;2016-01,&#160;<i>Financial Instruments&#160;&#8212; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities</i>. The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2018 for public entities and for all other entities in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In May 2017, the FASB issued ASU 2017-09,&#160;<i>Compensation - Stock Compensation (Topic 718):&#160;Scope of Modification Accounting (ASU 2016-09)</i>,&#160;which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#8217;s financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In July 2017, the FASB issued ASU No. 2017-11,&#160;<i>Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging</i>, which changes the accounting and earnings per share for certain instruments with down round features. The amendments in this ASU should be applied using a cumulative-effect adjustment as of the beginning of the fiscal year or retrospective adjustment to each period presented and is effective for annual periods beginning after December&#160;15, 2018 for public business entities and after December 15, 2019 for all other entities, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#8217;s financial statements.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IntellectualPropertyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy fori ntellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IntellectualPropertyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PremiumDebtConversionDerivativePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium debt conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PremiumDebtConversionDerivativePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6610018464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of unaudited pro forma consolidated statements of operations</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="6">September 30,</td><td style="font-weight: bold;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;" colspan="6">September 30,</td><td style="font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Nine months ended</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; padding-bottom: 1.5pt;">Total operating expenses</td><td style="width: 16px; padding-bottom: 1.5pt;">&#160;</td><td style="width: 16px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="width: 142px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">893,792</td><td style="width: 16px; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="width: 16px; padding-bottom: 1.5pt;">&#160;</td><td style="width: 16px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="width: 142px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,600</td><td style="width: 16px; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="width: 15px; padding-bottom: 1.5pt;">&#160;</td><td style="width: 15px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="width: 141px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,918,208</td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="width: 15px; padding-bottom: 1.5pt;">&#160;</td><td style="width: 15px; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="width: 141px; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">33,056</td><td style="width: 15px; text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Loss from operations</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(893,792</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(8,600</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(1,918,208</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(33,056</td><td style="text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Interest expense</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(515,377</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(3,635</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,134,529</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td
 style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(10,698</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt;">Net loss</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(1,409,169</td><td style="text-align: left; padding-bottom: 4pt;">)</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(12,235</td><td style="text-align: left; padding-bottom: 4pt;">)</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(3,052,737</td><td style="text-align: left; padding-bottom: 4pt;">)</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(43,754</td><td style="text-align: left; padding-bottom: 4pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Net loss per share:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Basic and diluted</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(0.18</td><td style="text-align: left; padding-bottom: 4pt;">)</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(0.01</td><td style="text-align: left; padding-bottom: 4pt;">)</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(0.41</td><td style="text-align: left; padding-bottom: 4pt;">)</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(0.03</td><td style="text-align: left; padding-bottom: 4pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Number of shares used in per share calculations:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Basic and diluted</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">7,864,994</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,658,051</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">7,369,457</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,658,051</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809568912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of financial instruments measured on a recurring basis</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of September 30,&#160;2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">774,172</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">774,172</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">441,823</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">441,823</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,215,995</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,215,995</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold;
 border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="14">As of December&#160;31,&#160;2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;1</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;2</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Level&#160;3</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>Liabilities:</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Warrant liability</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">345,960</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">&#8212;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">&#8212;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">137,650</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">137,650</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total liabilities at fair value</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">483,610</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">483,610</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of warrant liability and premium conversion derivative measured at fair value on a recurring basis</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-weight: bold;">Warrant liability</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Nine months ended&#160;<br />September&#160;30,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-indent: 0in; padding-left: 0in;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">345,960</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Issuance of warrants in connection with convertible promissory notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">440,919</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Change in fair value of warrant liability</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(12,707</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">774,172</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of computation of diluted net loss per share</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px;">Warrants</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">1,074,181</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Stock options</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">365,716</td><td style="text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of warrant liability and premium conversion derivative measured at fair value on a recurring basis</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold;">Premium conversion derivative</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Nine months ended&#160;<br />September&#160;30, 2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px;">Balance as of beginning of period</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">137,650</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Value assigned to the underlying derivative in connection with convertible notes</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">213,961</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt;">Change in fair value of premium conversion derivative</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">90,212</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 10pt;">Balance as of end of period</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">441,823</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803401488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangibles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: center; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Useful Life</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: center; text-indent: 0in; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 1191px; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">License agreement, October 27, 2016</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 173px; text-align: center; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">12-13 years</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 16px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 141px; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">182,159</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; width: 15px; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Less: amortization</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,269</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Net Intangibles, December 31, 2016</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman',
 times, serif; font-size:
 10pt;">180,890</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">License agreement amendment</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">23,115</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Less: amortization</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(13,368</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Net Intangibles, September 30, 2017</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: justify; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-align: right; text-indent: 0in; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">190,637</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0in; text-indent: 0in; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"></font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6811271280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0in 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">September&#160;30,<br />2017</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31,<br />2016</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left; text-indent: 0in; padding-left: 0in;">Accrued license fees</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">182,009</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">182,009</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Accrued services</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">531,607</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">31,186</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Accrued issuance costs</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">32,306</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">22,015</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-left: 0in;">Accrued compensation and payroll related costs</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">170,812</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">28,252</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0in; padding-bottom: 1.5pt; padding-left: 0in;">Accrued interest</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">881</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0in; padding-bottom: 4pt; padding-left: 0.125in;">Total accrued expenses</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">916,734</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">264,343</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6606199168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="6">Three Months Ended</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="6">Nine Months Ended</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">September 30,</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">September&#160;30,</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2017</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 540.66px; text-align: left;">General and administrative</td><td style="width: 10.66px;">&#160;</td><td style="width: 10.66px; text-align: left;">$</td><td style="width: 94px; text-align: right;">&#8212;</td><td style="width: 10.66px; text-align: left;">&#160;</td><td style="width: 10.66px;">&#160;</td><td style="width: 10.66px; text-align: left;">$</td><td style="width: 94px; text-align: right;">&#8212;</td><td style="width: 10.66px; text-align: left;">&#160;</td><td style="width: 10px;">&#160;</td><td style="width: 10px; text-align: left;">$</td><td style="width: 93.33px; text-align: right;">2,065</td><td style="width: 10px; text-align: left;">&#160;</td><td style="width: 10px;">&#160;</td><td style="width: 10px; text-align: left;">$</td><td style="width: 93.33px; text-align: right;">&#8212;</td><td style="width: 10px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Research and development</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">64,945</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">74,729</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#8212;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total stock-based compensation</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">64,945</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">76,794</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#8212;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used Black-Scholes option-pricing model</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Three Months&#160;<br />Ended</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Nine Months&#160;<br />Ended</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 790px; text-align: left;">Expected stock price volatility</td><td style="width: 10px;">&#160;</td><td style="width: 10px; text-align: left;">&#160;</td><td style="width: 93.33px; text-align: right;">&#8212;</td><td style="width: 11.33px; text-align: left;">%</td><td style="width: 10px;">&#160;</td><td style="width: 10px; text-align: left;">&#160;</td><td style="width: 93.33px; text-align: right;">47.8</td><td style="width: 11.33px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life of options (years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.0</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#8212;</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.9</td><td style="text-align: left;">%</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821349632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 20, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OrganizationAndBasisOfPresentationTextualAbstract', window );"><strong>Organization and Basis of Presentation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Description of acquisition</a></td>
<td class="text">(i) All outstanding shares of common stock of NeuroOne, par value $0.0001 per share (the "NeuroOne Shares") were exchanged for shares of the Company's common stock, par value $0.001 per share (the "Company Shares") based on the exchange ratio of 17.0103706 Company Shares for every one NeuroOne Share (the "Exchange Ratio"), resulting in the Company issuing, on July 20, 2017, an aggregate of 6,291,994 Company Shares for all of the then-outstanding NeuroOne Shares, (ii) all outstanding options of NeuroOne were replaced with options to purchase Company Shares based on the Exchange Ratio, with corresponding adjustments to their respective exercise prices, pursuant to which the Company reserved 992,265 Company Shares for issuance upon the exercise of options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Par value of Company's common stock issued in lieu of exchange | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OrganizationAndBasisOfPresentationTextualAbstract', window );"><strong>Organization and Basis of Presentation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Common stock, ownership percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Par value of outstanding shares of common stock of NeuroOne | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common shares exchange ratio</a></td>
<td class="nump">17.0103706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Aggregate shares issued of the then-outstanding NeuroOne Shares</a></td>
<td class="nump">6,291,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future issuance shares exercise of options</a></td>
<td class="nump">992,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Cancellation of shares</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OrganizationAndBasisOfPresentationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OrganizationAndBasisOfPresentationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809557584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 3,699,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term promissory note</a></td>
<td class="nump">253,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible promissory note financing</a></td>
<td class="nump">1,625,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from subscription</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember', window );">NeuroOne LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoingConcernTextualAbstract', window );"><strong>Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Cumulative losses</a></td>
<td class="nump">$ 49,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoingConcernTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoingConcernTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820893600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">$ 774,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivative</a></td>
<td class="nump">441,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">1,215,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivative</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">774,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivative</a></td>
<td class="nump">441,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">$ 1,215,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt premium to be amortized within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814607280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfWarrantLiabilityAbstract', window );"><strong>Schedule of warrant liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of end of period</a></td>
<td class="nump">$ 774,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfWarrantLiabilityAbstract', window );"><strong>Schedule of warrant liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of beginning of period</a></td>
<td class="nump">345,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Issuance of warrants in connection with convertible promissory notes</a></td>
<td class="nump">440,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(12,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance as of end of period</a></td>
<td class="nump">$ 774,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6653203504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract', window );"><strong>Schedule of Premium conversion derivative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Balance as of end of period</a></td>
<td class="nump">$ 441,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember', window );">Premium conversion derivative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract', window );"><strong>Schedule of Premium conversion derivative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Balance as of beginning of period</a></td>
<td class="nump">137,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes', window );">Value assigned to the underlying derivative in connection with convertible notes</a></td>
<td class="nump">213,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ChangeInFairValueOfPremiumConversionDerivative', window );">Change in fair value of premium conversion derivative</a></td>
<td class="nump">90,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent', window );">Balance as of end of period</a></td>
<td class="nump">$ 441,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ChangeInFairValueOfPremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ChangeInFairValueOfPremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ScheduleOfPremiumConversionDerivativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ScheduleOfPremiumConversionDerivativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value assigned to the underlying derivative in connection with convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ValueAssignedToUnderlyingDerivativeInConnectionWithConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremiumCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt premium to be amortized within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremiumCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nmtc_DebtConversionDerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803207408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 3)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive computation of diluted net loss per share</a></td>
<td class="nump">365,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive computation of diluted net loss per share</a></td>
<td class="nump">1,074,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803434832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionDescription', window );">Debt conversion description</a></td>
<td class="text">The Company issued convertible promissory notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.25 per common share (see Note 8 Convertible Promissory Notes and Warrant Agreements). We also issued 2017 Convertible Notes that contained a 125% conversion premium in the event that a qualified financing occurs at a price under $2.8125 per common share (see Note 13 Subsequent Events).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Financial instruments measured on a fair value recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) included in earnings, which have arisen from the use of significant unobservable inputs (level 3) to measure fair value of assets, liabilities, and financial instruments classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821282192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2014</div></th>
<th class="th"><div>Oct. 27, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">WARF License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Milestone payments in connection with WARF License Agreement</a></td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Estimated the fair value of consideration payable to WARF recorded as an intangible asset with a corresponding accrued expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing', window );">Contingent payment due in the event of completion of financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">Minimum royalties for the year 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthYear', window );">Minimum royalties for the year 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_OtherCommitmentDueAfterFourthYear', window );">Royalties per year beginning from 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Mayo Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Value of share issued as royalty upon the achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Share issued as royalty upon the achievment of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmountRecordedForIntellectualProperty', window );">Milestone amount recorded for intellectual property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Milestone payments accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,709<span></span>
</td>
<td class="nump">$ 91,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuanceDate1', window );">Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 25,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member] | Mayo Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Share issued as royalty upon the achievment of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Additional amount of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AmountRecordedForIntellectualProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Recorded For Intellectual Property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AmountRecordedForIntellectualProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies Textual [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payment due in the event of completion of financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ContingentPaymentDueInEventOfCompletionOfFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_OtherCommitmentDueAfterFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Commitment Due After Fourth Year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_OtherCommitmentDueAfterFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PercentageOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PercentageOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuanceDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was issued, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuanceDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the fourth fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the third fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809932240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Details) - Intangible Assets [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangibles, Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 180,890<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">License agreement</a></td>
<td class="nump">182,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">License agreement amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Less: amortization</a></td>
<td class="num">(1,269)<span></span>
</td>
<td class="num">(13,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangibles, Ending Balance</a></td>
<td class="nump">$ 180,890<span></span>
</td>
<td class="nump">$ 190,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">License agreement Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">License agreement Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820524320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangibles (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember', window );">NeuroOne LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoodwilAndIntangibleAssetsTextualAbstract', window );"><strong>Intangibles (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_GoodwilAndIntangibleAssetsTextualAbstract', window );"><strong>Intangibles (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 4,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_GoodwilAndIntangibleAssetsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwil And Intangible Assets Textual [Abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_GoodwilAndIntangibleAssetsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821286080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedLicenseFees', window );">Accrued license fees</a></td>
<td class="nump">$ 182,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued services</a></td>
<td class="nump">531,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCosts', window );">Accrued issuance costs</a></td>
<td class="nump">32,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedCompensationAndPayrollRelatedCosts', window );">Accrued compensation and payroll related costs</a></td>
<td class="nump">170,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedInterest', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 916,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedLicenseFees', window );">Accrued license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedIssuanceCosts', window );">Accrued issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedCompensationAndPayrollRelatedCosts', window );">Accrued compensation and payroll related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedCompensationAndPayrollRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation And Payroll Related Costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedCompensationAndPayrollRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Issuance Costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AccruedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued License Fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AccruedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809416000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Promissory Notes and Unsecured Loan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebtCurrent', window );">Short-term unsecured loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember', window );">Short-Term Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract', window );"><strong>Short-Term Promissory Notes and Unsecured Loan (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Aggregate gross proceeds of short-term unsecured promissory notes</a></td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Issuance costs discounted of short-term unsecured promissory notes</a></td>
<td class="nump">$ 3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Discount amortization charged to interest expense related to issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Short-term unsecured promissory notes maturity date</a></td>
<td class="text">Feb. 18,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommonStockPurchaseOfWarrants', window );">Common stock purchase warrants</a></td>
<td class="nump">126,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsMaturityTerm', window );">Warrants maturity term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants recorded as additional paid in capital and discounted from short-term notes</a></td>
<td class="nump">$ 61,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="nump">1.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense', window );">Discount related to warrants amortized to interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,868<span></span>
</td>
<td class="nump">$ 14,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CommonStockPurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock purchase of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CommonStockPurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount related to warrants amortized to interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DiscountRelatedToWarrantsAmortizedToInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ShortTermPromissoryNotesAndUnsecuredLoanTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants maturity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=d3e4724-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6821556896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes and Warrant Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Convertible promissory notes and common stock purchase warrants for aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes and common stock purchase warrants to investors</a></td>
<td class="nump">$ 1,625,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,625,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Convertible promissory notes and common stock purchase warrants for aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes and common stock purchase warrants to investors</a></td>
<td class="nump">$ 1,625,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,625,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Repay principal and accrued and unpaid interest earlier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds of equity qualified financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Description of outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If a Qualified Financing occurs before November 21, 2017, the outstanding principal and accrued and unpaid interest on the Convertible Notes automatically converts into the securities issued by the Company in such financing based on the greater number of securities resulting from either the outstanding principal and accrued interest on the Convertible Notes divided by $1.80, or the outstanding principal and accrued interest on the Convertible Notes multiplied by 1.25, divided by the price paid per security in the Qualified Financing. If the Company fails to complete a Qualified Financing by November 21, 2017, the Convertible Notes will be immediately due and payable on such date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity', window );">Description of maximum voting power of surviving entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Change of control means a merger or consolidation with another entity in which the Company's stockholders do not own more than 50 percent of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the assets of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder', window );">Amount of convertible note held by warrant holder</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date of issuance and expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value of warrants risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value of warrants expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value of warrants expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Fair value of warrants expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants', window );">Convertible promissory note proceeds assigned to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,640<span></span>
</td>
<td class="nump">$ 440,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense</a></td>
<td class="nump">284,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible notes to interest expense</a></td>
<td class="nump">$ 6,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Convertible notes conversion premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible notes conversion price per common share</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,564<span></span>
</td>
<td class="nump">$ 213,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense', window );">Convertible notes of conversion premium amortization expense</a></td>
<td class="nump">$ 133,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PremiumDebtConversionDerivativeInterestExpense', window );">Premium debt conversion derivative interest expense</a></td>
<td class="nump">15,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfCommonStockPurchaseWarrants', window );">Percentage of common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Promissory Notes [Member] | Private placement agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract', window );"><strong>Convertible Promissory Notes and Warrant Agreements (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Convertible notes to interest expense</a></td>
<td class="nump">27,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Discount to convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,469<span></span>
</td>
<td class="nump">$ 39,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Convertible notes incurred issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFee', window );">Description of convertible notes issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with the Convertible Notes, the Company incurred issuance costs in the amount of $151,915, which included (i) a placement agent cash fee, which was $113,610 for the Convertible Notes issued through June 19, 2017 (ii) the obligation to issue a warrant to the placement agent (the "placement agent warrant") which will have an exercise price of $2.00 per share of common stock and had a total fair value of $4,855 at September 30, 2017 and (iii) legal expenses of $33,450.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_WarrantsMaturityTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_CommonStockPurchaseOfWarrants', window );">Common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfCommonStockPurchaseWarrants', window );">Percentage of common stock purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants', window );">Issuance costs attributed to common stock purchase warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_AmountOfConvertibleNoteHeldByWarrantHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible note held by warrant holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_AmountOfConvertibleNoteHeldByWarrantHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_CommonStockPurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock purchase of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_CommonStockPurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible notes of conversion premium amortization expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertibleNotesOfConversionPremiumAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note proceeds assigned to warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNoteProceedsAssignedToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ConvertiblePromissoryNotesAndWarrantAgreementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of maximum voting power of surviving entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_DescriptionOfMaximumVotingPowerOfSurvivingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs attributed to common stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IssuanceCostsAttributedToCommonStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PercentageOfCommonStockPurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock purchase warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PercentageOfCommonStockPurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PremiumDebtConversionDerivativeInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium debt conversion derivative interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PremiumDebtConversionDerivativeInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_WarrantsMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants maturity term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_WarrantsMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6651608368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment Banker Fee (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_InvestmentBankerFeeTextualAbstract', window );"><strong>Investment Banker Fee (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_NonRefundableFeeToInvestmentBanker', window );">Non-refundable fee to investment banker</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_InvestmentBankerFeeTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_InvestmentBankerFeeTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_NonRefundableFeeToInvestmentBanker">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable fee to investment banker.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_NonRefundableFeeToInvestmentBanker</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810145440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 64,945<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 76,794<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,065<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 64,945<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 74,729<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803351184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">47.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809935904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Stock options granted weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 0.014<span></span>
</td>
<td class="nump">$ 0.014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares of restricted common stock vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Stock options vested shares</a></td>
<td class="nump">42,525<span></span>
</td>
<td class="nump">365,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost for stock options and restricted common stock | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Compensation expense associated with restricted common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenPlanMember', window );">2016 Plan [Member] | Employees, directors, and consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares of restricted common stock vested</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">1,711,096<span></span>
</td>
<td class="nump">1,711,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember', window );">2016 and 2017 Plans [Member] | Employees, directors, and consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockBasedCompensationTextualAbstract', window );"><strong>Stock-Based Compensation (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares of common stock for issuance</a></td>
<td class="nump">2,292,265<span></span>
</td>
<td class="nump">2,292,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options for shares of common stock granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">365,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock options weighted average exercise price for shares of common stock granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Stock options granted weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 0.014<span></span>
</td>
<td class="nump">$ 0.014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockBasedCompensationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockBasedCompensationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of compensation cost was accelerated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=nmtc_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=nmtc_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nmtc_TwoThousandSixteenAndSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808340336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember', window );">NeuroOne LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632246624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders'/Member Deficit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">NeuroOne, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_StockholdersMemberDeficitTextualAbstract', window );"><strong>Stockholders'/Member Deficit (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares', window );">Forgiveness of share subscription agreement for founders' shares</a></td>
<td class="nump">$ 9,051<span></span>
</td>
<td class="nump">$ 9,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of share subscription agreement for founders shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_ForgivenessOfShareSubscriptionAgreementForFoundersShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_StockholdersMemberDeficitTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_StockholdersMemberDeficitTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810523968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Events [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 04, 2017</div></th>
<th class="th"><div>Nov. 06, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">If the Company raises more than $3,000,000 in an equity financing before the Maturity Date (the "Qualified Financing"), the outstanding principal and accrued and unpaid interest on the Notes shall automatically convert into the securities issued by the Company in such financing based on the greater number of such securities resulting from either (i) the outstanding principal and accrued interest on the Notes divided by $2.25 or (ii) the outstanding principal and accrued interest on the Notes multiplied by 1.25, divided by the price paid per security in such financing. If a change of control transaction occurs prior to the earlier of a Qualified Financing or the Maturity Date, the Notes would, at the election of the holders of a majority of the outstanding principal of the Notes, either become payable on demand as of the closing date of such transaction or become convertible into shares of common stock immediately prior to such transaction at a price per share equal to the lesser of (i) the per share value of the common stock as determined by our Board of Directors as if in connection with the granting of stock based compensation or in a private sale to a third party in an arms' length transaction or (ii) at the per share consideration to be paid in such transaction (the date of any such conversion of the Notes pursuant to this paragraph, is referred to herein as the "Conversion Date"). Change of control means a merger or consolidation with another entity in which our stockholders do not own more than 50% of the outstanding voting power of the surviving entity or the disposition of all or substantially all of the Company's assets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of convertible promissory notes</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes bear interest at fixed rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct.  04,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent event, description</a></td>
<td class="text">The Company may conduct any number of additional closings so long as the final closing occurs on or before the five-month anniversary of the initial closing date and the amount does not exceed $1,000,000 or a higher amount determined by the Board of Directors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfCapitalReceived', window );">Total amount of capital received, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_PercentageOfNonaccountableExpense', window );">Percentage of non-accountable expense</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nmtc_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of convertible promissory notes</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PercentageOfCapitalReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PercentageOfCapitalReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_PercentageOfNonaccountableExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of nonaccountable expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_PercentageOfNonaccountableExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nmtc_SubsequentEventsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nmtc_SubsequentEventsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nmtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nmtc_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nmtc_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MM.@H 2\YL&Z:&$YCW\(5,,$(HTW?!=0+<:[^B9T[P,[),9DE-0Q#.31S+N_
MX>WI\65>MS ND70*\Z]D!)T"KMEE\FOSL-EM65=7_+[@O."W.[X2JT;P^GUR
M_>%W%;9>F[WYQ\87P:Z%7W?1?0%02P,$%     @ O7YN2YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MCZ^4"B+G$SS)F=3RBEXZ+;D*U4QEFTWWU-01=)CO8+#\$2C_ %!+ P04
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MVW$0"DEDQ44]R JMHT (J5/DBMJUW' (V(-X:.&#Z.FNM>XQ3[:C+05[L,\
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MD)W/QM'_$MY#T37O,^DTME71#']GV[>FK<JQERZ5,O]V_3R>AL_+V/]'F!P
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M5;6ARU)]ZF;B$/+=[:((^[;_FG3?Z^LYTO6BK<[C&=GR=E"W_AM02P,$%
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MX0FF>O:43,5_A0M(# ]*,$=AI(LK*7KGC9I84(H2[^/>ZK@/XPW?3[!U )\
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M8(LAH''A^,F?S31FD^%T/_\@LGSC\B]02P,$%     @ O7YN2R>H:8>S 0
MT@,  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q]4V%OW" ,_2N('U N
MN6RK3DFD7J=IE5;IU&G;9RYQ$E3 *9!+^^\'),VR+>T7P,;O^=F8?$3S:#L
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M^,F?S31FD^&PGW\06[YQ^1M02P,$%     @ O7YN2Y.5?]ZT 0  T@,  !D
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M-/_&V@ H97>'*]3A UL<!4V(YANTW;1FDQ-L/[\@MCSC\A=02P,$%     @
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M;#44-#X<W^'9SF,V&]X,RP]BZS<N?P-02P,$%     @ O7YN2XQD-"FS 0
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M9S>.V6@$VTT_B,W?N/@#4$L#!!0    ( +U^;DMF/J7V30(  #P(   9
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;'56VXZ;,!#]%<0'K#&W7$20DJVJ
M5FJE:*MNGQTR"6@!4]L)V[^O;5A*G>$EOITY9\;#>)+U7+S)$D!Y[TW=RIU?
M*M5M"9%%"0V33[R#5I]<N&B8TDMQ);(3P,[6J*E)& 0I:5C5^GEF]XXBS_A-
MU54+1^')6],P\>< ->]W/O4_-EZJ:ZG,!LFSCEWA!ZB?W5'H%9E8SE4#K:QX
MZPFX[/P]W1YH8@PLXK6"7L[FG@GEQ/F;67P][_S > 0U%,I0,#W<X1GJVC!I
M/WZ/I/ZD:0SG\P_VSS9X'<R)27CF]:_JK,J=O_:],US8K58OO/\"8T")[XW1
M?X,[U!IN/-$:!:^E_?6*FU2\&5FT*PU['\:JM6,_G"3Q:(8;A*-!.!FLK0X9
MA*SGGYAB>29X[XGA\CMF<DRWH;Z;PFS:J[!GVGFI=^\YC8.,W W1B#D,F'".
MF1!$LT\2(29Q"!_,0]P\0CV,K'DT5P\V.$&,$L26(/XO1.J$B&$6O$Q0D00A
MB!P1#!/C(BDJDB($B2."85)<9(6*K!""E2."8=:XR!H562,$&T<$P20!+K)!
M138(@9MX#+.0>!K@%10@%&[J4=!"[NE"I5*$PLT^"EI(/T7+=4]#A,+] %#0
MPA= \;JFT2-%Y*8' R4+U4_Q\J=(;:</3QP&6GCE*/X"4*2\T]#5P4"1HT-F
MCW<#XFK;EO0*?FMMSYSM3JUQ']K'_Q]\Z*O?F;A6K?1.7.D68A_Z"^<*M"_!
MD_:EU*U\6M1P46:ZTG,Q]+-AH7@W]FHR_6'(_P)02P,$%     @ O7YN2^-^
MAQRV 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&UL;5/;;MP@
M$/T5Q <$K]?91"O;4C95U4JMM$K5]IFUQS8*,"[@=?KW!>QUW=0OP SGG+DP
MY".:5]L!./*FI+8%[9SKCXS9J@/%[1WVH/U-@T9QYTW3,ML;X'4D*<G2)#DP
MQ86F91Y]9U/F.#@I-)P-L8-2W/P^@<2QH#MZ<[R(MG/!P<J\YRU\ _>]/QMO
ML46E%@JT%:B)@::@3[OC*0OX"/@A8+2K,PF57!!?@_&Y+F@2$@()E0L*W&]7
M> 8I@Y!/X]>L29>0@;@^W]0_QMI]+1=NX1GE3U&[KJ"/E-30\$&Z%QP_P5S/
M/25S\5_@"M+#0R8^1H72QI54@W6H9A6?BN)OTRYTW,?IYN%&VR:D,R%="(^1
MP*9 ,?,/W/$R-S@2,_6^Y^&)=\?4]Z8*SMB*>.>3M]Y[+7>'+&?7(#1C3A,F
M76,6!//J2XAT*\0I_8^>;M/WFQGN(WV_CI[LMP6R38$L"F3_E'C_KL0MS.%=
M$+;JJ0+3QFFRI,)!QTE>>9>!?4KCF_R%3]/^E9M6:$LNZ/S+QOXWB Y\*LF=
M'Z'.?[#%D-"X<'SP9S.-V60X[.<?Q)9O7/X!4$L#!!0    ( +U^;DO&,E?@
MZP$  (,%   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;(U4;8^;, S^
M*X@?<*&TA;8"I.M-TR9M4G73ML\IF!==0E@2RNW?+PF4<<R3[@N)S>/GL1W9
MR2#DBZH!M/?*6:M2O]:Z.Q&B\AHX50^B@];\*87D5!M35D1U$FCA@C@C81!$
MA-.F];/$^2XR2T2O6=/"17JJYYS*WV=@8DC]C7]W/#=5K:V#9$E'*_@&^GMW
MD<8B,TO1<&A5(UI/0IGZCYO3^6CQ#O"C@4$M[IZMY"K$BS4^%ZD?V(2 0:XM
M S7'#9Z ,4MDTO@U<?JSI U<WN_L'UWMII8K5? DV,^FT'7J'WRO@)+V3#^+
MX1-,]>Q];RK^"]R &;C-Q&CD@BGW]?)>:<$G%I,*IZ_CV;3N'";^>Q@>$$X!
MX2J C$(N\P]4TRR18O#DV/N.VB?>G$+3F]PZ72O</Y.\,MY;MHGBA-PLT80Y
MCYAPB9D1Q+#/$B$F<0[_"0_Q\"V:X=:%;]]D>, )=BC!SA'LWA <5R4BF#C
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M2S>;!Z:XT+3(HN]LB\ST7@H-9TM<KQ2WOT\@S9#3A-X<+Z)I?7"P(NMX ]_
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MGRU:;&&II(;.2=,1"W5.[]+C:1_B8\!/":-;G4FHY&+,<S"^53E-@B!04/K
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M<S\91G/S7^$"PL.#$Z]1:6'C+ZH&Z[2<6;P5R=ZGE:NXCC/_M2Q=0.<">E-
M)J'H_"-SK,R-'I&9SKYGX8JW!^K/I@K)>!3QFS=O??92;A]W.;D$HAESG#!T
MC5D0Q+,O$C0E<:3_E=-T^2[I<!?+=VMU^B%-L$\2["/!_I\6]S<MIC!96B1+
MBF0)@OL;D13FX4:$K"Y.@FGCD[6HTH.*X[+*+E/Q1./%_X5/(_6-F98KB\[:
M^><3+[G1VH&WLKGS7CH_Q4L@H'%A^^#W9GK+4^!T/X\I6?XKRC]02P,$%
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MOI?=3-<]*%';>37HA^;5/U!+ P04    " "]?FY+QS4ZV!T"  #^!0  &0
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M'VZ4TM+$#.],XCLIUN.@D!O=WB;FON[/S?U J_WPGT P_C&Q_ ]02P,$%
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M[1NVG"NF*=,;G?9>-ZOCI&%;98:E'HNA8QLFBO>N&TW&EGCY%U!+ P04
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MY9IUD[7;"-KT?PW6\.N2_ -02P,$%     @ O7YN2U69LS4S @  E 8  !D
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M]NL?A)^*2CA[)E4C,)_KD3$)ROSL0=UDKGX1_8+"4>KI7,UYVRC;A61U]P]
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MX7S#%!JM'6 RR1TN4H?/;%8$-,Z+6Y1-7+:H.#U,[XC-C[G\!U!+ P04
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M*JFGL9KSL3>-@63]U';1W/NS?U!+ P04    " "]?FY+;B[N OD"  "@#
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M0".2P*[)4 )0C)"?1G9E[@/[I&"U0(!<)&-YP2V.X@^4!FY0!'7HH#3)\%W
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M-!O 4_@\.*<*T*1L\@5\63;5LEC 0A;)=]DR*^<Y# #WL8'+]?/EJ^3PX"B
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MEI$AN<X*8!T"9UTI,#K1&%AD:5B=5M,SLQ=RNEU3I(-1S-#"#YJ*"+FI<_%
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M%5S/I[*Z/[[%[)_WH-5CM@<JZ \\,\?;L/G)61 7")"L+@D;M3(03'K3601
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M;+S_+[E$)_.NR>KMCO3A5]_O^;!_QT,W\,L4*WE]%Q%F#+6Q?"5"MXQ59H?
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M&;PYT^'@\-.1;)(#C0!Y+=<A1>;5163<V0G/B+YNQ?.\ZW;L($C N):-*?+
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MS"[<Z'X9LY5-UB)2MO1.$Y#@*(T3LKP7"=8<LI5@#0QX,)RDYR#N[E?KJR?
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M?J2,AT:4T/[12V4C<CN@&QF\LQ>;UQU6;[ %K;$9V-:[!A(2H,D 2;G[E$B
M+F3F5">1$:-5PZ1C_>*?HH811NJ)H@I>H'^6CBR;6[=CR3]76Q:^#E@29._;
M$)9%N'2B<W_WS7M^^Q7W.GS,NSNIY<BWT/CM%=N#O0VRHXPY5U3#>VM-:3!(
MPRMK8EI#5<2:3 RUU:',\1O>Y?=M0NO-O"[6[0HKY/S#RWLP2P?3(1T:S,;=
M(JZ<1N]>L2?7H!, M6WGW?G"3E#W&)'=.H&36 J67RN0!C!PL*6/O 3^Z"O6
M^XJ:F%K&,085FUW1!&HDCPQV)8>&(Z1<]5)\?T&<>>J'TUMW@3OL1WGZ49_:
MP6UE5G&K:=U5.3MG1<FYA@IUI=@AN<3:R3(MVO1E)K& 4$$U-9"T3'/]27G&
M[._NZT-^;[IOF+?C'M(8"]0\;.D)^A-9ASEY15,[Y,L @(3Y)L,L7[ATU"!6
MAD5FR7^<L2TE:NHP+D'D(R9BU0E>=L,6V$8?GLU)\IWT=+-!W(Z$8WX\VXGT
M<7R6XDH.GW,FUZ;CK>W$]X ZBMD#5ICR=N$:#+FY=XF\G-BGC:=VEB$'1879
ML,6\MLE%UN$<(X>I:4K.=259B>BT%S-A5I8%22*UR1QJ(P.9PU1(DBTMJER]
M!QC8BHF; ZF4C0'/R2WH59@4*6\'63=AEHU3[/DIN9B__>63,-NX/AIYM_*]
MEHQXE9G[?Q2DM)&'I?&2*@WD^#($_D+GX+PYO-E[4BZ?(7&RXUB SJ#>$<NA
M_$53*/'MG7F4AQII].C<B([=NIDH%.>IZ39/F^4Y$BE]N.V7JMC*1R07B5NM
M+QKO6H?HE_;!ZI=*7(Q/]]\N>U%QMYW!&(M3"+(:L73T+Y'%^(Q)C.;J?%$B
M(Q- /4@D)?1&F![5@:1KKR8I=OO+:A ,LS4VY21_O2G:BRP -]:X\IO;F=RC
M^<^<7XD'ND\^Y6]_Y43*B&V%5/G7:#YPA%3&KL:Y^KS*,)^2O'BQ_#%79&U-
MOU>R9 <&>(F'LC2^I_:&/BYSK&,BTXR1Q1Q7@D>/PU=..,U75,E>Z*Z;,&D0
MK96_J!(=MQB)"'2MSR5LV]\7V=<,Y E)#/2I%GV[CK2%N(RD]CIO;VJK<AIU
ML(,^;->@5YAF4+>$!!4 @T2K&AO-U!E#O^*/@AT2 H^_@&Z>E1H2CRC,35']
M/&JO9]*&;_CCH\^R:(SJ/WWXF1]6EOYJ866/C2=#HQ#+>SNW)":C1YV=QKCW
M'0N'?CMUI848M?-8C6DB0Y\*"L:-SB ?FSPZ@@3%G$F6!)OMU:-M+*AF56-#
MVSMK\)!FL8A)A5VZ;;LF=\=[;?4]"DIMT>'>Z$Q)*LE_#1?J9IXBGR& KD"A
MA=4N<JZ9P1FS,%&K(%X'8:5:M9;@I$91I=+\ 7/9;Q2EJDVVTN1NX?Q8$9]*
M/I/L@Z*BOWJNI6T:[-(_7?W<=D?B>Z5UZFFQTA1Q.)6F*]<")L06OQ5-V&I(
M/=)MXU51@@1<VLZBTK&@W5Z8712"G=I%3(A#D5./9>XH(V4R+1)9-V '^D1L
MGZN5<*=+;/>(:RO]_K!4Z1I-:_K747N0]UD)]QLG^%V#A9UQM->2!1T84^W+
M1E9I?R*%#CE+2="NHRAAU#S/<C7Z)6S52+LAT6,PZ$!"2%"2FF/O;6OV]WLY
MP?P7("T";-26T6#'*-F':5V2FPVPFF-].IR^R(V Z4*HQTT[)"##M7UOETX?
M6 KCX.KFV]K(L=(6KNL;GD6E<1'#]H:?N;:159K4&<<KR._9H"MTNE#/"BE.
M+KZJ1<$TA0.@T.YF !:K,(=DWY[_2[):4Q3$8]YU6@@73G=B.@_3_IE[/_U-
M#\<Q45$//G]P-I]3QKT6D&9&U-S&&Z03TRFL?(L5^Z^]516;[4;*> 6X=X+E
MPK="!Q<YJ03<N6E#*4B-6OVN\X7@,@S)M0Q!T-I0GR*#J;X[U?=O>2MI[ .$
M#O+T5"THUIU&+?O0.NG )/]<-!&BUCG7OI7I%L6"%"V2A@00=-5Q_PT-$8)
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MNK!%%$TI][G7W[Y3]'Z/U3P!S^OJ(5MR1(O$2%$Q>SC V:,_&0T"]<B\BO>
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MXV@6I4&8BP[C[#=-L_GC_P=02P,$%     @ O7YN2Z'? ?): @  ;0P   T
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MF0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ O7YN2YE<G",0!@
MG"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "]?FY+)*RV:60"   4"   &               @ 'X"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ O7YN2U,#N.8F!
M910  !@              ( !D@L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( +U^;DO:+P?0?0(  ,0)   8              "  >X/
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "]?FY+QW%.
M(B0$  #K$P  &               @ &A$@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ O7YN2['SYJ\5!0  M!L  !@
M ( !^Q8  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( +U^
M;DM"D;"DLP$  -(#   8              "  48<  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " "]?FY+YWII8+0!  #2 P  &
M        @ $O'@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ O7YN2Y*-5W>U 0  T@,  !@              ( !&2   'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( +U^;DLGJ&F'LP$  -(#   8
M              "  00B  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " "]?FY+DY5_WK0!  #2 P  &0              @ 'M(P  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( +U^;DM,XD*NM $
M -(#   9              "  =@E  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ O7YN2TYW$,JN 0  T@,  !D              ( !
MPR<  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "]?FY+
M^D']]*\!  #2 P  &0              @ &H*0  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( +U^;DLL4#K>M $  -(#   9
M      "  8XK  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ O7YN2Q\@?5ZU 0  T@,  !D              ( !>2T  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "]?FY+EYCVV+,!  #2 P
M&0              @ %E+P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( +U^;DN,9#0ILP$  -(#   9              "  4\Q  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ O7YN2X[&>WBU
M 0  T@,  !D              ( !.3,  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " "]?FY+9CZE]DT"   \"   &0
M@ $E-0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +U^
M;DOC?H<<M@$  -(#   9              "  :DW  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ O7YN2\8R5^#K 0  @P4  !D
M         ( !ECD  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " "]?FY+U5*J&[8!  #2 P  &0              @ &X.P  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( +U^;DMBJQ0)M@$  -(#
M   9              "  :4]  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ O7YN2PDS0VK! 0  -P0  !D              ( !DC\
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "]?FY+3;+/
M ]T"  ! "P  &0              @ &*00  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( +U^;DO'-3K8'0(  /X%   9
M  "  9Y$  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
MO7YN2\NW<BDK P  I!   !D              ( !\D8  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " "]?FY+48^BTQ@"  #]!0  &0
M            @ %42@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( +U^;DMS2X!,%@(  /P%   9              "  :-,  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ O7YN2_+ <E_L 0
M P4  !D              ( !\$X  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " "]?FY+^T>2@N$!  "A!   &0              @ $3
M40  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( +U^;DM1
M0BGAN (  !X+   9              "  2M3  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ O7YN2QZ SR6% @  Q@@  !D
M     ( !&E8  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +U^;DM,7ZKSO $  -@#   9              "
M 8YE  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ O7YN
M2WL0S=]D @  .P@  !D              ( !@6<  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " "]?FY+H^_3' @"   '!@  &0
M        @ $<:@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( +U^;DMN+NX"^0(  * ,   9              "  5ML  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ O7YN2Z1&W7Q# @  5@<
M !D              ( !BV\  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " "]?FY+7Q%".^,!  "P!   &0              @ $%<@
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( +U^;DM2:/^I
M60(  , (   9              "  1]T  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ O7YN2\-WTQ\I4P  86,! !0
M ( !KW8  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ O7YN2Z'?
M ?): @  ;0P   T              ( !"LH  'AL+W-T>6QE<RYX;6Q02P$"
M% ,4    " "]?FY+E_,J7GT#  #C'   #P              @ &/S   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ O7YN2WBR3"VZ 0  *1L  !H
M         ( !.=   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ O7YN2Q.D0[:U 0  4AL  !,              ( !*](  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #4 -0!E#@  $=0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>84</ContextCount>
  <ElementCount>195</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>25</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/GoingConcern</Role>
      <ShortName>Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Intangibles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/Intangibles</Role>
      <ShortName>Intangibles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Short-Term Promissory Notes and Unsecured Loan</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan</Role>
      <ShortName>Short-Term Promissory Notes and Unsecured Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Convertible Promissory Notes and Warrant Agreements</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Investment Banker Fee</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/InvestmentBankerFee</Role>
      <ShortName>Investment Banker Fee</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Stockholders'/Member Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockholdersmemberDeficit</Role>
      <ShortName>Stockholders'/Member Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Organization and Basis of Presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/OrganizationandBasisofPresentationTables</Role>
      <ShortName>Organization and Basis of Presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Intangibles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesTables</Role>
      <ShortName>Intangibles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/Intangibles</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/AccruedExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/OrganizationAndBasisOfPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/OrganizationandBasisofPresentationTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/GoingConcernDetails</Role>
      <ShortName>Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/GoingConcern</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Summary of Significant Accounting Policies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesDetails3</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesDetails</Role>
      <ShortName>Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IntangiblesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Intangibles (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IntangiblesDetailsTextual</Role>
      <ShortName>Intangibles (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IntangiblesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/AccruedExpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Short-Term Promissory Notes and Unsecured Loan (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoanDetails</Role>
      <ShortName>Short-Term Promissory Notes and Unsecured Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ShortTermPromissoryNotesAndUnsecuredLoan</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Convertible Promissory Notes and Warrant Agreements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesandWarrantAgreementsDetails</Role>
      <ShortName>Convertible Promissory Notes and Warrant Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/ConvertiblePromissoryNotesAndWarrantAgreements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Investment Banker Fee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/InvestmentBankerFeeDetails</Role>
      <ShortName>Investment Banker Fee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/InvestmentBankerFee</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Stock-Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockBasedCompensationDetails2</Role>
      <ShortName>Stock-Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Stockholders'/Member Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/StockholdersmemberDeficitDetails</Role>
      <ShortName>Stockholders'/Member Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/StockholdersmemberDeficit</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="nmtc-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.originalsourcemusic.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.originalsourcemusic.com/role/SubsequentEvents</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nmtc-20170930.xml</File>
    <File>nmtc-20170930.xsd</File>
    <File>nmtc-20170930_cal.xml</File>
    <File>nmtc-20170930_def.xml</File>
    <File>nmtc-20170930_lab.xml</File>
    <File>nmtc-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001213900-17-012064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-17-012064-xbrl.zip
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M[K:DZ*98-3)T9ZKU@)GB#%SZ!5,X?1^Y#AJ,Q!K<J0].0^_46X!X2E)P\4%
MO?VQ!**PPV"7%0#F3+,6I(:1;LM(7UC"P!&: W[?L$L61$O\R<-CHS7@?%1,
M-!%,Y(0/0O';AXE5H_AW>=0.E2F,XF^9XG^(C&04_^-D(A']J6,7HZ3V&^&K
MT'C+$;Z-:#R/XO0KBQ=OV#3]>KUD1&-8\!*3']. ?8Q2EGQVKAWX-T?$M_-L
MFOB>[\37YT[ /LW.T\C]+GC#OP1D?PX<ES!^( Q2AX.<058B8P6SK/_^)GSJ
M3%J'V$/GU-Y8IK"*G%K[N8E%WV\L>H2YI]YX^[P@\IQY/G,=9M@@SPD_8$'
MW#1S@L\\JWM]('QQF^1F,[A[L7=*"<J;[9T25VW=WOD87=;JPNKG[Z/P(BVK
MPM_!7'0SL!'PT\-@FSHX<OZH 6@?LL/>B1ZAF&B#%LDSFL;>,?;.1@)LO)$
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M7SBAJ(S*7PU_X)6IA.HL$L B_RA+?"QS?\/R\O;0 [IC(158()_A81R)^A4
M_RV ]VWGMMRO_QZD/WG^Y;]?I#\]P7\OK22]#M@O3V>PY"O+[B[3EV$4 ^C6
M_T[]!<C1D%U9(&N<\']W+/JD8R6@*V<_60LGOO##5U9W^>,G"_=SY 3^!7R
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M>7Y:K3:*LT#HDIA=B,)5Y4F<OP6WYS48F%A)ZH=(H/S.V"R*4JQ8P-)2-XC
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MP'HECU&4QM\R=-'H<L:/<+3T0Q%1@4>="U&&AE)4*R3L<-\F(=&/)7UA<"T
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MEL 0P77'6O@A#L4HX(7"+:(?J;B"+3-3M>^BFP^U>:UB5+1P*4(@0C:KP6L
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MK<8EQ*^YDX>R.O83I8_$XRC,02HC\E&,QTUKX;S[2^IET<%G@\PCJ0]:"PL
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MT,75'6;S& @^Y9)2$R66H?MEL0#] ]4T_87P(H@GCJHETUURP7#=B"<V TI
M3=!![,L8#+U,X9L3"6ZD[J#+((NR1$DC&*-[90G''E>U2;G&)&UR=8&*;/+
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M-?5GQD1>WJDE_&G[*T?GRF>*U.F&@)5W4)F;OAQLD+ :+1X3 HMB<K5:2J&
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M8Z'9'N624:/5HC;7;(B2,-EO,-GP9,TP63E/%I'+Q=*5!=Q#=2WM,GVT/ >
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MF8/5^AFLUL]G1;53M(CBZY3!_>+84_2HW8D<#8R=F*23;!!$(J01+[^;  O
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M8KM_*B2ME+<'W8$VV@<1Z3=>H,8[I>5^7,:WB/D@%\^Z:^R90+Z'"-^:87H
MF.J PCUDRRH*.U14,!@>%X>/VS_W6.1S:&RFA],*<]_/=^T_5I!3R6J/B)/B
MX^*HVO$(."F;+;>FT)^<L,HJ)#@.^DH45*\(?;DK[DZ&^[85W1T'?64?DVUY
MDO-IX(^/CO5^(3?FM<T'GOSB.EY)KO$[2[=O]#GWZ#X\.P\S)_!TV[@W7WS&
ML '</8W$A#_CK<*Y^V#ZZ-.]MBFK-M"MQ,Q;[])T83,Z+G;Y@I5A'C$5U.=L
M)%$&DV?C[1AD*6QXU)$LJY.)CTT;K]#[?V>8 <F,BR>P7Z<L48+_"FB6F?3%
M!5^G5X!NY2&V%)U8?/5?(%;9ZM=H*93R&@KE"KR.FQ"K=DO0HXM!>*I(K?4&
M><-TW,_1V2#U]9\>=:#C+HH&_0<_&(VD+&EDUQ&(]?.=NN;'*@DGI>P9,,!-
MEV[F;WU5B"X#(;EGQWX#XH#RA*$ RIG!EY5G\14SOW9:9TT@W<8\1[%GZX30
M/0[^#$@UM=?M=5X)N+7AGPJPNJM0NQB/F05'-D:$^!ERPVO'#R.:NEI/6[5D
MRP3C\#@J?P^FNFDJ1=(>/J KQYTPTP\ D.M-BD.UIUSY0!P#1^6STN%P%(K*
M>^8^F6.6_K4;AW)C&==AO0>L=9!_QXS@&\?_@_DX%7MJ8Q^B XWTJ!P.&5DK
M(OYP24R:)H&:OHH$42<3K O">C!,HWG07S L@DLS[0#$R>V"<06Y=,UV:_ L
M_])*!*C*8.IN $4W"^I]9#:;F'EF<AQH$J4$8<9:=P7G*(,UJP/G:/,D#T6A
MVH+$NUM]9?[,,>+BC=MGF[G>S%R\YJ9GN4$_.KX.T!,\LUAN+VRM5%S""GCG
MFY-CIK12Z60+N2Q0]T5'/^P2N8*.M.LE0D?@%8-NY2M2IZ>3&03S(%5YSW5J
M'F8$8U_!O\=MYO2HZ[LRMAP/]!-/\1S%<NRIHGM42(TMZZ)?P^Y[V#[+#7OP
M\;N>V-D<\(%=OVP3.Q$ :&'G+!P:;$IOP9.!*IZE(G/#81[U_F(OV 5'^4%M
M =WP7_R4KLS,*?82"^]FV%O4M.-&<A\=T.'Q@Y&31ZJ7SB;H$<A>@(HKG>Y<
MW<22\+@SV@^="$FF337KO%FEU&<PIE$X1T.AB4:\(#ZE3]Z[#R7T4.3U_&#.
M6E9Z]\1*FR?BW5L[*+X/VPD4;G2XWCD1V_D@F\8]"G9\Z7X=$Y-HHD:)NC)>
M:][GNSI8N+Q3A-C0\%+LRL IPG075L %1'H/3G>=H5H2%,].8!DM['1 K[-$
M5PHA#<)>?_3ZN?YOA]Z1TMDO1ISX472P$ 1\9*@3RNT8#38G%$<M^Q(")^2,
M!/C1:\92-PKB3>Z+6>OQ('>$C+"V]EX 70\I%;6+@,T)L @D6V"K<!R'C!C?
M&+6,(!@2'2:\%='G!&Z*Z,/[S FRQ#BE*<@4H[Q$QXEX+=]08\GW@9A!D8)
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MIMI!W7RT*M6A.:@^3IAMH'2/@U1JR316R_Y0RP;IC[3>/G_V?U!+ P04
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M0;B$2MX Y&8,4S!_H"@!"V*C=*FNG;W@AG+=)G8?X\\EC6-*G/C8%*T(&9O
M?;Q-M,,0SU'<(1QVR24:8X%LA:=,C8KPDHG?QXM##P3"!,(KQ(BZDK:#((G5
M^D+8@0$.L"V#<E&N"&DNIKS>%+9/PV4NM-5YGJ]:XIUBJVN/!XFJ=?$M5PM_
MSW0LU&U>&2:=7<B-"B2P$V/5JB115HM\3 'VD]!7C2:3I',&8#I!]MS;<R_D
MS]2+;@>W8V#I7/R!H$2F+^HLVD^W3]XT9?3_Y&$J>']H"&2HVR!LX<P@6_1V
M_@1$8HCD9FB',2:8"X5H AJ1!7RN9JD;/9.&]9V=:X:/IV</.,@5&4G4'9A
M1,=J ^1SEJ-7#<9RC*A2:<ZSV/4%1)=(Q'!#N2UNK<D5[?U+3W$":Y0NU=.-
MR[SNY4;8/L:B+A' @&N3]#:4)MJ[D3)4_.<E&_M.@><%\T'5-7L=T>G+IH.&
M6<K.!@V0B@^H"L0=HQ,L[;QX?)!PNV2YM]N!3#7RJA';#%+TYM_EQ"AQFV])
MRGH,6+/&QZC<#O].>%I7N*:L/6^72!?'6JO/U*DX81;+O*RQC!"#"Y2&ME@=
M,'G,92E4G+8LL_;[V<OFD:I>^28]92CO@02X/$I2)/=)GP<,IY.UAPQ .]0U
M38@J#*5"IBBXXW@597%'JYT_H"DRJOX0.FX'US(U(8%<@TO*[4]J6-4J2J^;
M<9K%7_UE4?46=C /I/L)W4[H3*51]Z#X-%JH2?W-*U*71_SM8-&[]4G]A% &
MEWM@$QQ8TVS7 :I.KZ.9FN-W+WK&]F""HD2[FG8OY7'SKFWUD'@'&)ZD!=FL
M<W6[,2K*WC,LU02^+XY [4Z+S]A,'PRZ*!T,19NF:4Y.?0J<\B;+0.;8'9C_
M[A+]'&]'MP<:G^>U5O>>-V!%>=_5[&7U(-LI&CYXQ>:S:%OY@$G]X!@W&;G@
M-[\\Y-D'4MZ63Y=WC%W*I\9!BF\VIP% R*^E=RX?*51'NK7E/%/'Q_UD(6NS
M(3W3,A]+K#_"[7*>J!;-IYS:D4&3X@'1:#+/QXJK&?.##(]!PE37L/.6S-0^
M2%;7;/2Q*?X./>H#+7V*5$//*]E9M:I.I<VV_+)K"=GH$^*T$7-[$DUJ!\.B
MR;C\NFOC->O,_K(TU8LM?ZE67WFA5\CN@&$:KJ?\ME[UK88IX8/[$CH3RMIM
MSZ'4\*&_L[$^IJOE7*8.D'&CL24U?^F"PZ)EMJ,>?(N>\^6>&0.]< M7QJP'
M\-U2NQ35EV,':E6N(;NGP"19[I>XY2WE2K7<!-_'T*EQRD P ,Y3. JLLY=D
M*E:#*U=K]GNQMV^.O"N 1;8:BVXQH)#V)SWUCXU7\CR5EPYI;M2#]&%JE\5W
M&:!ZC+A8M=\&IISMH+O2\W;"4JQZ2_Z$W;FGR)1K+;^87?[S'U!+ P04
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M"F!M7!TY<8/GQ3'1,B0L\8:V8_' .NIW'0GK*+P$*.UY)]5F!P7L@M]]C=!
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MM:T?+A$N=4-&YT%.AG$0RO.&0ZA/E0"LPZ_;.%+SIL?3H_^OWL8P4-@8'+V
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MIT(K3!_:RW4_! V=!NRP-'A_.H>JQFBDRWT)JFHO"JP+(O >"3XA=>,:) [
M=/NCTB_@=G1DD=$?W ;.,7\N29BNZ7WP,KS&LQ85M#75T]GU>/EHPH:#WU[[
M;[E3+H4:#P*.=+9:>AQ0)LE F9H)$8?RO&E"5)W#AN.T2E^+ *3JU5.ZBMBW
MY!T'"E$TT%>IF[!!ZW4CM;U>2@GPAS<_T/4#.^Z?TF4<Q@5F56_W6>U+3:E1
MX6#8 =K? 2&4*7"A6<O!1$*+&Q'$9F(T>@\D%HT-<69BK4&QQP9108+^MF6'
MEK/G(=$Y-1YPBZ*FL*\6A!Q*Y%C4!L3PY:S+(?0B@>9#=R.A1@!F%#0T6; >
M,HT_A!@\:MW$9GHUKH2>6UP^Y?1Z>987\3IP: JA@H96T1UJ#AGJDRP76P]9
MR,("._)S^5^<*69&NGX(DN!1I+G\(2>'1**S./U,9V5G#D#G?R;.J$X*677T
M-LY_/<EH%!?\7[;V18L"KKZ!CJZ>Y*MF-.&#%D0"E#]@$:K1:>7W.PVA:*R1
M!5L::C.HX><6L?,@SD3ORU8EVHN$>9,B"227+.5JJ"R10MLO6]H/F93#R<:V
MG$-K4-*"Q2.44#N S@PZ<;J5=;3#.$(N7T%7*QH6VV!UDZ4;FA4[B=LUI<\"
M#U!FGPV%/:^L:RA2@<TB<,X=7T8D$$7"GP\U^WD;05-L;",_V#+-8M*F>%.B
M1I,!:"V&ND1 ,Y+9;WK7&Z;(. M<9^PC;=(\6%TO+]/D\3)^II%\UF]6./H;
M<J\YH!T$SYWIR'&-AJ09J1!Q*>"HC@2NLBC&*_$;)MB8GLU YT(,D12[!!"?
M"2#><SGZ'UI0R'=<%F:+C<(CE0,).6B5!VY8+5C*^#X+6AQN:4X9[4_'271*
MG^DJW7#Y+6LP^)V?K5!"&T<[N@^YL((2KP9;<%71"CRB-B?Q8-(XG T=K)L-
MOL&GY<-VASXG92,.D%.RF;)#?NOT/L5Y.AZ!, 2G8G<J+$[$:/N86HJ9^B1L
M0C!8$=QD=!UO1>T#^7P]9U_RE&;Q,_NFS]3S0.N%&O0AMO,^'+)IB4!6!6E0
MD 8'!K4"N@&(.M@/IM9&*VW*'8GXCH3-CD3U/,CZS_LI _,C?D>\8(\X/,_K
M:GCPQQLVX?/JD0.>0\5X-&%\N.%SA%<"SRTK9T&6,#67W]!,O P<&/$VHH,^
MOYOI/62^"H(P$/FX=E;!&E)DTYW8*\J.%VG>(A:-17/D6*NSN0G7W-)X13^W
MNO%D:<+^&=+6O;JG17/'"V7I/':@R\.?][HZ[2%!;A1'(/^6\C0K]0Z@,:"^
MS*XUK,Y(9W\[$#[1:+L2+_23B,< HYYFZ/>\BJ]_54ZO.:!-L^?.]"132N!6
MAE8#3GX6") &V$?:@@H-/\INDV ;Q;P^R"9+^3%V'?"S:]E@FOTZ;_:&#>?)
M&>+XC2\P/T1R[-X7^4P IS_X*\2$1A]HPOY1W# .:)7XELNT]0\<D8*]47*D
M72<7)092HB "1^L1:Z4I\'2-\/KR^B="3AC!DK0_[.I__CUFZBD+GW:7_"KM
M^"5V?DYDBQ7:&EI3K\Y27I :@/S,1^-[%^KVC=WRD_4HP;CY!QIPH1*VI+O
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M0._A$<6YV)FL2YKG?^&OTFHP-&;/C@&U9L^ 8FZ1N@GX2Q)>ZC%(/!L*]:*
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ML,2>R [EA;KYQM6=&?@!C;YLX@S?T_]QA,R[")_#5--=!E<AGN,\CQ^3]DM
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MJ2/^*:-8;L:L#,#=?/#8^0F;(]JF;ZJ&UQS7YGU+$&\3+.K4LG'1/T3&0^'
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M2P$"% ,4    " "]?FY+F%<,4L,,  !BBP  $0              @ '^GP
M;FUT8RTR,#$W,#DS,"YX<V102P$"% ,4    " "]?FY+Q)/1\B\'  "/7@
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E,#$W,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$  (Y= 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
